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Abstract
Ulcerative colitis (UC) and Crohn's disease (CD), collectively known as inflammatory
bowel disease (IBD) are common, chronic inflammatory disorders of the intestines. The
pathogenesis and subsequent clinical course of IBD remain unclear; although, inter¬
relating factors such as environment triggers, dysregulated immune response, defective
gut barrier defence, variability of drug response and genetic susceptibility all contribute.
The current work described in this thesis involves a series of clinical and genetic studies
investigating their respective roles in determining susceptibility and course in UC.
Firstly, the importance of corticosteroid resistance/dependence as a co-factor in disease
progression was studied in a detailed 5-year inception cohort (1998-2003). This study
demonstrated remarkable concordance with older series and paediatric cohorts suggesting
a defined phenomenon within the innate response to corticosteroids. Secondly, a risk
score to stratify the likelihood of response to standard medical therapy (high dose
corticosteroids) identifying 3 distinct risk groups - low, intermediate and high risk; based
on 167 consecutive patients (largest series studied) with acute severe UC was developed.
A novel robust model was formulated with a sensitivity/specificity of 85% and 75%
respectively to predict failure of medical therapy. These initial studies have critically
provided the assimilation of highly accurate phenotypic and follow-up data, permitting
very detailed statistical analyses to be performed in subsequent genetic studies. The
multidrug resistance gene (MDR1 gene-encoding P-glycoprotein 170, an epithelial efflux
transporter protein) was studied in detail due to its potential role in conferring
susceptibility (based on knock-out animal models and genomic position within IBD locus
of susceptibility) and its function in corticosteroid resistance. In this study, allelic
10
variations of the MDR1 gene were found to be implicated in disease susceptibility in UC,
in particular extensive and severe disease subphenotype (p=0.003, OR 2.64 and T-allele,
p=0.009, OR 1.70. In this study, bi-directional haplotypic contribution to susceptibility in
UC (with protective and susceptible haplotypes) was observed. This led to a more
rigorous analysis of this gene by the application of the novel 'gene-wide' haplotype
tagging approach, confirming a more significant association with UC (p=4.22xl0"7) but
not CD (p=0.22). The strongest association was with the sub-phenotype; extensive UC
(p= 1.7 X 10"7), and critically dependent on one tSNP rs3789243 (p= 3.2 x 10"7- 3.6 x 10"
12). This catalysed further rational approaches to study the genetic variations of the genes
involved in xenobiotic-metabolism and epithelial transport such as the ATP-binding
cassette (ABC) efflux transporters and respective transcriptional regulators in our cohort.
Further significant and replicable association of haplotypic variations of the
ABCC3/MRP3 gene (also involved in epithelial barrier defence) with IBD (p=0.00004,
1200 IBD and 700 controls) was also shown. The characterisation of these genes in a
hitherto unknown pathway regulated by key transcriptional regulators such as Pregnane-
X receptor (PXR) has now implicated this novel class of transport proteins as important
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Ulcerative colitis represents one of the entities of inflammatory bowel diseases, a global
chronic idiopathic inflammatory condition affecting the colon and rectum. Increasing
data provide evidence of a complex interplay between components of the innate immune
system and environmental factors, notably the microflora of the intestinal mucosa. A
widely accepted hypothesis is that ubiquitous, commensal intestinal bacteria trigger an
inappropriate, overactive, and ongoing mucosal immune response that mediates intestinal
tissue damage in genetically susceptible individuals (Sartor 2006). There are now also
many studies suggesting that defective primary intestinal barrier defence plays an
important role in the pathogenesis of IBD and more recently has been referred to as 'an
archetypal barrier disease'(Schreiber et al. 2005).
1.1 Clinical features of ulcerative colitis
1.1.1 Epidemiology
In the United Kingdom, the incidence of UC is approximately 10/100 000 with a point
prevalence of 200/100 000. Ulcerative colitis may present at any age but typically in the
3rd to 4th decade (later than Crohn's disease). Men and women are equally affected. The
incidence rates for UC have remained constant in areas such as Northern Europe and
North America. In areas with previously low incidence, such as Southern Europe and
Asia, the incidence appears to be increasing although differences in case ascertainment
and study design introduce a degree of difficulty in comparing these studies(Loftus, Jr.
2004). In adults at presentation about 55% have proctitis, 30% left sided colitis, and 15%
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extensive colitis or total colitis. In children, only 25% present with proctitis alone, 30%
have left sided colitis, and in 45% the disease extends to the transverse colon or beyond.
1.1.2 Clinical presentation
The landmark paper by Felicity Edwards and Sidney Truelove in 1963, described the
clinical pattern and prognosis of 624 patients between 1938 and 1962. The age of onset
was <20 years in 10.0%, 20-59 years in 72.8% and >60 years in 17.2%. The median
decade of onset was 30-39 years (26.9%)(Edwards F.C. and Truelove 1963). This
historical data is in agreement with more recent studies(Riegler et al. 2000; Lennard-
Jones and Shivananda 1997). The major symptoms of UC include diarrhoea, rectal
bleeding and colicky abdominal pain. In a prospective Europe-wide study involving 1379
patients with UC presented over a two-year period, the predominant presenting symptoms
were increased bowel frequency (93%) and visible blood in stools (96%)(Lennard-Jones
and Shivananda 1997). This is in contrast with Crohn's disease where weight loss is
predominant (73%) and visible blood in stools occurring in only 48% of patients. The
clinical presentation varies widely but is determined by two important factors - disease
extent and severity. In patients with limited disease (rectosigmoid involvement), the
symptoms of rectal irritation namely tenesmus (the sensation of incomplete emptying),
small volume diarrhoea, proximal constipation and rectal bleeding predominate. In
contrast, in extensive colitis (beyond the splenic flexure), profuse bloody diarrhoea,
abdominal cramping and systemic features such as weight loss, fever and tachycardia are
more prominent. Symptoms tend to present insidiously but may also present acute
mimicking infective an infective aetiology.
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1.1.3 Diagnosis
The diagnosis of UC is principally based on clinical, endoscopic and histological
grounds. UC invariably affects the rectum and extends proximally to a variable distance.
The inflammation is characteristically confluent, with increased granularity and
haemorrhagic appearances. The earliest signs tend to be subtle loss of vascular patterns
with hyperaemia and oedema of the mucosa. With more active inflammation, the mucosa
becomes granular with presence of mucopus and contact bleeding. In advanced cases,
deep ulcerations may present which may mimic severe Crohn's disease. In diagnosis of
UC, 2 critical features are influential in the subsequent management namely: 1) disease
extent and 2) disease severity.
Assessment ofdisease extent
Patients with extensive disease (macroscopic evidence of colitis beyond the splenic
flexure) have an increased likelihood of medically refractory and severe disease. A
review of selected referral centre-based (Ritchie, Powell-Tuck, and Lennard-Jones 1978;
Mourn et al. 1997) and population based cohorts (Farmer, Easley, and Rankin 1993;
Langholz et al. 1994) have shown that the actuarial risk of colectomy is influenced by
disease extent. The risk of colectomy among patients with only limited proctitis ranged
from 2-9% while patients with extensive colitis had five-year colectomy rates of 30 to 44
%. The extent of disease in the acute setting can often be determined with non-invasive
methods such as a plain abdominal X-ray (demonstrating empty and/or oedematous colon
in the affected regions). Some centres advocate the use of colonoscopy but often in the
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acute setting, the medical treatment is unchanged regardless of disease extent, therefore
such practice is avoided for fear the precipitating a complication. In the subacute or
quiescent phase, disease extent can often be determined using histological methods if the
colonoscopic evidence is equivocal. Disease extent is not a static phenomenon and the
risk of disease extension of distal disease is a subject of debate. In a retrospective study
of 145 patients with distal colitis at presentation, disease extension proximal to sigmoid
was 36% at a median of 6 years, becoming extensive in 29%. Using actuarial analysis,
disease extension was predicted for 16% (95% CI 11-24%) at 5 years and 31% (95% CI
23-40%) 10 years after diagnosis(Ayres et al. 1996). In a further study, Langholz et al. in
a longitudinal population-based actuarial analysis suggest that 30% of patients with
originally limited disease may progress to more extensive disease after 5 years of follow-
up(Langholz et al. 1994). If progression can occur in limited disease, then regression
might be expected in a proportion with extensive disease. In a cohort comprising of 399
patients with UC, endoscopic regression occurred in 22% with histological regression in
24%(Moum et al. 1997). It is of course noteworthy that patient with extensive disease
may have no clinical or histological evidence of colitis when in remission (indeed in this
study, 30% of patients had a subsequently normal colonoscopy 14 months after




The risk of colectomy in UC is also strongly associated with initial presentation with
severe attack ofUC(Sinclair, Brunt, and Mowat 1983; Langholz et al. 1994). The severity
of disease is defined clinically by a series of observations basically describing profuse
bloody diarrhoea with the presence of systemic sypmtoms. The most widely use criteria
was defined by Truelove and Witts by the presence of stool frequency (>6 bloody
motions/day) together with one or more of these features, tachycardia, fever, anaemia or
elevated inflammatory markers (ESR > 30mm/hour). In the landmark paper describing
the first controlled trial of oral cortisone in patients with ulcerative colitis in 1955, the
mortality rate from severe UC in the placebo arm was 24%(Truelove SC and Witts LJ
1955). The morbidity associated with severe attacks ofUC remains high and much of this
is associated with delayed surgery and also prolonged exposure to high-dose
corticosteroid therapy. It remains uncertain however, which patients will develop severe
disease and in those who have severe disease, which patients are unlikely to respond to
corticosteroids. In a long term follow-up study involving 1116 patients in the Cleveland
Clinic diagnosed with UC between 1960 and 1983, Farmer et al. demonstrated that 13%
of these patients presented with severe UC within 2 years of diagnosis(Farmer, Easley,
and Rankin 1993). It is noteworthy that Langholz et al., in a cohort of 1161 patients with
UC based in Copenhagen, Denmark, also showed that 9% of patients required colectomy
for severe disease within the first 2 years of presentation(Langholz et al. 1994).
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1.1.4 Current therapeutic strategies and problems
Induction of remission
As with the clinical course of UC, treatment strategies depend on 2 critical factors:
namely disease extent and severity. The focus of treatment is based on the induction and
maintenance of remission. 5-aminosalicylic acid (sulphasalazine and mesalazine) is
considered as first-line therapy for active mild-moderate, left-sided or extensive
ulcerative colitis. With modern delayed-release formulations, conventional doses are very
well tolerated, and there is accumulating evidence that increasing the dose, to >4 g/day,
leads to higher response rates and earlier symptom relief in patients with ulcerative
colitis(Sutherland and Macdonald 2006a; Hanauer 2006). The combination of oral and
rectal (enema) formulations of 5-aminosalicylic acid leads to faster and higher remission
rates(Vecchi et al. 2001; Marteau et al. 2005). Despite the fact that clinical trials in
ulcerative colitis have often used different endpoints, making it difficult to make
objective comparisons, the evidence now strongly suggests that it is appropriate to start
patients with mild or moderately active ulcerative colitis on doses of 5-aminosalicylic
acid of at least 4 g/day(Hanauer 2006; Travis 2006). In left-sided disease, the treatment of
choice is topical therapy namely by the use of foam or retention enemas, and
suppositories. The use of topical therapy is advantageous in delivering high doses of anti¬
inflammatory therapy directly to the site of inflammation with little systemic absorption
and adverse effects. Typically the choice of topical therapy is either 5-aminosalicylate or
corticosteroids enemas. Recent data have shown that 5-ASA is more efficacious than the
latter, and therefore should be used as first-line. In patients with proctitis (rectal
involvement only), the use of enemas can by-pass the rectum and therefore result in
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apparent lack of efficacy. In these circumstances, rectal 5-ASA suppositories may be
more useful. The use of topical therapy is often the subject of personal preference; but is
superior to oral 5-ASA in distal disease. Traditionally, oral 5-ASA is given in the form of
sulphasalazine (5-ASA as an active ingredient linked to a carrier sulphpyridine molecule
which is absorbed systemically after the digestion of the Azo-bond by bacteria). The
more modern 5-ASA therapy is based on mesalazine formulation which relies on either
pH-dependent or time-release release formulation in the colon. Although the Cochrane
Systematic review revealed no differences in efficacy and cost-effectiveness between
sulphasalazine and mesalazine, the use of 5-ASA has shifted away from the
sulphasalazines due to the adverse effect of profiles of headache, nausea and in males,
reversible oligospermia(Sutherland and Macdonald 2006b; Sutherland et al. 2002).
In patients with more extensive or severe disease, or with disease unresponsive to oral 5-
ASA, corticosteroids are required to induce remission. Although effective in the short
term (in up to 70% of the cases), the adverse effect profile of corticosteroids needs to be
borne in mind as a substantial proportion of patients will relapse or fail to respond in the
medium term(True!ove SC and Witts LJ 1955). Based on 2 inception cohort studies,
approximately 50% of patients treated with corticosteroids will either require surgery or
be corticosteroid dependent after one year of the initiation of therapy(Faubion et al. 2001;
Ho et al. 2006a). Patients with extensive and severe disease are more likely to fail to
respond to corticosteroids(Ho et al. 2006a; Jarnerot, Rolny, and Sandberg-Gertzen 1985).
The use of corticosteroids indeed has no place in the maintenance of remission of UC.
Although factors such as underdosing and abrupt tapering of corticosteroids could be
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responsible for failure of this therapy, a prospective study involving 48 consecutive
patients with active CD, using a higher oral corticosteroids dose and a slower tapering
schedule than used in the previous studies reported steroid dependency and resistance
rates of 63% and 13%, respectively(Reinisch et al. 1995). In patients with acute severe
UC requiring intensive in-patient medical therapy, the typical dosing regime would be
60mg/day of intravenous methylprednisolone or 400 mg of hydrocortisone, for 5 days.
Oral corticosteroids are usually 40-60mg/day and reducing by 5mg/week (total duration
of therapy - 2 months)(Carter, Lobo, and Travis 2004).
There is considerable data on the short- and long-term use (with safety data) of
ciclosporin in acute severe UC. Ciclosporin acts mainly by inhibiting T lymphocyte
function, which is essential for the propagation of inflammation. Unlike most other
immunosuppressive agents, ciclosporin does not suppress the activity of other
haematopoietic cells, does not cause bone marrow suppression and has a rapid onset of
action. Controlled trial data have shown that high-dose intravenous ciclosporin (4 mg/kg)
induces clinical response in 60-80% of patients with severe active ulcerative
colitis(Lichtiger et al. 1994; Carbonnel et al. 1996). Although most side-effects are minor
and managed with mild adjustments in dose, the incidence of severe and sometimes fatal
opportunistic infections, most notably Pneumocystis carinii pneumonia, raises serious
concerns and has to an extent restrict the usefulness of such treatment(Quan et al. 1997).
Results data have shown that a lower dose of intravenous ciclosporin (2 mg/kg) or
ciclosporin monotherapy are equally in severe ulcerative colitis without increased
toxicity(Van Assche et al. 2003; D'Haens et al. 2001). Long-term follow-up studies of
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patients with severe ulcerative colitis treated with ciclosporin have shown that 53-62%
avoid colectomy at 3-5 year follow-up(Stack, Long, and Hawkey 1998; Cohen, Stein,
and Hanauer 1999; Campbell, Travis, and Jewell 2005). Nevertheless, the use of
ciclosporin is based on the premise of bridging to more effective longer term
immunosuppression. Addition of azathioprine or 6-mercaptopurine to treatment regimens
is recommended for all patients who respond to ciclosporin, since these drugs help avoid
further colectomy in the transition to long-term therapy and might give a better quality of
life than colectomy(Cohen RD, Brodsky AL, and Hanauer 1999). The use of oral
ciclosporin is considerably less efficacious, but results from unmasked studies suggest
that microemulsion ciclosporin (Neoral), which has better oral absorption, could be a
more cost effective maintenance therapy for some patients(Actis et al. 1998; Navazo et
al. 2001).
The use of infliximab, a chimeric monoclonal antibody directed against tumour necrosis
factor-alpha (TNF-a) has recently been shown to be effective in moderate to severe UC.
In the ACT-1 and 2 randomized controlled trial involving a total of 728 patients
comparing the use of infliximab with placebo, significantly higher response rates where
observed after 8 weeks and 1 year of therapy(Rutgeerts et al. 2005). In ACT 1 at week 8,
69.4 percent of patients in the group receiving 5 mg/kg of infliximab (84 of 121) and 61.5
percent of patients in the group receiving 10 mg/kg of infliximab (75 of 122) had had a
clinical response, as compared with 37.2 percent of patients in the placebo group (45 of
121, P<0.001 for both comparisons). In ACT 2 at week 8, 64.5 percent of patients in the
group receiving 5 mg of infliximab (78 of 121) and 69.2 percent of patients in the group
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receiving 10 mg of infliximab (83 of 120) had had a clinical response, as compared with
29.3 percent of patients in the placebo group (36 of 123, PO.OOl for both comparisons).
In both studies, the proportions of patients who had a clinical response or remission at
weeks 8 and 30, and at week 54 in the ACT 1 trial, were higher by a factor of 1.7 to more
than 2 in the infliximab groups than in the placebo groups. The rates of clinical response
were similar between the subpopulations of patients who were corticosteroid-refractory
and those who were not corticosteroid-refractory. In an earlier controlled-trial, infliximab
was not found to be superior in the subgroup of patients with moderate to severe
corticosteroid dependent/resistant UC(Probert et al. 2003). In acute moderate to severe
UC, Jarnerot et al. has demonstrated that a single infusion of infliximab at 5mg/kg to be
effective in inducing remission (p=0.017, odds ratio 4.7)(Jarnerot et al. 2005a). Patients
were randomized to infliximab/placebo either on day 4 after the initiation of
corticosteroid treatment if they fulfilled the index criteria for fulminant ulcerative colitis
on day 3 or on day 6-8 if they fulfilled index criteria on day 5-7 for a severe or
moderately severe acute attack of ulcerative colitis with the primary end-points being
colectomy or death 3 months after initiation of therapy. There were no differences in
adverse effects in this study. There is no extensive experience in the use of infliximab in
UC and the long term safety and efficacy of infliximab in UC is unclear. The current
strategy and positioning of infliximab, as with ciclosporin, is to use this as a 'bridge' to
longer term immunosuppressive maintenance treatment such as azathioprine.
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Maintenance of remission
The cornerstone of maintenance of remission is based on 5-ASA therapy. Several clinical
studies have shown that the use of 5-ASA therapy reduces the likelihood of relapse over a
year-therapy by threefold (from a likelihood of relapse of 70-80% without therapy to 10-
30% on 5-ASA maintenance therapy per year). Systematic reviews have confirmed the
superiority of sulphasalazine and mesalazine in maintaining remission(Sutherland and
Macdonald 2006a). A Peto odds ratio of 0.47 (95% CI, 0.36 to 0.62) and number-needed
to treat of 6 based on meta-analysis of 881 patients with the failure to maintain
endoscopic or clinical remission used as outcomes (withdrawals and relapses as defined
by each study). 5-ASA was observed to be significantly more effective than placebo in all
dosage subgroups (<1 g/d, 1-1.9 g/d, >or=2 g/d); however, a dose-dependent trend was
not observed (P = 0.489). There are less data regarding dose-related benefits of
aminosalicylates to maintain remissions in UC greater than 1.6 g/day of mesalazine,
although the absence of dose-related side effects allows continuation of the same
inductive dose through maintenance treatment without dose-related toxicity(Hanauer et
al. 2005; Paoluzi et al. 2005; Fockens et al. 1995).
Azathioprine and 6-mercaptopurine are purine analogues that competitively inhibit the
biosynthesis of purine nucleotides. Azathioprine is the pro-drug of 6-mercaptopurine.
These immunosuppressants are established therapy in the management of IBD and have
been used in the clinical setting for 30 years with clinical benefit evident in up to two-
thirds of the patients although the specific mode of action in IBD is not well-understood
(George et al. 1996; Pearson DC et al. 1995; George et al. 1996; Lamers CB et al. 1999).
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Clinical data pertaining to their respective efficacy are based on older clinical studies
(Jewell and Truelove 1974; Kirk and Lennard-Jones 1982; Rosenberg et al. 1975;
Hawthorne et al. 1992; Fraser, Orchard, and Jewell 2002). The use of Azathioprine has
been focussed on the group of patients with corticosteroid-dependent UC or frequent
relapses (>2 episodes/year). In a recent study by Ardizzone et al., azathioprine has been
shown to be particular benefit in patients with corticosteroid dependency compared with
mesalazine therapy(Ardizzone et al. 2006). In this study, significantly more patients in
the azathioprine than in the 5-aminosalicylic acid group had clinical and endoscopic
remission, and discontinued steroid therapy, both in the intention to treat (azathioprine v
5-aminosalicylic acid: 19/36 patients (53%) v 7/36 (21%); odds ratio (OR) 4.78 (95%
confidence interval (CI) 1.57-14.5)) and per protocol (azathioprine v 5-aminosalicylic
acid: 19/33 patients (58%) v 7/34 (21%); OR 5.26 (95% CI 1.59-18.1))
analysis(Ardizzone et al. 2006). One limitation of this drug is that adverse drug reactions
to AZA or 6-MP occur in 15% to 28% of patients(Present et al. 1989; Schwab et al. 2002;
Lennard 2002; Ansari et al. 2002; Sandborn 1998) and often necessitate withdrawal of
therapy. These side-effects are typically gastrointestinal in nature (nausea, vomiting and
abdominal pain - up to 28%) and less commonly leucopaenia (5%), pancreatitis (3%),
hepatitis (0.3%) and infections (7.4%). The most serious adverse effect is profound bone
marrow suppression in patients (1 in 300 individuals) who are deficient in thiopurine
methyl transferase (TPMT) enzyme involved in the metabolism of Azathioprine/6-
mercaptopurine. Genetic polymorphisms within the TPMT gene are associated with this
deficiency and the genotype or TPMT activity is routinely measure at or before the
commencement of this therapy(Black et al. 1998; Collie-Duguid et al. 1999; Colombel et
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al. 2000; Evans et al. 1991). In patients who cannot tolerate Azathioprine due to
predominantly gastrointestinal side-effects (excluding those with hypersensitive or
idiosyncratic reactions - pancreatitis and severe myelosuppression), 6-mercaptopurine
can be used and effective in up to 50% in this subgroup(Carter, Lobo, and Travis 2004).
The therapeutic regime is based on 2mg/kg for Azathioprine or 1 mg/kg for 6-
mercaptopurine. The therapeutic effect for Azathioprine and 6-mercaptopurine is usually
optimally observed 2-3 months after the initiation of therapy therefore a good overlap
with corticosteroid therapy is often necessary. Patients who take azathioprine should
avoid allopurinol (a xanthine oxidase inhibitor) as it inhibits the breakdown of
azathioprine and results in an increased risk ofmyelosuppression.
Other therapies such as methotrexate(Oren et al. 1996; Cummings et al. 2005),
tacrolimus(Baumgart et al. 2006; Hogenauer et al. 2003), mycophenolate mofetil(Orth et
al. 2000), heparin(Ang et al. 2000; Panes et al. 2000; Dotan I et al. 2001; Torkvist L et al.
1999), nicotine, antibiotics(Gionchetti et al. 2006), probiotics(Bibiloni et al. 2005),
biological therapies such as anti-CD25 (basiliximab) (Creed et al. 2003; Van Assche et
al. 2006), anti-alpha4 beta7 integrin (natalizumab)(Feagan et al. 2005), ICAM-1
(alicaforsen)(van Deventer et al. 2006), epidermal growth factor enemas(Sinha et al.
2003); helminth therapy(Summers et al. 2005), leukocyte apheresis(Sandborn 2006) and
aloe vera(Langmead et al. 2004) have been described. These therapies are not presently
established within clinical practice, in particular some biological therapies remain in
evaluation within clinical trials.
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1.1.5 Corticosteroid resistance/dependence in IBD
As discussed earlier, corticosteroid therapy remains the first-line therapy in the treatment
of active moderate to severe IBD. It is evident that a subset of patients will fail to respond
to this treatment, whether acutely or chronically and require surgery as a consequence. It
is conceivable that the both elements of the function of 'aggressive' disease and
corticosteroid resistance play significant roles in the ultimate failure of medical therapy
and the need for surgery as the definitive treatment for UC. It is often assumed that
responsiveness to corticosteroid treatment in IBD is simply a function of disease severity.
However, even in some mild cases, failure of this therapy is not uncommonly seen. As
with other inflammatory conditions, this phenomenon is also seen in conditions such as
rheumatoid arthritis, asthma and systemic lupus erythematosus (SLE)(Carmichael et al.
1981; Seki M etal. 1998; van Schaardenburg D etal. 1995).
Historically, two pivotal studies have highlighted the scale of the problem associated with
corticosteroid resistance and dependence(Munkholm et al. 1994; Faubion et al. 2001).
Munkholm and colleagues prospectively studied the outcome of the first corticosteroid
treatment in patients with newly diagnosed Crohn's disease between 1979 and 1987 in
Copenhagen, Denmark(Munkholm et al. 1994). In this cohort, 109 patients (56%) were
treated with corticosteroids. Complete remission was obtained in 48%, partial remission
in 32%, and no response in 20% within 30 days of treatment. Among the primary
responders (complete and partial remission), only 55% remained in prolonged response
after treatment had finished, while as many as 45% relapsed or could not be withdrawn
from treatment within one year. There were no relationships between the outcomes of
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therapy with disease localization, age, sex or clinical symptoms. Therefore, a prolonged
steroid response was only evident in 44%; with 36% and 20% of patients demonstrating
corticosteroid dependence and resistance respectively.
Faubion and colleagues further demonstrated that the rates of corticosteroid dependence
and resistance were similar in Crohn's disease and UC(Faubion et al. 2001). In this
inception cohort based in Olmstead County, Minnesota, all newly diagnosed patients
(173 Crohn's disease and 185 UC) diagnosed between 1970 and 1993 were assessed. The
investigators found the use of corticosteroids at diagnosis to be common, seen in 43%
and 34% patients with UC and Crohn's disease respectively. Within 30 days of the
initiation of therapy, 58% and 26% of patients with Crohn's disease responded
completely and partially respectively; whereas 16% showed no response. In UC, 54% and
30% responded completely and partially respectively; whereas 16% showed no response.
One-year outcomes for Crohn's disease were prolonged response in 24 (32%),
corticosteroid dependence in 21 (28%), operation in 28 (38%), and lost to follow-up in 1
(1%). One-year outcomes for ulcerative colitis were prolonged response in 31 (49%),
corticosteroid dependence in 14 (22%), and operation in 18 (29%). A high frequency of
surgical intervention was reported in corticosteroid dependent (26%) and resistant
patients (59%) within 1 month after corticosteroid treatment(Munkholm et al. 1994).
Although factors such as underdosing and abrupt tapering of corticosteroids could be
responsible for failure of this therapy, a prospective study involving 48 consecutive
patients with active CD , using a higher oral corticosteroids dose and a slower tapering
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schedule than used in the previous studies reported steroid dependency and resistance
rates of 63% and 13%, respectively(Reinisch et al. 1995).
1.1.6 Pharmacogenetics in corticosteroid therapy
In general, although the molecular mechanisms of corticosteroids are well-known, the
underlying causes accounting for the highly variable efficacy of corticosteroid resistance
and dependence remains unresolved in inflammatory bowel disease and other
inflammatory conditions such as asthma and rheumatoid arthritis(Payne and Adcock
2001). In IBD, the overexpression of P-glycoprotein 170 (PgP, an efflux transporter gene
encoded by the multidrug resistance gene, MDR1/ABCB1) has been suggested to play an
important role. Compelling data from Farrell et al. showed that PgP expression on
peripheral blood lymphocytes in patients with IBD who have required surgery as a
consequence to failure of corticosteroid therapy, were increased compared to those
patients who have required surgery for dysplasia/obstruction(Farrell et al. 2000). Recent
genetic data have demonstrated an association between carriage of an exonic variant in
the gene, single nucleotide polymorphism (SNP) C3435T with the expression levels of
PgP(Hoffmeyer et al. 2000a). These findings are clearly exciting in light of the possibility
of identifying patients who are less likely to respond to corticosteroids using a simple
genetic test. More recently, the C3435T polymorphism has been shown to be associated
with drug-resistant epilepsy(Siddiqui et al. 2003). Patients with drug-resistant epilepsy
were more likely to have the CC genotype (high PgP expression phenotype) compared
with the TT genotype (odds ratio 2.66, 95% CI 1.32-5.38, p=0.006). Fellay et al.
demonstrated that this SNP also predicts immune recovery after initiation of antiretroviral
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treatment in HIV-infection. Patients with the TT genotype 6 months after starting
treatment had a greater rise in CD4-cell count than patients with the CT and CC genotype
(p=0.0048), and the best recovery of naive CD4-cell(Fellay et al. 2002). The
pharmacogenetic contributions of these SNPs in predicting surgery in IBD have been
studied and will be discussed in Chapter 4.
Mutations of the glucocorticoid receptor gene (GR) associated with functional changes in
the glucocorticoid receptor resulting in clinical corticosteroid resistance syndromes have
been described, but these are rare(DeRijk RH et al. 2002). However, splice variants of the
human glucocorticoid receptor are commonly present (GR-A, GR-B, GR(3, GRy and GR-
P). The GRP (an isoform of the GR-gene) in particular, has been shown to be associated
with glucocorticoid resistance although its particular function remains unclear. Honda
and colleagues reported that, GRp mRNA was detected in 83% of patients with
corticosteroid-resistant ulcerative colitis but present only in 10% of glucocorticoid
sensitive patients and controls(Honda M et al. 2000). Increased GRP expression has been
associated with corticosteroid resistance in several other inflammatory conditions, most
consistently in asthma(Hamid Q et al. 1999; Hamilos DL et al. 2001; Leung DY et al.
2000). Additional data suggests that the phenomenon of corticosteroid resistance is not
generalized but somehow compartmentalized to T-lymphocytes and possibly other target
inflammatory cells. In a prospective study of 18 patients with acute severe UC, T-
lymphocyte corticosteroid resistance was found to be an important factor in determining
response to corticosteroid treatment(Hearing et al. 1999). The clinical relevance of these
findings have now led to the development of a novel therapy, basiliximab (anti-CD25)
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which acts as a corticosteroid-sensitizing agent and is currently under evaluation(Creed et
al. 2003).
In asthma, a reduced inhibitory effect of corticosteroids on Activated Protein-1 (AP-1)
activation and cytokine expression has been shown in corticosteroid resistant patients,
possibly due to enhanced AP-1 activation(Matthews et al. 2004; Adcock et al. 1995)
(Sousa et al. 1999). The resultant increased activation of AP-1 was postulated to lead to
sequestration ofGR, thus preventing interaction with other proteins resulting in resistance
at the site of inflammation where cytokines are produced, for example, in the airways of
asthmatic patients but not at non-inflamed sites. This may explain why patients with
corticosteroid-resistant asthma are not resistant to the endocrine and metabolic effects of
corticosteroids and therefore develop corticosteroid side-effects(Lane et al. 1996). Other
explanations for these differential responses have also been suggested including abnormal
histone deacytelation activity in controlling gene transcription(Ito et al. 2006).
1.1.7 Surgery
The indications for surgery are usually categorised into emergency and elective
operations. In the former, the absolute indications for surgery are perforation, massive
haemorrhage with commoner indications being failed medical therapy and toxic
megacolon. The timing of emergency in the case of failed medical therapy or toxic
megacolon is dependent on careful joint medical-surgical decision. The consideration of
whether second-line medical therapy is indicated ahead of early colectomy in severe
disease can be difficult. Some centres view the presence of megacolon as an indication
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itself for surgery whereas other centres adopt a more conservative medical
approach(Kamm 2004; Cima and Pemberton 2004). For the elective indications for
surgery, these are usually based on patients with chronic continuous symptoms,
corticosteroid dependency, partial response to medical therapy and the presence of
malignancy/dysplasia. Generally, 4 surgical approaches are considered:
• Total colectomy with end ileostomy
• Proctocolectomy with the formation of ileo-anal pouch (IPAA).
• Protocolectomy with ileo-rectal anastamosis
• Proctocolectomy with the formation of a continent ileostomy or Kock's pouch.
There is general agreement that the operation of choice in the emergency situation is
colectomy with ileostomy and the preservation of the rectum(Nicholls 2002). In the acute
post-operative setting, the risk of serious complication relates in part to the possibility of
rectal stump dehiscence. In this setting, the principle of operation has centred on the
preservation of a lengthy rectal remnant (with or without a mucous fistula) which would
enable the exteriorization in the case of rectal stump leak or retraction.
The choice of surgery is rather individualised in part depending on patient's perceptions
and psycho-social situations. Total proctocolectomy with construction of an ileal pouch
anal anastomosis (IPAA) has become the standard of care for patients with UC who
require removal of the colorectum. This surgery involves abdominal colectomy and
construction of an ileal pouch that is anastomosed to the anus. In younger patients, the
option of ileo-anal pouch is more attractive as it would avoid the need of a stoma thus
preserving continence allowing a more active lifestyle e.g. sports. The majority of
patients with UC that undergo IPAA report improved quality of life after surgery (Bach
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and Mortensen 2006). A growing number of complications however, can impact
adversely on the long-term outcome of these patients. The most common and widely
reported of these complications is a nonspecific inflammation of the ileal pouch, a
condition referred to as "pouchitis". Pouchitis is manifest clinically as a syndrome of
watery, frequent diarrhea or hematochezia, accompanied by urgency, incontinence,
abdominal cramping, malaise, and fever. The cumulative probability of pouchitis,
determined on the basis of symptoms, endoscopy, and histopathology in 468 IPAA
patients was 20% at 1 year, 32% at 5 years, and 40% at 10 years(Lepisto, Luukkonen,
and Jarvinen 2002). In contrast, no pouchitis occurred following operation for FAP (7%
of the total). These rates are in accordance with those of other centers. The incidence of
pouchitis appears to be independent of surgical technique with respect to pouch
construction, use of a defunctioning stoma, or laparoscopic techniques (Oresland et al.
1990; Heuschen et al. 2001a; Sagar et al. 1992; Pace et al. 2002). Patients with primary
sclerosing cholangitis are more prone to develop pouchitis, with a cumulative probability
of 79% at 10 years(Penna et al. 1996). Persistence of extraintestinal manifestations of UC
has also been linked to an increased risk of developing pouchitis, and certain patients
exhibit a temporal relationship between their pouchitis and extraintestinal symptoms akin
to that described for UC, fueling speculation that these 2 inflammatory processes
represent variations of the same underlying condition(Lohmuller et al. 1990).
Perpetuating this theme, smoking is considered to be protective against UC(Beaugerie et
al. 2001) and also reduces the incidence of pouchitis(Merrett et al. 1996; Stahlberg et al.
1996). The incidence of pouch failure is reported to be 10% at 10 years, with severe
pouchitis accounting for 10% of failures(Bach and Mortensen 2006).
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Other complications of IPAA include the subsequent development of Crohn's disease in
the pouch, cuffitis (inflammation in the rectal cuff), and irritable pouch syndrome
(symptoms of abdominal pain and/or diarrhea in the absence of ileal pouch mucosal
inflammation).In some cases, ileo-rectal anastamosis maybe a more attractive option in
young females patients in order to avoid protectomy and pelvic dissection, with the issues
of fecundity and fertility in mind. Johnson et al examined fertility rates in married or
cohabiting females ages 18 to 44 years with a history of UC(Johnson et al. 2004). Of 153
patients, 59 (38%) who had undergone IPAA were unable to conceive following 1 year of
unprotected intercourse compared with 8/60 patients (13%) subject to medical
management alone. The authors concluded that whereas a diagnosis of UC did not affect
fertility, pouch surgery was associated with a 98% reduction. Surgeons may consider
delaying proctectomy until a family has been established.
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1.1.8 Malignancy risk
Patients with ulcerative colitis have a higher risk of colorectal cancer than the general
population. Disease extent and duration are the two critical factors underlying this
association although recent data also suggest disease severity may also be influential.
Ekbom and colleagues reported standardised incidence ratios for colorectal cancer risk of
1.7 for patients with proctitis, 2.8 for patients with disease extending beyond the rectum
but no further than the hepatic flexure, and 14.8 for patients with disease extending
beyond the hepatic flexure(Ekbom et al. 1990). A family history of colorectal
cancer(Askling et al. 2001)and the presence of primary sclerosing cholangitis(Jayaram,
Satsangi, and Chapman 2001) and backwash ileitis(Heuschen et al. 2001b) are also
independently associated with increased cancer risk. Continuation of maintenance 5-
aminosalicylate(Eaden et al. 2000) and sulfasalazine(Pinczowski et al. 1994), cigarette
smoking(Pinczowski et al. 1994), and possibly folic-acid' and vitamin-E supplementation
are protective factors(Lashner et al. 1997). In a study by Eaden et al., a relative reduction
of 75% in risk of cancer was demonstrated in those patients regularly taking 5-
aminosalicylates, even adjustment for low-dose mesalazine (1.2 g daily)(Eaden et al.
2000). A further study by Rutter et al., showed that histological evidence of severe
disease further substratify patients who developed dysplasia or malignancy(Rutter et al.
2004a). The biological explanation of the protective effect of 5-ASA is unclear but may
represent a surrogate marker of good disease control. Colorectal cancer in ulcerative
colitis is more likely to have a uniform distribution throughout the colon, affect more
than one area, and present at a higher grade at diagnosis(Ekbom et al. 1990). Recognition
of dysplasia as a precursor to cancer in ulcerative colitis supports the rationale for
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performing regular surveillance by colonoscopy, but the benefits, reliability, and cost of
surveillance programmes are not clear(Eaden and Mayberry 2002; Rutter et al. 2006).
The current guidelines recommend those patients who have had extensive ulcerative
colitis for 7-8 years and those who have had left-sided disease for 15 years should be
enrolled in surveillance programmes, but there are inconsistencies exist in clinical
practice. A further recent study by Rutter et al., suggest that endoscopic appearances
predict the risk of dysplasia/malignancy(Rutter et al. 2004b). In this case-control study,
cases were significantly more likely to have post-inflammatory polyps (OR 2.14 95%
confidence interval 1.24-3.70), strictures (OR 4.22; 1.08-15.54), shortened colons (OR
10.0; 1.17-85.6), tubular colons (OR 2.03; 1.00-4.08), or segments of severe
inflammation (OR 3.38; 1.41-10.13), and less likely to have had a macroscopically
normal looking colonoscopy (OR 0.40; 0.21-0.74). After multivariate analysis, a
macroscopically normal looking colonoscopy (OR 0.38; 0.19-0.73), post-inflammatory
polyps (2.29; 1.28-4.11), and strictures (4.62; 1.03-20.8) remained significant. The five
year risk of colorectal cancer with a macroscopically normal colon was no different from
that of matched general population controls.
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1.2 Predicting outcome in severe ulcerative colitis
Historically, 15% of patients with ulcerative colitis will develop a severe attack of colitis
requiring intensive in-patient medical therapy. In those who have developed severe
disease, consistent data over the last 40 years have shown that 30-40% of patients will
fail to respond to high dose intravenous corticosteroids and in-patient supportive
management and require colectomy (Table 1). The mortality associated with such attacks
has fallen from levels of 31-61% to the present level of 1-2% following the introduction
of high dose corticosteroid therapy, better joint medical-surgical management and the
acceptance of a policy of early surgery in patients not responding to medical
therapy(Truelove et al. 1978). The morbidity associated with severe attacks of UC
remains high and much of this is associated with delayed surgery and also prolonged
exposure to high-dose corticosteroid therapy.
1.2.1 Clinical predictive factors
The current improvements in the rates of morbidity and mortality in severe UC have
arisen from the development of an integrated medical-surgical care and the policy of
early selection of patients requiring emergency colectomy in severe UC. These
developments are catalysed by studies identifying clinical parameters and early
prognostic markers associated with failure of medical therapy. Truelove and Witts
initially demonstrated that the severity of presentation of UC predicted the likelihood of
non-response to corticosteroid therapy. In their study involving a cohort of 210 patients
with chronic UC, 10 of 31 patients (32%) with severe disease entered remission
compared with 18 of 24 patients (75%) with mild disease (p=0.075).
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Table 1: Rate of failed medical therapy in acute severe ulcerative colitis
Author Year Rate of medical failure (%)
Lennard Jones et al. 1975 25
Jarnerot et al. 1985 40
Chakaravarty et al. 1993 28
Travis et al. 1996 29
Lindgren et al. 1998 34
Carbonnel et al. 2000 48
Ho et al. 2004 40
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Further clinical studies have therefore attempted to improve the ability to predict failure
of medical therapy within the patients wuth acute severe UC. In a large cohort from St.
Mark's Hospital, London; Lennard-Jones et al. examined 56 clinical features in 181 acute
colitis admissions over a 5-year period, and showed that the variables most predictive of
surgery were a combination of fever (>38 C) and a stool frequency of > 8/24 hours. X-ray
features of colonic dilatation and mucosal islands were also associated with more severe
disease(Lennard-Jones et al. 1975). The importance of serum albumin as a prognostic
factor was demonstrated in a parallel publication, where the serum proteins were
evaluated by the same investigators in 36 patients presenting with 39 episodes of acute
severe UC(Buckell and Lennard-Jones 1979). Hypoalbuminaemia (<20g/L) and total
protein concentrations <60g/L were each associated with an operative rate of >60%
(p<0.05). A subsequent study reported a significant correlation between serum albumin
levels and colonoscopic activity of UC (r=50.48; p<0.05)(Buckell et al. 1979).
Chakravarty et al. reported a single centre experience involving 89 patients with acute
UC treated over a 6-year period (Chakravarty 1993). In this study, the need for surgery
was significantly associated with high stool frequency (p=0.0001) and low albumin levels
(mean 30.0 vs. 38.1 g/L; p=0.0001).
1.2.2 Endoscopic and radiological predictors of outcome
So far, the studies described have only shown the discriminant values of simple clinical
features and laboratory parameters in severe UC. There remains a question of whether
radiological or endoscopic tests can be beneficial or additive to the above. It is currently
accepted that the most useful radiological finding is the presence of colonic dilatation
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(defined by the presence of an inflamed colon with the transverse colon or caecum dilated
to 5.5 or 9 cm respectively). This finding reflects the loss of tensile strength of the colon
as a result of very advanced tissue damage from inflammation leading dilatation and an
increased likelihood of perforation. In some centres, colonic dilatation may itself be an
indication for surgery. In addition, the development of colonic dilatation in severe UC
may be heralded by abnormal small bowel distension. The presence of small bowel
distension (more than 2-3 loops) has been shown to be increased in non-responders
compared with responders to medical therapy in severe UC (73% vs. 43%,
p<0.05)(Chew, Nolan, and Jewell 1991). In a further study involving 69 consecutive
patients with severe UC, the presence of small bowel distension was shown to be
associated with future development of colonic dilation(Caprilli et al. 1987). The presence
of mucosal islands may indicate impending dilatation and disintegration, and are
associated with a poor outcome(Travis et al. 1996).
In a cohort consisting of 85 patients with severe UC, Carbonnel and colleagues studied
the value of combined colonoscopic findings with clinical and laboratory data(Carbonnel
et al. 1996). The presence of severe colitis at endoscopy, the presence of Truelove and
Witts' criteria and duration of relapse of greater than 6 weeks, were demonstrated to be
significant predictors of colectomy in this study. The presence of two of these criteria
would lead to 75-86% risk of colectomy within 30 days of presentation. The importance
of deep ulcerations as determined endoscopically was highlighted in this study. Forty-
three patients (94%) demonstrating this endoscopic feature, required emergency
colectomy, with 5 (11%) patients demonstrating features of colonic dilatation.
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Although the use of air, barium and air/barium enemas have been shown to be useful in
detecting deep ulceration and to correlate well with histological assessment (Aimer et al.
1995; Buckell et al. 1979), none of the above imaging modalities has gained widespread
acceptance.
Table 2: The identification of clinical, radiological, endoscopic and biological
parameters of poor outcome in severe ulcerative colitis
Author (year) Prognostic factors
Truelove (1955) Truelove and Witts' criteria
Lennard-Jones (1975)
Fever >38°C + >8 stools/day at 24h
Colonic dilatation and hypoalbuminaemia
Buckell (1979) Hypoalbuminaenia
Buckell (1980) Colonic dilatation on AXR
Chew (1991) Small bowel distension, pan-colitis on AXR
Aimer (1985) Ulcers on air enema, fever >380C, low albumin
Carbonnel (2000)
Severe endoscopic colitis, relapse>6 weeks, Truelove and
Witts' criteria
Chakravarty (1993) Stool frequency, hypoalbuminaemia
Travis (1996)
Stool frequency >8, or 3-8 stools and CRP > 25 mg/1 at
day 3
Lindgren (1998) Fever for >24h, day 3 stools >4 and CRP > 25 mg/L
Rowe (2000) High percentage of band neutrophils on admission
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1.2.3 Statistical modelling in predicting outcome
Although the identification of clinical and endoscopic/radiological features of poor
outcome have been forthcoming, the translational challenge has lied in the assimilation of
these features into a clinically applicable model which allows for the early identification
of patients who are at high risk of failure to respond to medical therapy. This has
important implications in counselling and the reduction of morbidity/mortality which are
associated with delayed surgery and prolonged exposure to high-dose corticosteroid
therapy. The current British Society of Gastroenterology guidelines recommend the
objective evaluation of all patients with acute severe UC at day 3 of intravenous
corticosteroid therapy, to determine which patients will benefit early surgery(Carter,
Lobo, and Travis 2004).
Two models have been described in the literature to aid such clinical-decision making,
e.g. to select patients for early colectomy - the Travis criteria and the Lindgren
model(Travis et al. 1996; Lindgren et al. 1998). In a prospective study involving 49
patients with severe UC, Travis and colleagues proposed that 85% of patients with a stool
frequency of >8/day or 3-8/day with C-reactive protein of 45 mg/dl after 3 days of
intravenous corticosteroid therapy will fail to respond and require colectomy(Travis et al.
1996). During the first five days of medical therapy, stool frequency and C reactive
protein (CRP) distinguished between outcomes of surgery and early response (p <
0.00625). Lindgren and colleagues developed a regressional formulae to predict the
likelihood of medical failure - number of bowel movements +0.14x CRP (mg/l)>8.0, as
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the optimum theoretical cut-off level to predict failure of corticosteroid therapy(Lindgren
et al. 1998). Patients with a score of >8, has a 75% chance of requiring colectomy.
The clinical focus of the prediction of patients requiring early surgery using the above
two models has changed with the expansion of effective 2nd line medical therapy,
pertinently, ciclosporin and infliximab(Lichtiger et al. 1994; Jarnerot et al. 2005b). It is
now accepted that a proportion of patients will respond very favourably to intravenous
corticosteroids - and in the group of patients who do not, the dilemma arises in which
patients to treat with second-line medical therapy or early surgery. The existing models
by Travis and Lindgren do not critically assist decision-making in the selection of these
patients. For example, the Lindgren model, together with a further activity index (Seo-
index) has been applied in a Swedish-Danish study in assessing the efficacy of infliximab
in acute UC. The Seo-index is calculated at using the following formula: 60 x blood in
faeces + 13 x bowel movements/day + 0.5 x ESR - 0.4 x Hb (g/1) - 1.5 x albumin (g/1) +
200. Constants used are for blood in faeces: 0 = none, 1 = present and for bowel
movements 0 - 3 = 0, 4 = 1, 5-7 = 2, > 8 = 3. A value < 150 corresponds to remission or
mild UC, 150-220 moderately severe UC and > 220 severe UC. Only the Seo-index
appeared to be beneficial in identifying a subset of patient who may benefit from
infliximab at a later stage (days 5-7). In patients with low Seo-index, no patients treated
with infliximab compared with 62.5 % in the placebo group required a colectomy
(p=0.009). In this study, the Lindgren model (calculated at day 3) was not useful and
again highlighted the difficulties in the selection of patients who can benefit from early
2nd line medical therapy.
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1.3 Pathogenesis of inflammatory bowel disease
Both human and animal studies suggest that the intestinal inflammation in ulcerative
colitis are likely to be a consequence of environmental factors triggering a breakdown in
the regulatory constraints on mucosal immune responses to enteric bacteria in genetically
susceptible individuals(Fiocchi 1998; Podolsky 2002). The relatively weaker
concordance in monozygotic twin pairs with ulcerative colitis (6-14%) compared with
Crohn's disease (44-50%) suggest that environmental factors are more important than
genetic factors in the pathogenesis of ulcerative colitis (Orholm et al. 2000; Tysk et al.
1988b). Cigarette smoking and appendectomy are the two best-characterized
environmental factors. The protective effect of smoking (and the detrimental effect on
Crohn's disease) is the most consistent environmental factor within IBD. In a study by
Lindberg et al., the relative risks of developing ulcerative colitis in heavy ex-smokers, all
ex-smokers, non-smokers, and smokers were 4.4, 2.5, 1.0, and 0.6, respectively(Lindberg
et al. 1988). In the case for appendectomy, thirteen published studies summarised by a
recent meta-analysis have consistently demonstrated a protective effect of appendectomy
against the development of UC(Koutroubakis and Vlachonikolis 2000).
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1.3.1 Evidence of genetic susceptibility in disease pathogenesis
There are considerable epidemiological data, which implicate genetic susceptibility in the
pathogenesis of Crohn's disease and ulcerative colitis. Most notably these include the
familial prevalence of inflammatory bowel disease, concordance rates in twin pairs, and
ethnic differences in disease susceptibility. In fact, the studies of twin pairs have
provided the strongest impetus towards further investigation of genetic susceptibility in
inflammatory bowel disease. Three studies have been carried out in Europe, including
Tysk's important review of the Swedish Twin Registry in 1988(Tysk et al. 1988a;
Thompson et al. 1996; Orholm et al. 2000). The data from these studies, in Sweden,
Denmark and the United Kingdom combine to provide powerful evidence for the role of
both genetic and environmental factors in disease susceptibility. The concordance rates
for Crohn's disease in monozygotic and dizygotic twin pairs from these studies are
estimated as, respectively 37% and 7%; in ulcerative colitis, the equivalent results are
10% and 3%.
From these data, the coefficient of heritability (an estimate of the proportion of
susceptibility attributable to inherited factors alone) may be calculated. The derived
coefficient of heritability in Crohn's disease is similar to the value calculated from twin
studies carried out in insulin dependent diabetes and multiple sclerosis, and in fact is
stronger that many other common complex diseases. The genetic contribution is clearly
less strong in ulcerative colitis, but the concordance between monozygotic and dizygotic
prevalence rates again argues for a genetic and perhaps a stronger relative environmental
contribution to disease susceptibility in ulcerative colitis.
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A large number of studies have now been reported, investigating the familial aggregation
of inflammatory bowel disease. Overall, it is apparent that between 6 and 32% of
patients with inflammatory bowel disease have an affected first or second-degree relative.
The prevalence of a positive family history is highest in certain groups - risk factors for
familial inflammatory bowel disease include Jewish ancestry, and early onset disease
(Orholm et al. 1991; Roth et al. 1989; Halfvarson et al. 2003; Monsen et al. 1991; Probert
et al. 1993). These observations in themselves are important, suggesting that these
subgroups of inflammatory bowel disease may have a particularly strong genetic
contribution. The exact size of the relative risk to family members of patients with
Crohn's disease and ulcerative colitis varies from one study to another. This may reflect
the study design, or effects of ethnic and phenotypic variability on genetic contribution.
However, consistent themes are present. The relative most commonly affected is the
sibling of the patient with inflammatory bowel disease. Parents, offspring and second-
degree relatives appear to have a lower risk. The data, which have further excited
geneticists, have been the relative risk to siblings (lambda S) in Crohn's disease and
ulcerative colitis. This ratio has been estimated as between 13 and 36 in Crohn's disease,
and between 7 and 17 in ulcerative colitis. Equivalent figures in type I diabetes,
schizophrenia and cystic fibrosis are 15, 8.6, and 400 respectively.
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The development of a linkage map of the human genome with informative microsatellite
markers has enabled hypothesis-free scanning of the human genome for loci associated
with susceptibility to simple monogenic and polygenic diseases. In the recent years,
significant progress has been achieved using molecular data from genome-wide linkage
studies of multiply affected IBD families. Genome wide scanning has identified
susceptibility loci for Crohn's disease on chromosomes 1 (Cho et al. 1998b), 5
(IBD5)(Rioux et al. 2000a; Rioux et al. 2001b), 6 (1BD3; HLA)(Hampe et al. 1999a;
Rioux et al. 2000b), 12 (IBD2)(Satsangi et al. 1996a), 14 (IBD4) (Ma et al. 1999b; Duerr
et al. 2000b), 16 (lBDl)(Hugot et al. 1996a; Satsangi et al. 1996c) and 19 (IBD6) (Rioux
et al. 2000c). The most consistently replicated Crohn's disease susceptibility locus is
located on chromosome 16 (IBD1) and the susceptibility gene has been identified as the
CARD15 (NOD2) gene (Hugot et al. 2001b; Ogura et al. 2001a). These studies have been
remarkably successful in identifying a number of susceptibility loci, with convincing
replication shown for at least 7 loci (IBD1-7) (Table 3). Until 2006, the success of
identifying genes that confer susceptibility to IBD has been based on the platform of the
data generated from these genome-wide linkage studies, which is discussed in the
following chapter. The publication of genome wide association studies (GWAS) which
utilised up to 500 000 SNPs per individual represents a further shift in the progress of
IBD genetics.
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IBD1 16ql 2 (Hugot et al. 1996b) CD
IBD2 12q 13 (Satsangi et al. 1996b) UC
IBD3 6p 13 (Hampe et al. 1999b) CD, UC
IBD4 14q 11 (Ma et al. 1999a), (Duerr et al.2000a)
CD
IBD5 5q31-33 (Rioux et al. 2001a) CD
IBD6 19pl3 (Rioux et al. 2000d) CD, UC
Other loci lp36 (Cho et al. 1998a) CD, UC
Other loci 7q22 (Satsangi etal. 1996b) CD, UC
Other loci 3p (Satsangi et al. 1996b) CD, UC
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1.3.2 Genetics of Crohn's disease: from linkage to gene discovery
NOD2/CARD15 gene
Following the success of genome-wide scan studies in identifying chromosomal locus of
disease susceptibility, significant progress has been made particularly in Crohn's disease.
In 2001, 3 independent groups reported the identification of the first Crohn's disease
(CD) susceptibility gene, NOD2 (subsequently renamed CARD15 by the International
Nomenclature Committee), on chromosome 16ql2 (the IBD1 locus)(Ogura et al. 2001b;
Hugot et al. 2001a; Hampe et al. 2001). This breakthrough firmly established a role for
genetics in determining susceptibility to CD and has provided proof of principle that
model-free linkage analyses may be used successfully to identify disease susceptibility
gene loci.
Hugot and colleagues employing a classical positional cloning strategy refined the IBD1
susceptibility locus by genotyping 26 microsatellite markers spaced at an average
distance of 1 centimorgan in the pericentromeric region of chromosome 16, in 77
multiply affected families. Further genotyping and sequence analysis led to the
identification of a single gene, the now known NOD2/CARD15 gene. Within this gene,
3 SNPs showed significant evidence for linkage disequilibrium, and association with
Crohn's disease. These findings were also shown in a parallel publication by Ogura and
colleagues; these investigators utilized a candidate gene approach based on prior
knowledge of the chromosomal location of NOD2/CARD15, and encouraged by
functional and expression data implicating NOD2/CARD15 as a possible candidate in
disease pathophysiology. In addition, Hampe and colleagues reported the association of
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the 3020insC frameshift mutation with Crohn's disease in German and British
populations using parallel strategies of a family based association study, and case control
study. The authors demonstrated genotypes specific disease risks of 2.6 (heterozygous
genotype) and 42.1 (homozygous for the mutant 3020insC frameshift NOD2/CARD15
mutant allele).
Recent studies have further shown a number of associations between genotype and
phenotype(Ahmad et al. 2002; Cuthbert et al. 2002), thus adding to the complexities of
IBD and reinforcing the point that the term, IBD may in fact represent several forms of
diseases. Cuthbert and colleagues demonstrated the association between NOD2/CARD15
mutations and IBD are primarily based on the phenotype of ileal Crohn's disease. This
association was also shown in the Oxford dataset by Ahmad and colleagues who reported
detail genotype-phenotype analysis of 244 patients with Crohn's disease. The phenotype
of fibro-stenosing Crohn's disease was also associated with NOD2/CARD15 mutations,
but this association was not shown to be independent of the association with ileal
involvement. The NOD2/CARD15 gene does not appear to be associated with colonic
involvement, and may indeed be protective against colonic involvement in Crohn's
disease and ulcerative colitis.
The association of NOD2/CARD15 gene with CD also highlighted yet a further
important point - the importance of genetic heterogeneity. Reported NOD2/CARD15
carriage rates in Crohn's disease vary between 0 and 50.0%, with highest rates seen in
central European populations (Hugot et al. 2001c; Lesage et al. 2002) while mutations are
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absent in Japanese and Chinese series (Inoue et al. 2002; Leong et al. 2003). Lower
frequencies have been reported from Finland, Ireland and Scotland suggesting further
heterogeneity even within Europe (Arnott et al. 2004b; Helio et al. 2003). This would
suggest that the genetic contribution ofNOD2/CARD15 gene is less significant for some
populations, and that other genes maybe pertient in disease aetiopathogenesis.
The NOD2/CARD15 undoubtedly is the most successful example of progress from
linkage (IBD1 linkage region in chromosome 16) to gene discovery. In CD, other
progress has been forthcoming with postulated implicated genes of organic cation
transporter, OCTN1/2 (Peltekova et al. 2004) and drosophila large disc, DLG5 (Stoll et
al. 2004) genes in the IBD5 (chromosome 5q22) and IBD4 (chromosome 14q) regions
respectively. The roles of these genes however, have not been fully defined and the
associations have been inconsistent. The effects of linkage, genetic and phenotypic
heterogeneity are likely to explain some of these inconsistencies. Some authorities have
suggested that the size effect of NOD2/CARD15 gene is likely to be the ceiling of the
genetic contribution in IBD e.g. the genetic contributions of other genes will be
significantly less.
1.3.3 Genomewide association studies
With the availability and the increasing economy in high-throughput genotyping, coupled
with the knowledge of linkage disequilibrium and complete genomic variations; the
ability to catalogue the majority of the polymorphisms (300 000-500 000 SNPs using
array-based technology) in large case-control association study settings is now feasible.
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In 2007, genomewide association studies have been remarkably successful in Crohn's
disease, with the identification at the time ofwriting of 30 confirmed susceptibility genes
or loci yielding major pathogenic insights. These studies have most importantly
implicated hithertho unknown novel mechanisms involving the Thl7 (in interleukin
receptor 23 IL23R gene) and autophagy pathways (the process of self cellular digestion).
Duerr et al. observed a highly significant association between Crohn's disease and the
interleukin receptor 23, IL23R gene on chromosome 1 p31, which encodes a subunit of the
receptor for the proinflammatory cytokine interleukin-23 in an enriched cohort of ileal
CD (Duerr RH et al. 2006). This approach was used in order to address phenotypic
heterogeneity. In this study, three markers achieved genome-wide significance for which
2 of these were within the NOD2/CARD15 gene. The third marker, rsl 1209026 (P
=5.05xl0~9, corrected P =1.56 x 10^3), is a nonsynonymous SNP (c.1142G>A,
p.Arg381Gln) in the IL23R gene (GenBank accession: NM_144701 fGenBankl . GenelD:
149233) on chromosome lp31. This gene encodes a subunit of the receptor for the
proinflammatory cytokine, interleukin-23 (IL-23), and is therefore an intriguing
functional candidate. In addition to Arg381Gln, nine other markers in IL23R and in the
intergenic region between IL23R and the adjacent IL-12 receptor, beta-2 gene (IL12RB2),
had association P-values < 0.0001 in the non-Jewish, ileal CD case-control cohort. It is of
interest to note that a further uncommon coding variant (rsl 1209026, c.1142G>A,
p.Arg381Gln) confers strong protection against Crohn's disease. Replication studies
confirmed IL23R associations in independent cohorts of patients with Crohn's disease or
ulcerative colitis. These results and previous studies on the proinflammatory role of IL-23
prioritize this signaling pathway as a therapeutic target in inflammatory bowel disease.
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The presence of a protective variant also imply that the contribution of the IL23R
pathway to 1BD will likely involve more than simple gain- or loss-of-function IL23R
variants, and therapeutic interventions will be improved by a better understanding of the
context and tissue-specific events associated with functional IL23R polymorphisms.
Hampe and colleagues analysed approximately 20,000 coding SNPs (SNPlex Genotyping
system) in a North German cohort of 735 CD patients and 368 healthy controls (Hampe,
2007). 7,159 out of the 16,360 successful assays had a minor allelic frequency of >1%.
On allele-based testing for association 72 of these 7,159 were significant at p<0.01.
These SNPs were then tested in a second panel consisting 380 CD trios, 498 CD
singletons and 1,032 healthy controls. 3/72 SNPs satisfied a pre-defined statistical cut¬
off of p<0.05: rs2066845 in CARD15 (rs206684 failed genotyping; rs2066847 was not
feasible on SNPlex due to the necessary insertion design), rs 1050152 (L503F) in
SLC22A4, and rs2241880 (T300A) in ATG16L1 (autophagy-related 16-like 1 gene) on
chromosome 2q37 near a locus of susceptibility (case-control p=1.6 x 10"5; TDT p=2.7 x
10"5). After re-sequencing of ATG16L1 in 47 CD samples failed to detect any further
coding or splice site variants, 28 tagging SNPs (r2 > 0.8; MAF > 1%) were selected from
the CEU HapMap data. The results of logistic regression and haplotype analysis
suggested that the CD risk from ATG16L1 was confined to the G allele of rs241880.
Analysis of the combined cohorts gave an odds ratio of 1.45 (95% C.I. 1.21-1.74) and
population attributable risk (PAR) of 0.26 for carriage of this variant, with some evidence
for a gene dosage effect (homozygote OR 1.77, C.I. 1.43-2.18; PAR 0.17). There was no
specific sub-phenotype in CD associated with this variant, and no association with UC.
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There was, however, a statistical interaction between rs2241880 and CARD15 low-risk
haplotypes (p=0.039).
The Wellcome Trust Case Control Consortium (WTCCC) undertaken as a major
collaborative effort involving 14 000 individuals in 7 major common complex diseases
with 3 000 shared control in United Kingdom, utilizing genomewide association study
has now provided remarkable insights into the genetic architecture and new mechanisms
in disease pathogenesis (Crohn's disease, bipolar disorder, coronary artery disease,
hypertension, rheumatoid arthritis, Type 1 and 2 diabetes)(WTCC Nature). The Crohn's
dataset which represents the largest study group to date, was based on cohorts from
Edinburgh, Oxford, Cambridge, London and Newcastle (1748 CD). This study confirmed
previous associations with CARD15 (rs 17221417 p=9.4xl0"12), IL23R (rsl 1805303
p=6.5xl0"13) and ATGL16 (rsl0210302; p=5.7 x 10"14) genes in addition to several new
loci with genome-wide significance such as immunity related guanosine triphosphatase,
1RGM(p=5.1xl0"8), bassoon, BSN(p=l .4x10"8), NK2 transcription factor related, locus 3,
NKX2-3 (p=7.7xlCT7) and protein tyrosine phosphatase, nonreceptor type 2, PTPN2 genes
(p=4.6xl0~8). Parkes and colleagues have subsequently genotyped 37 SNPs from 31
distinct loci, associated at significance level of p<10"5 on initial analysis of the WTCCC
dataset. Among new loci with genome-wide significance in the WTCCC scan, the
strongest replication adjacent to a known gene was for SNPs rs 13361189 and rs4958847
(PreP=6.6xl0 4 and 3.1x10"4, respectively) immediately flanking IRGM on chromosome
5q33.1. Association in the combined panels of 2,930 cases and 4,962 controls was highly
significant (PCOmb =2.1xlO"10 and 3.8 xlO"9) together with replication for nine other loci,
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including NKX2-3, PTPN2 and gene deserts on chromosomes lq and 5pl3(Parkes et al.
2007).
Two further studies which were published prior to the WTCCC dataset (North American
and European datasets) also demonstrated highly consistent findings. Rioux et al. utilised
a cohort comprising of ileal Crohn disease with a further two independent replication
cohort also confirmed established CARD15, ATGL16 and IL23R genetic associations, and
novel loci which with significantly replicated associations (combined P < 10~10); in the
intergenic region on 10q21.1 and genomic regions encoding PHOX2B, NCF4 and a
predicted gene on 16q24.1 {FAM92B){K\o\i\ et al. 2007). In a Belgian CD scan, Libioulle
et al., also confirmed associations with CARD15 and IL23R, in addition to a 1.2-Mb
region of chromosome 5p 13.1 that contains no known genes(Libioulle et al. 2007).
These highly significant genetic evidence regarding 1RGM, ATG16L1 (converging on
autophagy pathways), CARD15 and IL23R collectively implicates defects in the early
immune response, particularly innate immune pathways and the handling of intracellular
bacteria, in the pathogenesis ofCrohn's disease. Whether the latter is restricted to a single
pathogen (or, more likely, to a class of subpathogenic bacteria relying on defective host
innate immunity for survival) awaits further investigation. A recent meta-analysis of the
published GWAS studies has now shown more than 30 novel loci will provide further
tantalising clues to the pathogenesis of CD (Barrett et al. submitted to Nature 2008).
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1.3.4 Genetics of ulcerative colitis
The current evidence for the genetic contribution to the disease susceptibility is weaker in
UC compared with CD. It is conceivable that the genetic contribution in UC may be more
of a modifying effect to environmental stimuli rather than directly causally linked (as in
CD). Although most current linkage studies contained relatively more CD-CD affected
relative pairs (hence linkage regions have shown relatively greater evidence for CD
compared with UC), several loci demonstrate a stronger evidence of linkage with UC
compared with CD. These loci are 12q 13 (IBD2), 6p 13 (IBD3, HLA region) and 7q22
(Satsangi et al. 1996b; Duerr et al. 1998).
Many of the early studies focused on the highly polymorphic region, the HLA locus on
chromosome 6pl3, provided conflicting results, possibly due to a lack of statistical power
and because typing was done serologically rather than by direct genotyping. Only one
consistently replicated finding has been associated with UC. The HLA DRB1 *0103 allele
situated at the HLA Class II region has been shown to be associated with extensive
disease, the need for surgery and extraintestinal manifestation in the Caucasian
population. Although a rare allele in the general population, this association has been
consistently replicated in at least three independent studies and a meta analysis(Bouma et
al. 1999; Roussomoustakaki et al. 1997; Duerr and Chesny IJ 1997). While the allele is
only carried by 1-3% of the general population, carriage is 7.4-11% in UC patients with
extensive or pan-colitis. Furthermore, in a study of patients who have undergone surgery
and ileo-anal anastamosis for severe UC, HLA DRB1*0103 allele was present in 15.8%
of patients with extensive colitis at time of surgery, and in 22.8% of a subset of patients
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who also had extraintestinal manifestations (Roussomoustakaki et al. 1997). An
association between the HLA DRB1*1502 (DR2) with UC has also been observed in
several studies, notably in USA and Japan(Toyoda et al. 1993; Futami et al. 1995;
Sugimura et al. 1993). Moreover, in the Japanese population, FILA DRB1*1502 (a sub¬
group of DR1*15) is common and has been associated with intractable disease. HLA-
DR4 allele has been shown in several studies to be protective against UC, and this was
confirmed in a meta-analysis by Stokkers et al.
The contribution of the FILA Class I and III regions have received less attention than the
Class II determinants. The tumour necrosis factor-a (TNF- a) genes are located within the
major histocompatibility region and IBD3 linkage interval on chromosome 6p. Koss and
colleagues have suggested that TNF-2 haplotype maybe predictive of disease extent
(Koss et al. 2000). However, this observation may simply reflect linkage disequilibrium
within the HLA region. De La Concha et al. have recently demonstrated that
susceptibility to severe UC may be associated with polymorphism of the IKB-like
(IKBL) gene(de la Concha et al. 2000). The IKBL +738C allele lies in tight linkage
disequilibrium with HLA DRB1 *0103-these two allelic variants were significantly
increased in individuals with severe UC. Nevertheless, a significant association was also
observed in HLA DRB 1*0103 negative patients. These findings have not been replicated
yet to date.
Mansfield et al. found that the carriage of the less common allele 2 of the interleukin-1
receptor antagonist (IL-1RA) was increased in patients with extensive UC (35% vs. 24%
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in controls) (Mansfield et al. 1994). However, this association has not been uniformly
replicated (Bouma et al. 1996b; Tountas et al. 1999). A larger study from the same center
by Carter and colleagues confirmed a minor association conferring a small risk,
especially in patients with extensive disease (Carter et al. 2001a). A subsequent study by
the same author reported on IL-1RA allele 2 carriage in 109 patients with UC treated
with colectomy. The investigators suggested that the rate of allele 2 carriage might be
predictive of the development of inflammation within the ileo-anal pouch (pouchitis)
(Carter et al. 2001a). However, a larger study has again questioned any association of IL-
1RA with IBD (Aithal et al. 2001).
Cytokines play a crucial role in the initiation and regulation of the immune
response(Louis et al. 1996). The genes that encode these proteins by virtue of their
function make these attractive candidate genes for susceptibility, and perhaps, severity, to
UC. Nevertheless, studies to date have not yet provided a consistent evidence of a strong
effect on disease susceptibility or severity(Mansfield et al. 1994; Carter et al. 2001a;
Carter et al. 2001b; Olavesen et al. 2000; Parkes, Satsangi, and Jewell 1998b; Aithal et al.
2001; Klein et al. 2001). Others studies looking at the effect of cytokine polymorphisms,
such as IL-10, IL-6, IL-4, and IL-2,(Olavesen et al. 2000; Parkes, Satsangi, and Jewell
1998a) have not yet provided consistent evidence of a strong effect on disease
susceptibility or severity (Aithal et al. 2001).
There have been suggestions that genetic markers may be useful in predicting the course
of disease in UC. Recent data presented in abstract form by McGovern et al. suggest that
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a panel of genetic markers may be useful in predicting colectomy in UC. The authors
utilized a combination of markers involving 3 genes, MEKK1 (MAP3K), MDR1 and the
HLA DRB1*0103 allele - and showed using a Bayesian approach the odds of prediction
can be significantly improved. Nevertheless, no further insights have been shed on the
contribution of these genes to pathophysiology of disease and given the clear evidence of
both phenotypic and genetic heterogeneity; these data has yet to be shown to be of value
in clinical practice. Achkar et al. in an IBD linkage study involving 904 affected relative
pairs also provided strong linkage evidence for the subset of extensive ulcerative colitis
in the region of IBD2 (lod 3.27; p < 0.001)(Achkar et al. 2006).
Recently, inherited variations of myosin IX (MYOB9B) gene have also been shown to be
associated with UC in three independent populations(van Bodegraven et al. 2006). It is of
interest to note that the initial association was primarily observed with coeliac disease in
the Dutch population (Monsuur et al. 2005). The mechanism underlying this is unclear.
Overexpression of rat myosin IXB leads to actin filament related morphological changes
in epithelial cells, and human myosin IXB is expressed in intestinal epithelial cells. It is
postulated that variations of the MYOB9 gene may influence intestinal permeability
leading to inflammatory intestinal disease susceptibility. As with the recent progress
with CD, the results of genome-wide association studies in UC are anticipated to reveal
significant new insights into the disease pathogenesis ofUC.
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1.3.5 Association studies and linkage disequilibrium
An influential paper by Risch and Merikangas suggested that in complex diseases where
the genetic contribution is only modest (low penetrance), direct examination of the risk
variant itself using for example, a case control study can be more powerful than the
examination of the indirect effect of a risk factor has on allele sharing among siblings, in
the case of linkage studies(Risch and Merikangas 1996). Two experiences have led to a
broader acceptance of the strategy proposed therein. Firstly, highly significant linkage
results are very uncommon in common diseases (despite numerous genome scans in
many diseases and some considerably large meta-analysis in a number of diseases such as
Type 2 diabetes and multiple sclerosis) suggesting that a major high-penetrance risk
factor is not typical in most common diseases. Secondly, recent positive results in a
number of diseases suggest that common genetic variations with a modest associated
disease risk does have a significant role in the contribution to disease susceptibility
(Stefansson et al. 2002; Strittmatter et al. 1994; Ueda et al. 2003; Altshuler et al. 2000).
The latter point lend further support to the now widely-described, 'Frequent disease-
frequent variant hypothesis', which suggest that the genetic factors predisposing to, or
associated with a disease of high prevalence should also be frequent in the same
population.
Studies of common diseases have fallen into two broad categories: family-based linkage
studies across the entire genome, and population-based association studies of individual
candidate genes. Although there have been notable successes, progress has been slow due
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to the inherent limitations of the methods; linkage analysis has low power except when a
single locus explains a substantial fraction of disease. The earlier association studies
relies on the selection of candidate SNPs based on location and on the basis of their
respective effects in coding changes within exonic or promoter sequences that may have
biological or functional consequence. This approach examines only a small fraction of
the 'universe' of sequence variation in each patient.
The arrival of denser SNP maps and the completion of the International HapMap project,
it is now possible to determine the patterns of linkage disequilibrium of genomic
sequences(A haplotype map of the human genome 2005). Linkage disequilibrium is the
non-random association between alleles at different loci with a particular combination of
alleles along a chromosome is termed a haplotype. In some cases, an allele at one locus
predicts which allele which would be found in another locus, making one of the loci
redundant in mapping purposes. Thus in principle, with the knowledge of LD of a
particular genomic region or gene, it is now possible to identify and genotype only a
small number of SNPs which would represent the variations from that region or gene,
thus allowing the possibility of examining a very larger number of genes with high
throughput genotyping with very good economy of effort. Nevertheless, this knowledge
has introduced a further difficulty in the interpretation of earlier association studies which
were implicitly candidate polymorphism rather than candidate gene studies. Failure of a
candidate-polymorphism study does not rule out involvement of the gene or genes. The
selection of highly informative SNPs (tagging SNPs) is critical in the validity of an
association study, and is influenced by many factors as discussed in the following sub-
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chapter. A negative candidate-gene study can provide a statistical limit to the importance
of any common variant in the gene. However, there remain practical difficulties in
demonstrating causality of SNPs once association is achieved(Trinh and Rioux 2005).
1.3.6 Haplotype-tagging approach
The concept of haplotype-tagging is based on the knowledge that the human genome is
composed of long tracts of limited diversity (haplotype 'blocks') interspersed by areas of
recombination ('hotspots')(Gabriel et al. 2002). In these haplotype blocks, it is
considered that redundant information exist even amongst densely spaced SNP markers,
and usually a subset of markers can retain all or most of the information in the region
studied. The recently completed International HapMap Project has now confirmed the
generality of hotspots of recombination, with long segments of strong LD which
displayed limited haplotype diversity(A haplotype map of the human genome 2005). The
confirmation of the extensive redundancy of SNPs has lead to the potential to extract
extensive information about genomic variation without complete resequencing, the
development of selection methods of tag SNPs and the optimization of association
analyses. Current thinking about the design of association studies has been greatly
influenced by the above data, where the common haplotypes can be represented by
knowledge of only a few genotypes in the block, with stretches of more rapid breakdown
of linkage disequilibrium, where a few sentinel SNPs cannot reliably represent haplotype
diversity; in many cases, the latter regions correspond to hot spots of meiotic
recombination(Daly et al. 2001). This structure of linkage disequilibrium inspired the idea
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of haplotype tagging, in which a set of SNPs is identified that tags each of the common
haplotypes within a block of linkage disequilibrium.
Since the seminal paper by Johnson et al. describing the haplotype-tagging approach in
2001 (Johnson et al. 2001), many different statistical methods and algorithms have been
developed(Zeggini et al. 2005). These methods usually differ on one of the following
aspects:
• Source of genetic information
■ Haplotype
■ Genotype








■ Analytical and heuristic operations
■ Hierachical clustering and graph methods
■ Greedy algorithms and dynamic programming
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Despite these differences, the basic template of approach is the same. Firstly, a
representative sample of a population is extensively sequenced to provide the reference
data; and the extent of linkage disequilibrium is assessed. Secondly, a set of SNPs is
selected to represent the variations of the gene/region studied. These SNPs are then
genotyped in a case-control or a family based study cohort. Such association raises 2
fundamental questions: a) how well the selected SNPs represent the undetected variations
in the original sample and b) how well these SNPs will represent variation (both detected
and undetected in a new sample from the same population?
Several studies have now examined this issue and demonstrated no obvious discrepancies
in terms of the efficiency and effectiveness in these methods(Ke et al. 2005; de Bakker et
al. 2005; Burkett et al. 2005). Given practical limitations on genotyping, investigators are
forced to make several practical decisions: (i) selecting and prioritizing tag SNPs (ii)
deciding which tests of association to use and (iii) evaluating statistical significance of
putative findings. Genotyping a higher density of tag SNPs increases the fraction of sites
captured through LD, but the quantitative relationship between additional genotyping and
increased power in association studies is not well described. The use of multimarker
haplotypes shifts this relationship toward greater efficiency(Goldstein et al. 2003) has
certain drawbacks: if haplotype testing increases the degrees of freedom or number of
tests in statistical analysis, it may decrease, rather than increase, overall power(Chapman
et al. 2003). Many studies will rely on data from the International HapMap Project, which
is an extensive but incomplete inventory of common genetic variation(A haplotype map
of the human genome 2005). Recently De Bakker et al. demonstrated that specified
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multimarker tests substantially increase tagging efficiency relative to single-marker
approaches, without loss of power(de Bakker et al. 2005). Second, when selecting SNPs
from very dense reference panels, a method such as the best N strategy, which ranks
SNPs according to the number of proxies they have, allows marked reductions in
genotyping with limited loss of power, substantially outperforming a method based on
relaxing r2 thresholds. Third, sparser sets of tags selected from a pseudo phase I HapMap
are almost as powerful as equally sized sets chosen from complete reference panels.
Fourth, exhaustive multimarker tests improve power for less common causal alleles but
are neutral or reduce power when the causal SNP is common. These relationships hold
for each of the different population samples studied by HapMap, although the number
and performance of tags varies, as expected, according to the general extent of LD in
each sample.
Haplotype tagging: haplotype r2 method
At its essential core, the most direct approach to identify a set of tSNPs that maintains a
high r2 value directly with other (tagged) SNPs (or to define a set of tSNPs that do so), r2
values can be defined as coefficients of determination (i.e. the proportion of explained
variations) obtained from fitting linear models predicting the state of tagged SNPs from
the set of tSNPs. For haplotype r2, the model is fitted to the G haplotypes defined by:
Yj = Xibi + xi2b2 + x/cbc.
Where Yj is the predicted state of the tagged SNP of interest on the ,th chromosome (e.g.
representing observed values as 0 or 1), Xj x,Gare indicator variables (0 or 1 depending
on which haplotypes are present) and bj bGare coefficients estimated by standard least
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squares from the observed data. Pairwise r2 values between two SNPs (or between aSNP
and the presence or absence of a single haplotype) can be defined by setting G = 2. If the
tagged SNP state or the haplotype state on chromosome i are not known with certainty,
weighted least squares can be used, either by splitting each observed chromosome into all
possible SNP and haplotype states with weights equal to their estimated probabilities, or
equivalently by listing all SNP and haplotype combinations consistent with the data and
using weights equal to their estimated population frequencies (e.g. from EM estimation).
Software for the fitting and evaluation of r2 values is available in the TagIT package
(http://popgen.biol.ucl.ac.uk/software.html).
Pritchard and Przeworski showed, under simplifying assumptions and when G=2, that the
power of a case-control study comprising it observations looking directly at a causal SNP
was equivalent to the power of a case-control study comprising n/r2 observations looking
at a marker, where r2 is the coefficient of determination between the marker and the
causal SNP. We have verified this simple power relationship using simulations, and have
also found that the relationship holds when G>2 (M.E.W., unpublished). To illustrate
these approaches, Goldstein and colleagues identified four tSNPs for region 25b in the
Gabriel et al. dataset using different criteria. The 4 tSNPs for the European sample
provide a haplotype r2 of 0.96 or above for each of the seven 'tagged' SNPs in this
region. Many of the tagged SNPs in this region, however, fail to show high pairwise r2
values with any single SNP. For example, the tSNPs are SNPs 4, 5, 8 and 11 in order
through the region. For tagged SNP 1, however, the pairwise r2 values against the tSNPs
are 0.32, 0.08, 0.02, and 0.05 (Figure I). Similarly, the pairwise r2 values between the
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haplotypes defined by these tags and the tagged SNPs do not perform better; they are all
below our cut-off of 0.85. These comparisons suggest that in the selection of tagging
SNPs, and in the subsequent association study, it might be necessary to consider
association tests that either use a regression model with haplotypes as independent
predictors or employ other approaches which consider clusterings of haplotypes. After
selecting a set of tSNPs, it is necessary to assess how well they represent as yet
undetected SNPs. The terminology ofWeale and Goldstein defined K as the total number
of SNPs identified in the region of interest, H as the tSNPs identified from K, and A the
set of all common SNPs in the region (http://popgen.biol.ucl.ac.uk/software). The
question to answer is how well H represents the set of SNPs in A. To assess this, we have
used a sub-sampling procedure in which we sequentially drop out SNPs from the set K
and identify a set of tSNPs in the reduced set. The performance of the tSNPs in predicting
the state of each of the dropped SNPs in turn, and so estimate the performance against the
(unknown) elements of A is then subsequently checked. The haplotype r2 tagging method
is used in the association studies described in this thesis.
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Fig. I. Illustration of relative SNP positions and pairwise r2 values for the 11
SNPs in region 25b of the Gabriel ef at, f 13] da taset, as described in Box 1, The
tSNPs for this region are SNPs 4,5,8 and 11. As shown, none has a high pair-
wise r* against SNP 1, although SNP 1, like the other SNPs, is well predicted
by the hapfotype r2 criterion. Abbreviations: SNP, single nucleotide poly¬
morphism; tSNP, tagging single nucleotide polymorphism.
Figure 1: Illustration of relative SNP positions and r2 values (adapted from Goldstein et
al. Trends in Genetics).
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1.4.1 Mucosal immunology and luminal flora in ulcerative colitis
Populations of mucosal B cells and plasma cells increase in ulcerative colitis, which
initially suggested that the disease was antibody mediated and complement dependent
(Halstensen, Das, and Brandtzaeg 1995). However, the main abnormality driving the
inflammation is now considered to be secondary to an exaggerated T-cell response
causing mucosal hyper-responsiveness to commensal bacteria(Sartor 2006). The B-cell
response and increased production of IgGl and autoantibodies are a secondary, protective
response aimed at clearing apoptotic cells (Mizoguchi, Mizoguchi, and Bhan 1999).
Crossreactivity of peripheral-blood and colonic-lamina-propria CD4+ T cells with
indigenous flora (bacteroides, bifidobacteria, and various enterobacteria) in patients with
ulcerative colitis and Crohn's disease suggests that abnormal T-cell-specific immune
responses to host flora are important in disease pathogenesis (Duchmann et al. 1999).
Compared with circulating T cells, T cells in the lamina propria are more susceptible to
Fas-mediated apoptosis(Boirivant et al. 1996)—a physiological process of cell death that,
if altered, could contribute to inflammation. Furthermore, the Fas ligand (FasL) is
strongly expressed by T cells in active ulcerative colitis but not in Crohn's disease
lesions, suggesting that Fas-FasL induced apoptosis plays a part in mucosal damage of
ulcerative colitis (Ueyema).
Although cytokine patterns are less clear in ulcerative colitis than Crohn's disease, in
established colitis there seems to be a modified Th-2 response associated with
upregulation of cytokines such as interleukin-5 and interleukin-10, but not interleukin-4
(Fuss et al. 1996). This disease was considered to have a Th2 profile, but the
concentrations of 1L-4 and IL-5, which are normally elevated in Th2 responses, have
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been variable in ulcerative colitis tissues(Fuss et al. 1996). On the basis of results
obtained from studies of the oxazalone colitis model, one of the few models to exhibit a
Th2 profile, Fuss and colleagues have suggested that ulcerative colitis has an atypical
Th2 response, mediated by natural killer T cells that secrete IL-13 (Fuss IJ 2004 JCI).
These natural killer T cells are activated by APCs that express the nonclassical major
histocompatibility complex (MHC) molecule, CDld, which presents lipid rather than
protein antigens to T cells. These unique observations could explain some of the
discrepancies of past studies, but will require confirmation before being accepted. If true,
blockade of IL-13 could provide an exciting new approach to ulcerative colitis treatment.
By contrast, mucosal cytokine and double-knock-out mouse studies have underscored the
pivotal part played by interleukin-4 in the development of active colitis(Inoue et al. 1999;
Mizoguchi et al. 2003). Results from knock-out mice have also shown that the
immunoregulatory cytokines, interleukin-10 and tumour growth factor P, produced by the
regulatory CD4+T cell subsets T-regulatory-1 (Tr-1) and Th-3, respectively, have pivotal
roles in mediating tolerance towards luminal antigens(Liu et al. 2000; Groux et al. 1997).
Furthermore, oral intake of antigen can induce tolerance and resolution of colitis by
stimulating Th-3 regulatory cells specific for these antigens and thereby resetting the
regulator-effector T-cell balance(Neurath et al. 1996), which has important implications
for treatment and might account for the benefits of probiotics in clinical trials.
The gut mucosal immune system is in permanent contact with billions of commensal
intestinal bacterial flora (1012 bacteria/g faeces in the colon, and consisting of 400
different species, with anaerobes predominating). Mucosal tolerance is an active process
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by which an injurious immune response is prevented, suppressed or shifted to a non-
injurious type of immune reaction. The most compelling evidence for the importance of
gut microflora with the pathogenesis of ulcerative colitis comes from genetically
engineered animals that develop colitis when exposed to non-pathogenic colonic bacterial
microflora (in an environment free of specific pathogens), but not when they are in a
sterile germ-free environment. Furthermore, experimental colitis is attenuated when
animals are treated with broad spectrum antibiotics(Strober, Fuss, and Blumberg 2002).
Enteric microflora can stimulate immune responses either by functioning as adjuvants or
antigens. As adjuvants they activate innate immune responses, including dendritic cells
and other APCs, and as antigens they stimulate the clonal expansion of T cells that
selectively recognize the antigen through their T-cell receptor.
Numerous bacterial adjuvants, most notably lipopolysaccharide, peptidoglycan, flagellin
and nonmethylated DNA (CpG motif), can bind selectively to various TLRs on innate
immune cells, intestinal epithelial cells and mesenchymal cells (Cario, 2005 3189 /id).
Ligation of these TLRs activates NFkB and the mitogen-activated protein kinases, which
stimulate the transcription of a host of proinflammatory and regulatory genes. Activation
of macrophages from susceptible individuals, by enteric lipopolysaccharide,
peptidoglycan, flagellin or CpG, stimulates the production of IL-ip, TNF, IL-6, IL-8 and
other chemokines, IL-12 p40 (and thus IL-12 and IL-23), adhesion molecules, IL-18,
reactive oxygen species, nitric oxide and leukotrienes, which can all participate in the
inflammatory response. In addition, NFkB activation of APCs (including dendritic cells)
by microbial adjuvants induces the expression of MHC class II antigens, co-stimulatory
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molecules, IL-12 and IL-23, which can activate TH1 and TH17 cells, respectively, if the
appropriate antigen is present. Lipopolysaccharide can stimulate IL-12 p40 production by
bone-marrow-derived dendritic cells in IL-10-deficient mice, and colonization of
previously germ-free rodents with various commensal bacterial species can induce
ICAM1 and IL-6 expression by intestinal epithelial cells. In vivo studies show that
commensal bacteria selectively activate IL-12 p40 in dendritic cells of the distal ileum.
Bacterial flagellin is both an antigen and adjuvant. A form of flagellin was shown to be a
dominant antigen in experimental colitis and to induce serum antibody production in 50%
of Crohn's disease patients(Lodes et al. 2004; Targan et al. 2005). Flagellin binds to
TLR5 to activate NFkB. In addition to their proinflammatory properties, bacterial
adjuvants can induce protective anti-inflammatory responses. For example,
lipopolysaccharide stimulates IL-10 production in dendritic cells from normal mice,
(Hoentjen Blood 105) and certain CpG preparations can prevent the onset of
experimental colitis by inducing the production of type 1 IFN (IFN-a/p) in plasmacytoid
dendritic cells, via TLR9 ligation(Katakura et al. 2005).
The role of the antigenic properties of bacteria in the pathogenesis of IBD is less clear.
The concept of dysbiosis, where the altered balance of beneficial versus aggressive
microbial species leading to a pro-inflammatory luminal milieu, resulting in a chronic
inflammatory state in a susceptible host has recently received much attention. Numerous
studies have implicated several commensal organisms, such as E. coli, Bacteroides,
Enterococcus and Klebsiella species, in the pathogenesis of experimental intestinal
inflammation and human IBD(Sartor 2006) By contrast, various Lactobacillus and
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Bifidobacterium species have predominantly protective effects and have been used
therapeutically as probiotics. Several groups have documented alterations in luminal or
adherent microbial commensal flora in patients with Crohn's disease, ulcerative colitis
and pouchitis(Swidsinski et al. 2002).
The high prevalence (about 70%) of pANCA in ulcerative colitis(Saxon et al. 1990) and
even higher prevalence in patients with primary sclerosing cholangitis, refractory left-
sided ulcerative colitis(Sandborn et al. 1996), and those who develop chronic pouchitis
after ileal-pouch anastomosis(Sandborn et al. 1995) are the most reproducible data
supporting non-epithelial autoimmunity. However, evidence that pANCA is a marker of
genetic susceptibility to ulcerative colitis has been less convincing(Papo et al. 1996).
These autoimmune proteins clearly occur more frequently in ulcerative colitis than
Crohn's disease, but they have not been shown to cause tissue damage. Rather, they seem
to be markers of underlying immune dysregulation or show crossreactivity with
environmental factors, including commensal colonic bacteria.
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1.4.2 The importance of gut barrier defence in ulcerative colitis
In the recent years, the importance of gut barrier defence in the aetiopathogenesis of 1BD
has been subject of considerable research interest and has been in part catalysed by
genetic studies. The ABCB1/MDR1 (discussed in detail below), DLG5, OCTN1/2 and
MYOB9 genes implicated in genetic susceptibility of IBD are all involved in the
maintanence of epithelial integrity/defence. ABCB1/MDR1 and MYOB9 are both linked
to the development of UC. The CARD15 gene might mediate intracellular bacterial
clearance and also gut barrier defence by the production of antimicrobial a-defensins by
Paneth cells.
The interface between luminal contents and intestinal epithelium constitutes the largest
area of interaction between the host and environment. Critical to this interface is the
ability to allow transcellular permeation of essential luminal molecules such as nutrients,
but at the same time, to exclude or counter potentially harmful substances in the intestinal
lumen. The cells of the mucosal immune system are protected from the large antigenic
load in the gut lumen by a single layer of epithelial cells. Detoxification of xenobiotics,
including toxins, carcinogens, and drugs, is the central task of many metabolising
enzymes in the body. Detoxification and biotransformation of luminal agents is an
important protective function of intestinal epithelial cells(Roediger and Babidge 1997).
Several results from animal models of colitis as well as studies in human patients with
IBD suggest that detoxification enzyme depletion may be an important event in the
initiation and progression of UC and that excess biotransformation may result in colon
cancer(Roediger and Babidge 1997). In animals, glutathione deficiency leads to enhanced
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oxidative damage ofmucosa cells and causes colitis(Martensson, Jain, and Meister 1990),
whereas trinitrobenzene sulfonic acid- induced colitis can be significantly improved by
glutathione supplementation(Loguercio C et al. 2003). In addition, mice with a combined
deficiency of glutathione peroxidase 1 (Gpxl) and 2 (Gpx2) develop symptoms
consistent with IBD(Esworthy et al. 2001; Esworthy et al. 2003) and low glutathione
levels have been found in noninflamed as well as inflamed mucosa of patients with
CD(Sido et al. 1998). Two groups of enzymes are known to handle metabolism of
harmful compounds. The group of cytochrome P450 isoenzymes (CYPs) comprises
numerous isoforms (approximately 60 are expected in humans) leading to oxidation
(mostly hydroxylation) of molecules. Isoforms in the CYP groups 1, 2, and 3 mediate
metabolism of many exogenous compounds. Many toxins and carcinogens require
activation by CYP450 isoenzymes to obtain their reactive (that is, alkylating) properties
in the body.
In general, three phases of detoxification processes can be defined. Phase 1 reactions
include redox reactions via cytochrome P450 (CYP) enzymes(Ding and Kaminsky 2003),
hydration by carbonic anhydrases(Fonti et al. 1998), and hydrolysis of compounds by
carboxylesterases(Schwer et al. 1997). Phase 2 reactions comprise the sulfation,
glucuronidation, acetylation, methylation, and glutathione conjugation of reactive
intermediates leading to more hydrophilic molecules, which can be more easily exported
from cells(Chen et al. 2003; Back and Rogers 1987; Pacifici et al. 1988). Most recently,
the focus has been on the Phase 3 reactions- in the 'excretion' of xenobiotic compound
back to the gut lumen(Dietrich, Geier, and Oude Elferink 2003).
78
Recent interests have focused on the class of proteins, the ABC efflux export
transporters, which are highly expressed in the intestinal epithelium. These
proteins/pumps reduce the local cellular burden of toxic compounds giving the individual
cell protection against toxic effects. These transport proteins are primarily expressed in
the apical membrane of epithelial cells, such as enterocytes, subjected to highest
concentrations of exogenous xenobiotics. In these cells the same transporters function on
the one hand to reduce the entrance of harmful substances and on the other hand to
eliminate their detoxification products. The latter step has been called "phase III
metabolism", indicating the close connection to the oxidation and conjugation steps of
detoxification. The first function (that is, direct elimination of xenobiotics on entrance
into the cell) represents a first defence line against xenobiotics and likewise could be
called "phase 0 metabolism". It is pertinent that ABC proteins and CYP450 proteins co-
localize in the intestinal epithelial cells. With a considerable overlap of an extensive list
of substrates, there is a symbiotic relationship between these two classes of proteins in
xenobiotic defence and metabolism(Benet and Cummins 2001).
P-glycoprotein 170 encoded by MDR1 gene is the archetypal efflux transporter protein,
responsible in the the transport of a vast range of substrates. The role of this protein in
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1.4.2 Multidrug resistance gene (ABCB1/MDR1) gene: a key determinant of
gastrointestinal disease.
The multidrug resistance pump (P-glycoprotein) is a 170 kDa phosphorylated and
glycosylated plasma membrane protein belonging to the ATP-binding cassette
superfamily of transport proteins encoded by the multidrug resistance genes (MDR),
first described by Juliano and Ling in 1976(Juliano and Ling 1976). In man, two
MDR genes, MDR1 and MDR3 (also called MDR2) have been described; in rodents,
three - mdrla, mdr lb and mdr2(Hsu, Lothstein, and Horwitz 1989; Chen et al. 1986;
Ueda et al. 1987). Only the MDR1 gene in humans and mdrlb and mdrla genes in
rodents, appear to be involved in drug transport and the development of drug
resistance(Fardel et al. 2001). The human MDR3 and murine mdr2 genes encodes a P-
glycoprotein that does not seem to have a role in drug transport in intestinal
epithelium, but has a role in the secretion of phosphatidylcholine into bile in the
biliary tract(Smit et al. 1993). In humans, mutations in the MDR3 genes are linked to
the development of progressive familial cholestasis(Deleuze et al. 1996; Jacquemin
2000).
P-glycoprotein is a transmembrane protein which is 1280 amino acid long and
consists of two homologous halves of 610 amino acids joined by a flexible linker
consisting of 60 amino acids. Each half has an N-terminal hydrophobic domain
containing six transmembrane domains followed by a hydrophilic domain containing
a nucleotide-binding site. The nucleotide binding sites can bind ATP and its analogues
and both halves are essential since inactivation of either site inhibits substrate
stimulated ATPase activity (Fig 3). However, the two sites are likely to be
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functionally independent and cleavage probably occurs at one site at a time(Nagata et
al. 2000).
In the human gastrointestinal tract, P-glycoprotein is found in high concentrations on
the apical surfaces of superficial columnar epithelial cells of the colon and distal small
bowel. High levels of P-glycoprotein are also found on the apical surfaces of
epithelial cells in small biliary ductules, small ductules of the pancreas, proximal
ductules of the kidneys and adrenal gIands(Thiebaut et al. 1987). P-glycoprotein is
richly expressed on the subapical surface of the epithelium of the choroid plexus of
the brain (which forms the blood-CSF-barrier) as well as the luminal surface of the
endothelium of the blood capillaries of the brain (blood-brain-barrier)(Wijnholds et al.
1997; Rao et al. 1999; Cordon-Cardo et al. 1989; Zhao et al. 1993). In the
haemopoeitic system, peripheral blood mononuclear cells, macrophages, natural
killer, dendritic cells, T and B-lymphocytes all express P-glycoprotein at varying
levels(Klimecki et al. 1994). In the gastrointestinal tract, there is a regional variation
in P-glycoprotein expression. Various methodologies have been used to investigate
this (Table 1). Within the small intestine, there is clear evidence demonstrating that P-
glycoprotein is maximally expressed in the epithelial cells of the ileum with a gradual
decrease proximally into the jejunum, duodenum and stomach. Variations of P-
glycoprotein expression across the length of the colon are less well-defined (Chianale
et al. 1995).
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The role ofP-glycoprotein: Host-bacterial interactions
The available literature suggests that P-glycoprotein act as a transmembrane efflux
pump, which removes drugs from the cell membrane and cytoplasm. However, the
normal physiological function of P-glycoprotein in the healthy gastrointestinal tract
remains under investigation and may be complex. Expression of P-glycoprotein on the
luminal surfaces of the epithelial cells of the small and large intestines, biliary
ductules and proximal tubules of the kidneys suggest a role in decreasing (Yumoto et
al. 2001; Fricker et al. 1996; Fojo et al. 1987)the absorption from the gut and
secretion of endogenous and exogenous hydrophobic amphipathic toxins(Trezise et al.
1992).
Perhaps the greatest insight into the physiological importance of P-glycoprotein in the
gastrointestinal tract has from the description of the phenotype of genetically
engineered mice lacking the mdrla gene. The investigators had been stimulated to
develop this model by the finding that the MDR1 gene is present in a region of the
human genome (7q21.1) that may harbour a disease gene involved in susceptibility to
inflammatory bowel disease (Satsangi et al. 1996b). Panwala et al. demonstrated that
spontaneous colitis developed in these mdrla knockout mice when maintained under
specific pathogen free conditions (Panwala, Jones, and Viney 1998). This was
reversed and prevented by the administration of antibiotics, suggesting that intestinal
flora was necessary in the initiation and perpetuation of colitis in this model. Other
studies have confirmed that these mice have normal viability, fertility, immunology
and range of biochemical parameters (Schinkel et al. 1997; Wijnholds et al. 1997).
Together with the protective effect of antibiotics, these observations imply that the
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loss of xenobiotic efflux mechanism underlies the development of colitis in this
model. Bone marrow transfer studies involving the wild type donor cells into mdrla
deficient recipients demonstrated that the colitis develops in these mice because of the
mdrla deficiency in the epithelial cells rather than in lymphoid or myeloid cells. The
colitis associated with mdrla deficiency has been regarded as a model of ulcerative
colitis with the presence of long dysregulated crypts, crypt abscesses and superficial
mucosal inflammation. However, transmural infiltration of B and T-cells was also
observed, not dissimilar to the histological appearances ofCrohn's disease.
The susceptibility to the development of colitis increased as the mice (mdrla -/-) aged
(Panwala, Jones, and Viney 1998). The gradual acquisition of commensal luminal
organisms in the background of defective efflux capacity of epithelial cells may be the
reason although clearly other effects of ageing maybe pertinent. In addition, a recent
study has added further intriguing insight into the interaction between P-glycoprotein
and the gut flora. In mdrla -/- mice, infection with helicobacter bills, accelerated the
development of colitis while helicobacter hepaticus infection delayed the
development of spontaneous disease. Helicobacter-induced IBD in mdrla -/- mice
maybe mediated via a family of bacterial toxins (eg. cytolethal distending toxins)
which are virulence factors in certain helicobacter infections. However, it is important
to emphasise that these mice developed spontaneous colitis independent of
helicobacter infection. The mechanisms for these findings suggest that different
luminal bacteria may influence the development of colitis and its progression. Both
helicobacter bilis and hepaticus have been shown to induce colitis in mice lacking T
and B cells (SC1D mice)(Shomer et al. 1998; Cahill et al. 1997; Burich et al. 2001;
Cahill et al. 1997). Recently, other models such as dextran-sulphate induced colitis;
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TCRa knockout and CD45RB colitis have all been characterised by reduced
expression of intestinal mdrla in the presence of inflammation(Iizasa et al. 2003;
Mizoguchi et al. 2003). In support of this, data from our unit have specifically showed
that the PgP expression is significantly lower in the HLA B27 transgenic models
compared with non-transgenic mice(Moodie et al. 2004), of the same background.
Expression in this model is again affected critically by germ-free conditions.
It is of great interest to note that PgP function has now been linked to the development
of colorectal carcinoma in mdr-la deficient mice. Maggio-Price et al. demonstrated
that a proportion of dual-infected mdrla(-/-) with Helicobacter bilis and hepaticus
mice showed IBD with foci of low- to high-grade dysplasia(Maggio-Price et al.
2005). A group of dual-infected mdrla(-/-) animals which were maintained long term
by intermittent feeding of medicated wafers to model chronic and relapsing disease
showed a higher frequency of high-grade crypt dysplasia, including invasive
adenocarcinoma. Colonic epithelial preparations from co-infected mdrla (-/-) mice
showed increased expression of c-myc (5- to 12-fold) and interleukin-1 alpha/beta
(600-fold) by real-time polymerase chain reaction relative to uninfected wild-type and
mdrla (-/-) animals. It remains speculative but the circumstantial evidence based on
the mdr-la mice has a number of similarities to the clinical course of human UC.
These findings support the hypothesis that mdrla deficient mice developed mucosal
inflammation not because of increased permeability but as a result of an increase of
bacterial activation of the epithelial cells. This effect might be pro or anti¬
inflammatory and again, the identity of the bacterium involved may be the critical
determinant. It has been demonstrated that bacterial flagellin signalling through the
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TLR5 receptor can lead to increased NFkB expression in epithelial cells (Gewirtz et
al. 2001). On the other hand, Neish et al demonstrated that certain non-pathological
organisms can lead to a block in the ubiquitination of IxBa (necessary for IxBa
degradation) and thus a subsequent block in NFKB translocation to the nucleus (Neish
et al. 2000). In either of these cases, if these events are caused by bacteria entering the
epithelial cells, it is possible to envisage how the function of the epithelial cells can be
influenced by a defective efflux transporter and the bacterial contents of the lumen.
Pharmacokinetic effects
The effect of P-glycoprotein on the pharmacokinetics of drugs has been well
demonstrated in two studies (Sparreboom et al. 1997; Mayer et al. 1996). In mdrla-l-
mice, the systemic bioavailability for the substrates, digoxin and paclitaxel was
markedly increased compared with wild-type mice following oral administration.
Similarly, faecal levels of these drugs were reduced following intravenous
administration. The range of substrates transported by P-glycoprotein is enormous and
includes a variety of structurally and pharmacologically distinct hydrophobic
compounds (Table 2). There is accumulating evidence that interactive alliances also
exist between xenobiotic metabolising enzymes and P-glycoprotein. The best-defined
alliance is between cytochrome P450 3A (CYP3A) and P-glycoprotein. These
proteins co-localise in the small intestinal epithelial cells and have a considerable
overlap in substrate specificities (Benet and Cummins 2001). As P-glycoprotein can
influence the intracellular concentrations of many CYP3A substrates, it may also
affect the availability of those substrates to CYP3A and thereby, the extent of CYP3A
metabolism of those substrates.
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1.4.4 Regulation of P-glycoprotein
The transcriptional regulation of MDR-1 gene is unexpectedly complex and far from
being understood. The transcriptional regulators of the human multidrug resistance
gene are discussed in detail in the review by Labialle et al (Labialle et al. 2002). P-
glycoprotein dependent drug transport activity depends on the level of expression of
the MDR1 gene as well as on the functionality of the MDR-1 encoded P-glycoprotein.
The level of intestinal P-glycoprotein shows wide interindividual differences
controlled by both environment and genetic factors.
Pharmacological regulation ofP-glycoprotein
Shapiro et al. showed that P-glycoprotein mediated drug transport was stimulated by
the antihypertensive drug, prazosin, and the hormone, progesterone (Shapiro et al.
1999). Rifampicin also has been shown to induce P-glycoprotein expression and
underlies the mechanism responsible for reduced digoxin levels during concomitant
therapy (Greiner et al. 1999). In healthy male volunteers, the oral bioavailability of
digoxin decreased by 30% and the intestinal P-glycoprotein levels were induced 3.5
fold during rifampicin therapy. Induction appears to take place at transcriptional level,
as MDR1 mRNA levels are elevated as well after treatment with inducer drugs
(Asghar et al. 2002) (Westphal et al. 2000). It has been suggested that the induction of
the MDR1 is mediated by the pregnane X receptor (which is also responsible for the
induction of CYP3A) which binds to PXR response elements situated upstream in the
MDR1 gene (Geick, Eichelbaum, and Burk 2001).
The role of corticosteroids on the expression of P-glycoprotein has been an area of
considerable interest as a possible mechanism for corticosteroid resistance. The high
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levels of expression in the adrenal glands and endometrium suggest a role in the
transport of steroid-related compounds. In addition, these compounds are all
substrates of P-glycoprotein. Nevertheless, the available literature is conflicting and
complex (Table 3). In mouse hepatoma cell cultures treated with dexamethasone,
Zhao et al. demonstrated induction of mdrl and mdr3, but not mdr2 transcripts.
Similarly, MDR1 mRNA levels were elevated in dexamethasone treated human
hepatoma line. This effect was not seen in non-hepatoma cell line (HeLa)(Zhao et al.
1993). In another study examining the expression of CYP3A and mdr in rat liver,
dexamethasone was found to induce mdr2 expression only in male livers. Curiously,
mdr la and lb were not induced in either sex (Salphati and Benet 1998). Lin et al
showed that dexamethasone induces P-glycoprotein in the intestines and liver of rats
with the functional effect of a decreased plasma substrate level (indinavir) (Lin et al.
1999). However, Demuele et al. found no increase in the intestinal expression. In
these animals, the expression was upregulated in the lungs and liver where as an
opposite effect was observed in kidney tissue (Demeule et al. 1999).
Although P-glycoprotein expression maybe influenced by corticosteroids or other
pharmacological agents, recent data illustrates that the level of expression may not
necessarily correlate with its function. Murakami et al. demonstrated that although,
increased P-glycoprotein expression was evident in rats with induced acute renal and
liver failure, the in vivo P-glycoprotein activity was significantly depressed. The
plasma from these diseased rats (with renal and liver failure) demonstrated a
significantly greater inhibitory effect on P-glycoprotein function (in Caco-2 cell line)
compared with dexamethasone treated-rats (Murakami et al. 2002). It is hypothesised
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that in disease states, endogenous related compounds such as corticosterone (a P-
glycoprotein inhibitor) may participate to suppress the in vivo function.
Another intriguing aspect of the pharmacological regulation of the expression of P-
glycoprotein is seen in the multidrug resistance phenomenon. This is observed in
tumour cells which, following initial contact with on one anticancer agent, become
rapidly resistant to other unrelated agents. This phenotype is mainly due to the over
expression of the MDR-1 gene. One possible mechanism for this may be through gene
rearrangement. Mickley et al. found that in several drug resistant cancer cell lines as
well as samples from two leukaemic patients who had developed drug resistance, gene
rearrangement had occurred resulting in the activation or increased expression of
MDR1 (Mickley et al. 1997). Although a feasible hypothesis, there is no evidence to
support selection of aberrant clones of the MDR gene as the cause of the development
of multi-drug resistance(Van Den Heuvel-Eibrink et al. 2001; Bouma et al. 1996a).
The above studies suggest that regulation of the MDR1 gene expression is likely to be
gene, cell and perhaps gender specific. Furthermore, future work in this area will have
to consider not only the expression but also the function of P-glycoprotein as well.
Genetic influences on P-glycoprotein function and expression
The MDR1 gene lies on chromosome 7q21.1. Several polymorphisms of the gene
have been characterised (Table 4) (Cascorbi et al. 2001b). Hoffmeyer et al. first
described a single base polymorphism in exon 26 (C3435T) and suggest that this
variant influences P-glycoprotein expression in the duodenum and P-glycoprotein
activity(Hoffmeyer et al. 2000a). In this study, healthy individuals homozygous for
this variant (TT genotype) has significantly lower duodenal expression of P-
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glycoprotein and higher serum digoxin levels. Moreover, evaluation of maximum
plasma concentrations during steady state of digoxin administration showed
statistically significant mean increase of 38% in the homozygous TT genotype
compared with the CC genotype.
This variant has received considerable attention. However, controversy still exists
regarding the functional effect of this polymorphism and the current literature remains
rather contradictory. It is particularly noteworthy that the MDR1 C3435T allelic
variant, a single nucleotide polymorphism, is non-coding and does not affect amino
acid sequence change. Although a number of coding mutations within the MDR-1
gene (Table 4) have been identified, none of this variants are in strong linkage
disequilibrium with the C3435T variant(Cascorbi et al. 2001b; Drescher et al. 2002).
The extent of linkage disequilibrium also depends strongly on ethnicity (Tang et al.
2002). Kimchi-Sarfaty et al. demonstrated that there were no functional consequences
of the five commoner amino-acid altering single nucleotide polymorphisms (including
2677 SNP) in this gene, on both cellular localisation and transport function of P-
glycoprotein (Kimchi-Sarfaty, Gribar, and Gottesman 2002). The observed functional
effect ascribed to the C3435T variant may reflect linkage disequilibrium with a
polymorphism elsewhere in the genome that modifies MDR1 expression and function.
However, at present this hypothesis requires further detailed studies of the gene.
Overall, the available evidence suggests that the C3435T polymorphism is predictive
ofMDR-1 expression. Kim et al showed that MDR 1*2 haplotype (G2677T/C3435T)
was associated with increased P-glycoprotein function in vitro and low concentrations
of a known substrate, fexofenadine(Kim et al. 2001a). Fellay and colleagues,
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demonstrated that the MDR1 3445 TT genotype was associated with a low expression
of MDR1 transcripts and P-glycoprotein expression in peripheral blood mononuclear
cells with low plasma levels of nelfinavir and efavirenz (antiretroviral agents)(Fellay
et al. 2002). Hitzl and colleagues showed that in CD56+ cells (NK cells), MDR1 3445
TT had lower P-glycoprotein function and expression compared with the CC genotype
(Hitzl et al. 2001). In another study, Nakamura et al. investigated the effect of the
C3445T mutation on the expression level ofMDR1 mRNA in duodenal enterocytes of
healthy Japanese subjects (Nakamura et al. 2002) and found significantly elevated
levels of transcripts in those patients with TT compared with CC allele. Given the
likely complicated interactions with cytochrome P450 system and the presence of
other poorly characterised transporter systems, the relationship between the function
of P-glycoprotein and drug substrate level is debatable. This consideration and the
differences in study designs may explain these apparently contradictory results.
Moreover, there maybe cell specific differences in regulation. There is a clear need for
further well-designed studies using in vivo and ex vivo systems to reconcile these
differences.
The model of the involvement of PgP in the aetiopathogenesis of IBD that logically
follows from consideration of the phenotype of the mdrla (-/-) model is that low
intestinal PgP expression may predispose to inflammation, and high levels of
expression may protect. Thus genetic influences that determine the expression and
functionality of PgP may be expected to influence the susceptibility to IBD (assuming
that PgP plays a pivotal role in pathogenesis). It is noteworthy that the MDR1 gene
maps to chromosome 7q22, a locus of IBD susceptibility as identified by genome
wide scanning (Satsangi et al. 1996b). The MDR1 gene is composed of 28 exons and
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is 209 kb in length, and more than 30 SNPs have been described(Hoffmeyer et al.
2000a; Cascorbi et al. 2001a; Kim et al. 2001b).
The two previously described SNPs, exonic variant C3435T and G2677T/A have been
shown to correlate with activity/expression of P-glycoprotein 170 and have received
most attention. The C3435T SNP in exon 26 has been most extensively investigated
and was first shown to correlate with expression of PgP(Hoffmeyer et al. 2000a). In
this study, the TT genotype was associated with decreased intestinal P-glycoprotein
170 expression with functional consequence, as inferred from measurements of the
systemic bioavailability of digoxin , a PgP substrate, following oral administration
(due to decreased excretion of digoxin by PgP). This has been replicated in other
pharmacokinetic studies(Hitzl et al. 2001; Kim et al. 2001a; Johne et al. 2002b). In
addition, the effect of the MDR1 C3435T SNP and its postulated correlation with P-
glycoprotein 170 activity/expression has been shown to play a role in drug-resistant
epilepsy(Siddiqui et al. 2003), immune recovery after initiation of anti-retroviral
therapy in HIV(Fellay et al. 2002) and the development of renal cell
carcinoma(Siegsmund et al. 2002).
1.4.5 The role of ABCB1/MDR1 gene in pharmacogenetics
The multidrug resistant gene has been postulated to contribute to the phenomenon of
corticosteroid resistance in inflammatory bowel disease. Farrell and colleagues,
demonstrated that P-glycoprotein 170 expression in peripheral blood lymphocytes was
associated with failure of medical treatment in IBD(Farrell et al. 2000). The authors
also demonstrated that PgP expression appeared to be constitutive as levels were
similar when active IBD patients were followed up 3 months later; and suggested that
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genetic factors may play an important role in determining corticosteroid resistance in
IBD. Farrell and his colleagues investigated the role of P-glycoprotein on
lymphocytes as a factor in determining responsiveness to medical therapy (Farrell et
al. 2000). Corticosteroids and cyclosporin are both substrates of P-glycoprotein (Ueda
et al. 1992). Peripheral blood lymphocytes in patients with active Crohn's disease (15
patients) and ulcerative colitis (28 patients) in whom medical therapy had failed and
surgical intervention had been necessary, were shown to have a higher expression of
P-glycoprotein compared with those who had inactive disease and required surgery
for obstruction (25 patients) and dyplasia (13 patients) respectively (p=<0.0001 and
0.0002 respectively). Interestingly, in ulcerative colitis, there was no significant
difference when P-glycoprotein expression was compared between the patients
requiring colectomy for failed medical treatment and the group with active UC
(p=0.6). The intraepithelial lymphocyte expression of P-glycoprotein was shown to
correlate significantly with peripheral blood lymphocyte expression. Farrell et al.
went on to demonstrate that by blocking the action of P-glycoprotein on human cell
lines, higher intracellular levels of cyclosporin and corticosteroids were achieved
(Farrell et al. 2002) and speculated that this may be a potential target for
pharmacotherapy in a later study.
The functional consequences of this increased MDR1 expression and the effects of
genetic polymorphisms within the MDR-1 gene on expression and function are
important questions generated by this study. Perhaps most crucially, there is a need to
elucidate whether there is a correlation between lymphocyte expression of MDR and
the expression on intestinal epithelial cells in both the healthy gut and disease states.
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With respect to MDR1 over-expression as a factor in corticosteroid-resistance, this
has been studied in other conditions. In patients with glucocorticoid resistant asthma,
P-glycoprotein expression on peripheral blood lymphocytes was not found to be
increased compared with those with responsive or mild asthma (Montano et al. 1996).
In patients with rheumatoid arthritis treated with glucocorticoids, the expression of P-
glycoprotein on peripheral blood lymphocytes was increased compared with those
without therapy (Maillefert et al. 1996). Patients with rheumatoid arthritis without
corticosteroid therapy did not demonstrate a higher expression of MDR1 and this
again may reflect a secondary effect to corticosteroids. Farrell et al. did not find any
difference in the expression of P-glycoprotein in patients with active disease
inflammatory bowel disease (80% on corticosteroids) compared with those with
inactive disease (20% on corticosteroids)(Farrell et al. 2000). There are several
caveats to these studies. Firstly, peripheral blood lymphocytes consist of different
subsets of lymphocytes which express MDR-1 at varying levels (Ludescher et al.
1998). Indeed within the gastrointestinal tract, it is accepted that the lymphocytes
homing to the gut-associated mucosal lymphoid tissue are phenotypically distinct to
the circulatory lymphocytes. In addition, Yacyshyn et al, has demonstrated that the
intra-epithelial, lamina propria and peripheral blood lymphocytes all demonstrated
different levels of MDR-1 expression and activity in UC, CD and healthy controls.
CD3 and CD8 lymphocytes also were present in different proportions in these groups
of subjects. Furthermore, these subsets have intrinsically different levels of P-
glycoprotein function (CD8 has higher levels of P-glycoprotein). Overall, MDR-1
expression and function were found by these investigators to be lower in UC
compared with CD and healthy controls (Yacyshyn, Maksymowych, and Bowen-
Yacyshyn 1999). Secondly, the effect of corticosteroids (or indeed other treatments
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used in inflammatory bowel disease) on MDR-1 expression is not fully established. It
remains to be seen whether higher expression of P-glycoprotein reflects a secondary
phenomenon to corticosteroid therapy or a primary one, influencing the response to
treatment. Finally, as discussed earlier, increased expression does not necessarily
imply increased function in diseased states.
1.4.6 The role of Pregnane X-Receptor: Does defective detoxification impair
barrier defence in IBD?
The importance of defective detoxification mechanisms coordinated by Pregnane-X
receptor at the epithelial celullar level in IBD has recently been demonstrated
(Langmann et al. 2004). PXR is a nuclear hormone receptor that is ligand-activated by
a large number of structurally and pharmacological diverse endogenous compounds
(including pregnanes, corticosteroids, rifampicin and bile acids)(Staudinger et al.
2001; Chrencik et al. 2005; Schuetz et al. 2001; Willson and Kliewer 2002). It is of
interest to note that the function and expression of MDR1 is closely regulated by
PXR(Kliewer, Goodwin, and Willson 2002). Central to the recent human microarray
data Langmann et al., is the suggestion that PXR may also act in conjunction with
MDR1 in determining susceptibility to IBD (in particular UC). Dysregulated PXR
expression and function leading to the resultant widespread effect on the downstream
detoxification genes therefore predisposes to increased risk of inflammation.
Preliminary data (in abstract form) by Blokzijl et al. showed that PXR expression is
indeed reduced in IBD, but this was also the case in non-IBD inflammatory tissues
(such as collagenous colitis and diverticulitis)(H.Blokzijl 2005). Further detailed
functional studies are clearly required to investigate this hypothesis. As highlighted
earlier, these findings now also suggest that PXR itself may represent an attractive
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candidate gene for IBD. In Langman's study, DNA microarray analysis involving
non-affected colonic tissue of CD and UC, revealed a cluster of strongly down
regulated detoxification genes (of the glutathione and sulfo-transferase family) and
ABC transporters (including MDR1) in UC, together with the near complete loss of
the transcriptional regulator pregnane X receptor (PXR). Strikingly also, the
expressions of MDR1 and PXR were both reduced in tissues of patients with UC in
subsequent rt-PCR analysis in the same study. PXR regulates the induction of many
genes including CYP3A4 and the ABC transporter family genes (which includes
MDR1). It is of interest to note that two earlier separate DNA microarray studies also
showed downregulation of the MDR1 gene along with several other detoxification
genes studied (carboxylesterase 2, oestrogen SULT and CYP1A1).
Therefore, the current available data suggest that efflux transport mechanisms
mediated by ABC-transporters (and others such organic cation transporters) and also
detoxification mechanisms at the epithelial interphase, play critical roles in barrier
defence. Their respective precise mechanistic roles and cross-talk between the
innate/adaptive immunity and inflammation remain unknown but represent important
scientific questions. Several hypotheses are possible: a defect in mucosal barrier
defence could lead to increased uptake of luminal antigens and/or adjuvants that
overwhelm the net suppressive tone of the mucosal immune system. Alternatively, a
defect in epithelial repair could potentiate damage by environmental triggers such as
NSAIDs or infections that cause only transient damage in normal hosts. The net effect
of either pathway is constant stimulation of innate and acquired mucosal immune
responses by luminal adjuvants and antigens, respectively.
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Table 4: Regional variation in P-glycoprotein expression in humans and rodents
Authors Subjects Methods Findings
Yumoto et al
(2001)
Mice Efflux rate via
rhodamine-123
assays
High in ileum compared
with duodenum
Fojo (1987) Human tissues MDR1 mRNA Colon > Jejunum >
Rectum >
Stomach/Oesophagus
Fricker (1996) Human GI tract MDR1 mRNA Colon > Jejunum/Ileum
> Stomach
Chianale (1995) Rat intestine mdr3 mRNA and
rhodamine-123
assay
Ileum > Jejunum >
Duodenum





proximal to distal colon.
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Table 6: Studies in the effects of corticosteroids on MDR/P-glycoprotein 170
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Salpati et al
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Table 7: Cell populations and transporter substances in studies of MDR1 3445TT
genotype.
Study Cell type Expression/functionMDR1 3445T
Plasma drug
concentrations
Hoffmeyer et al Enterocytes ^MDRl mRNA tDigoxin






Kim et al Transfected murine
NIH-3T3









Nakamura et al. Duodenal
enterocytes
tMDRl mRNA idigoxin
Pgp - P-glycoprotein; MDR1 *2 haplotype - G677T/C3445T; NA - not available,
MDR - multidrug resistance, mRNA - messenger RNA, 4= decrease and T=increase.
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Table 8. Single nucleotide polymorphisms (SNPs) in the MDR1 gene.




T-12C Exon 1 85 11.8 0 0.4 Non-coding
G-1A Exon 2 188 11.2 0 0.4 Translation
A61G Exon 2 188 17.6 0.5 0.81 Asn21 Asp
G-25T Intron 4 85 26.0 3.5 2.3 Unknown
G-35C Intron 4 85 1.2 0 0.01 Unknown
T307C Exon 5 85 1.2 0 0.01 Phel03Leu
C+139T Intron 5 85 48.2 16.5 16.8 Unknown
C+145T Intron 5 85 2.4 0 0.01 Unknown
G1199A Exon 11 85 12.9 0 0.4 Ser400Asn
C1236T Exon 12 188 48.9 13.3 14.4 Gly412Gly
C+44T Intron 12 188 11.7 0 0.4 Unknown
T-76A Intron 16 85 45.9 22.4 20.3 Unknown
A+137G Intron 17 85 1.2 0 0.01 Unknown
G2677T Exon 21 83 43.4 42.2 38.4 Ala893Ser
G2995A Exon 24 36 11.1 0 Ala999Thr
C3445T Exon 26 537 47.7 26.4 24.1 Ilel 145Ile
C3396T Exon 26 188 0.53 0 0.01 Wobble
The positions of identified SNPs correspond to positions of the MDR1 cDNA (gb :
Ml 4758, codon TTC in exon 10) with the first base of the ATG start codon set to 1.
SNPs that are located in introns are presented as exon +/-n, where n = nucleotide
upstream (+) or downstream (-) of exons. The predicted ratios of homozygous
genotypes (q2) were calculated on the basis of the Hardy-Weinberg distribution.
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Fig 3: 2-Dimensional hypothetical structure ofP-glycoprotein 170 pump.
A B
Fig 4.: 3-Dimensional hypothetical structure of P-glycoprotein (NBD - nuclear
binding domain, P - pore, TMD - transmembrane domain, A- view from above, B -
view from below.
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1.5 Rationale and plan of thesis
The overall aims of this thesis are to investigate the roles of clinical and genetic
factors in determining the course of ulcerative colitis. The rest of the thesis will
describe the rational approach adopted, starting with clinical studies, followed by
genetic association studies based on the highly accurate phenotypic data assimilated
from the former. Chapter 2 will describe the overall material and methods employed
in this thesis. Each of the subsequent chapters will start with a short introduction and
more detailed description ofmethods pertinent to the respesctive chapter.
In chapter 3, the importance of corticosteroid dependence and resistance is examined
in the first United Kingdom dataset in inflammatory bowel disease and the only the
second study worldwide in ulcerative colitis. Detailed clinical parameters which may
identify patients at increased likelihood of early non-response within 30 days of
therapy and surgery within 1-year of follow-up are investigated. The current data
highlighted the consistent nature of corticosteroid dependence/resistance and the need
to understand the molecular mechanisms underlying this phenomenon.
In chapter 4, the development of a predictive model, which aids the selection of
patients for early second-line medical therapy or surgery in severe ulcerative colitis, is
presented. This study is based on the largest cohort of patients with unequivocal
severe disease as defined by the modified Truelove and Witts criteria. A simple
numerical index involving the stool frequency within 1st 3 days of intravenous
corticosteroid therapy, serum albumin and radiological finding of colonic dilatation
defines 3 risk groups: low, intermediate and high (10%, 45% and 85% risk of
colectomy) is formulated and discussed.
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In chapter 5, the association study involving 2 candidate polymorphisms (C3435T and
G2677T/A) within the MDR1 gene in a Scottish-Caucasian cohort of 335 UC, 268
CD and 370 healthy controls is described. The overall association with T-allele and
TT-genotype of the MDR1 3435 SNP is shown with UC. In addition, the novel
associations with extensive UC (from detailed genotype-phenotype analysis)
confirming the importance of phenotypic heterogeneity in association studies in IBD;
and 2-locus haplotype analysis which demonstrated protective and susceptible
haplotypes are discussed in depth. The latter has led to the generation of the
hypothesis that genetic contribution may influence the functionality or expression of
the gene product, P-glycoprotein 17o which in turn influences susceptibility to UC in
a bi-directional fashion. The pharmacogenetic contributions of these polymorphisms
in IBD are also investigated.
In chapter 6, the successful application of a gene-wide haplotype tagging strategy is
shown using the MDR1 gene in assessing the overall contribution of the gene and to
discriminate critical variants associated with disease susceptibility. The gene was re-
sequenced in 24 CEPH trios and the haplotypic structure was determined. By using a
haplotype r2 method, the association of MDR1 gene was demonstrated in UC (and the
phenotype of extensive disease). This association is shown to be critically dependent
on an upstream intronic variant, rs3789243 and to be additive to other selected
tagging SNPs.
In chapter 7, the application of candidate gene-wide tagging strategy is extended to
investigate the contribution of the Pregnane-X Receptor gene to disease susceptibility
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in IBD. Pregnane-X receptor is a transcriptional regulator of xenobiotic metabolizing
enzymes and efflux transporters from the ATP-binding cassette, ABC-superfamily.
Allelic variations of this gene have recently been shown to be associated with
inflammatory bowel disease in an Irish dataset. The data generated is used to re¬
examine these associations within the Scottish dataset.
In chapter 8, we presented further genetic association of mutiresistant protein 3
ABCC3/MRP3) with inflammatory bowel disease. Haplotypic analyses revealed
significant associations in independent Scottish and Swedish case-control cohorts. In
addition, we have presented detailed haplotypic-phenotypic subanalyses and also
stratification with ABCB1/MDR1 and PXR genotypes to determine gene-gene and
gene-environmental interactions with ABCC3/MRP3 gene.







1.1.1 Definition of ulcerative colitis and Crohn's disease
The definitions of ulcerative colitis and Crohn's disease were based on the
classifications as described by Lennard-Jones(Lennard-Jones 1989). This original
classification set out a list of exclusion criteria (infection, ischaemia for example) and;
histological and clinical features associated with each respective entity. There was
ratification by an experienced histopathologist for each diagnosis, and patients with
indeterminate disease, were excluded. Patients with acute severe UC were defined
according to the modified Truelove and Witts criteria (Presence >6 bloody stoos with
one or more the following features: tachycardia, fever, anaemia or elevated ESR).
2.1.2 Recruitment of patients and healthy controls
3.1.3 Patients were recruited from the gastroenterology units of Western General
Hospital, Royal Infirmary Edinburgh and St. John's Hospital, Livingston (all
in Lothian region serving a catchment population of approximately 500 000
patients) between 1997-2003. In the genetic case-control studies, controls were
actively recruited from healthy volunteers and also obtained from anonymous
Scottish-Caucasian blood donors from the Lothian region. The demographic
details and numbers used are described in detail in the subsequent chapters
(4,5,6,7 and 8). The number of IBD patients varied between chapters, due to
differences in study recruitment phases and designs. In chapter 3, the IBD
cohort comprised of newly diagnosed patients commenced on corticosteroids;
in chapter 4, the cohorts were recruited with acute severe UC (satisfying
Truelove and Witts criteria). In chapters 5 to 8, the increasing number of IBD
patients reflected on-going recruitment as genotyping were performed at
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different time points. There is an overlap between the clinical cohorts in
chapters 3 and 4, but these are addressed separately in the respective chapters.
All patients were unrelated. A further replication case-control cohort from
Sweden was also used and recruited from the Gastroenterology Units,
Karolinske Institute, Sweden. All patients and controls were coded
anonymously prior to entry to database as described below. In each of these
patients, 10 mis of whole blood were obtained for DNA extraction (method
described in following subsection).
4.1.4 Phenotypic data acquisition
Phenotypic data was extracted using standard proforma datasheets (see Appendix). In
patients with acute severe UC, a further total of 56 parameters where collected for
patients during the acute phase of illness in order to investigate their respective
discriminant value in predicting outcome during an attack of severe UC (n=167).
Further phenotypic classifications are based on the Vienna and Montreal disease
classifications. In the latter, this classification has allowed the further
subcategorisation of UC by disease extent (El-proctitis, E2-left-sided and E3-
extensive disease) and severity (S3-severe disease as defined by the modified
Truelove and Witts criteria. The descriptions of the current cohort in the association
studies will be presented in detail in Chapters 7 and 8.
5.1.5 Database/Statistical Programs
All original phenotypic data was stored in Access Database, which was independently
maintained by a database manager (Hazel Drummond). Additonal data sorting was
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performed using the Excel Database. The main statistical analyses were performed
using the Minitab version 10, GraphPad Instat and Prism programs. Log-likelihood
analyses were described in detail in the relevant chapters, and carried out using EH+
and partition-ligation expectation-maximization (PLEM) programs accessed via the
Medical Reseach Council-Rosalind Franklin Centre of Genomic Research
(www.rfcgr.mrc.ac.uk). Flaplotype construction/analyses were performed using
Haploview 3v2, Cocaphase Software and also SNP-HAP (latter 2 progrmas accessed
at www.rfcgr.mrc.ac.uk). The re-sequencing scoring was undertaken using the
Sequencher software (Gene Codes Corporation, Ann Arbour, Michigan, USA).
2.1.5 Genomic Databases
The sequence variations to design SNP primers were derived from the Ensembl
(www.ensembl.org). HapMap (www.hapmap.org) and NCBI Genbank sequence
databases (http://www.ncbi.nlm.nih.gov/Genbank/index.html). In addition, the
Haploview program (http://www.broad.mit.edu/mpg/haploview/) was used to assess
linkage disequilibrium.
2.1.6 Ethics Approval
The Lothian Research and Ethics Committee (LREC) approved this study and written
consent was obtained from all patients.
2.2 Cellular methods: Genotyping
1.2.1 DNA extraction and storage
Genomic DNA was extracted from peripheral venous blood by a modified salting-out
technique and resuspended in lxTE (lOmM Tris (pH 8.0), ImM EDTA (pH 8.0) at a
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final concentration of 100 ng/ml. The optical density of the resultant DNA was
measured using a Gene Quant Pro instrument to estimate the actual DNA
concentration. Using a standard protocol, 10 mis of whole blood were added into a
50ml conical tube together with 40 mis of red cell lysis buffer, and mixed and
resuspended for 5 minutes. This was then centrifuged at 3000 rpm for 10 minutes.
Following this, the supernatant was removed, the pellet resuspended with 10 mis of
RCLB and re-centrifuged at 3000 rpm for a further 5 minutes. The pellet was then
further resuspended in 3 mis of nuclear lysis buffer and sodium dodecyl sulphate. One
ml of 6M sodium chloride and 3mls of chloroform were subsequently added leading
to emulsification of DNA (after vigorous mixing). This was then centrifuged at 3000
rpm for 20 minutes. The contents of the tube separate into 3 layers for which the
middle was that of DNA material. This layer was then removed and added into
ethanol to allow precipitation of DNA. This DNA pellet was then removed and
washed in lOmls of 70% ethanol and then dried in room air for 5 minutes. The
precipitated DNA was transferred into 0.5 mis of TE buffer and stored at 4°C until
dissolves. Genomic DNA is diluted to lOOng/pl for PCR analysis.
2.2.2 PCR reaction: TaqMan technology
The main genotyping in this thesis was performed using TaqMan® (ABI, San Diego,
CA). This PCR-based assay uses laser scanning technology which excites fluorescent
dyes present in the specially designed TaqMan® probes. The system includes a built-
in thermal cycler, a laser to induce fluorescence, CCD (charge-coupled device)
detector, real-time sequence detection software, and TaqMan® reagents for the
fluorogenic 5' nuclease assay. The cycle-by-cycle detection of the increase in the
amount of PCR product is quantified in real time as the special probes, "reporter dye",
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fluoresces when the "quencher" is removed from the fragment during the PCR
extension cycle. The primers for respective SNPs studied in this study are selected
using the generic Assay-on-Demand or Assay-by-design service by ABI, Inc. The
prepared genomic DNA was laid-out in 96-well plates prior to genotyping at the
Wellcome Genetics Core, Western General Hospital, Edinburgh. In each plate,
negative control wells are used to check the quality of reaction.
TaqMan reaction volumes and cycling conditions
Reaction Component Assay by Design 40X mix
Abgene Absolute QPCR ROX
mix
2.5pl
Genotyping Assay Mix 0.125pl
dH2Q 2.375pl
Thermal cycling conditions were two initial holds (50° C for 2 min and 95° C for 10
min) followed by a 40-cycle two-step program (95° C for 15 sec and 60° C for 1 min).
3.2.3 Allelic discrimination in TaqMan
Allelic discrimination was scored independently by 2 blinded-laboratory scientists
(Angie Fawkes and Stuart Bayliss, Wellcome Genetics Core, Edinburgh). As quality
control, a random selection of DNAs was re-genotyped and compared with original
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4.2.4 DNA sequencing reaction
PCR reaction mix (14 pi of PCR mix as described below and 2 |al DNA gives a final
volume of 16 gl). The components were assembled in 1.5 ml eppendorf using filtered
tips. The cycling conditions for the sequencing PCR reaction was 25 cycles of 96°C
(10 seconds), 50°C (5 seconds) and 60°C (4 minutes).
x 1 x 100 (one plate)
MQ water 9.952 995.2
Qiagen buffer 1.6 160
25 mM MgCl2 0.64
64
(final concentration 2.5mM)
dNTP mix (25 mM each) 0.128 12.8
Qiagen HotStart Taq 0.08 8.0
Forward primer (10 puM) 0.8 80
Reverse primer (10 guM) 0.8 80
Total volume 14.0 1400
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2.2.5 PCR clean-up and re-sequencing protocol
Following confirmation of PCR products, 4 pi of Exo-Sap was added to the remaining
10 pi of the PCR products. The reaction plate was then put into the PCR machine with
this cycling parameter: 37°C (45 minutes), 80°C (15 minutes) and 4°C (hold). The
80°C temperature will inactivate most of the enzyme. However, Exo-Sap will still be
active in 4°C; therefore if the plates were not used immediately, these were stored at -
20°C. Two pi of this cleaned-up PCR were used in direct sequencing as detailed
below.
To clean up the sequencing reaction products, 80 pi of 80% isopropranol were added
to each reaction, mixed thoroughly and left in room temperature for 10 minutes.
Thereafter, the PCR plates were centrifuged at 3780 rpm for 60 minutes. Following
this process, the PCR plates were inverted on a blotting paper and centrifuged for 1
minute at 1000 rpm. The whole step was repeated once more; this time 150 pi of 70%
isopropranol was added to each reaction and centrifuged at 3870 rpm for 10 minutes.
Following further inversion of the plates and low speed centrifugation, the plates were
left to dry in room temperature for 15 minutes.
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2.2.6 Equipments and reagents
PCR machines
TaqMan ABI Fast Real Time PCR 7600 HT (Applied Biosystems)
AB1 3700 Big Dye Terminator Sequencer (Applied Biosystems)
Techne Touchgene PCR Gradient machine
Electrophoresis reagents
Agarose gel:
Multipurpose agarose (2.25g) was added to 150 millilitres (ml) of half strength TBE
into a 250 ml beaker. This was then microwaved on full power for between 2 and 3
minutes agitating halfway through until all of the agarose had dissolved into solution.
The agarose was then cooled to around 50°C by running under a cold water tap,
before 10 microlitres (pi) of ethidium bromide was added and then agitated further to
ensure even distribution. The agarose solution was then poured into a transparent gel-
casting tray, which was sealed at each end using autoclave tape. Four combs
containing either 12 or 16 wells were then inserted into the gel. The gel was then left
to cool and solidify at room temperature for at least 30 minutes.
Loading Buffer:
Orange G in 40% sucrose was used aas loading buffer. 5pl was added to each PCR
well prior to loading.
Agarose gel electrophoresis
lOOmls of liquid agarose was poured into a transparent gel-casting tray, which was
sealed at each end using autoclave tape. Twelve combs, each comprising 12 wells,
were placed into their slots and the gel left to solidify for 30 minutes at room
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temperature. The tape and combs were removed before placing in a horizontal
electrophoresis tank fdled with 0.5x TBS. Prior to pipetting, PCR reaction was pre-
mixed with Orange G loading buffer. lOpl of PCR mix was then loaded from each
well into the gel. The samples were electrophoresed for 30 minutes (150 V, 150 mA,
150 W).
Interpretation ofgel images
Gels were photographed digitally under UV light (320nm) using a 3 second exposure.
Images were anonymised and stored on a computer network for later genotyping. All
digital images were read manually. Each PCR reaction was deemed to have worked if
the control amplicon was present. Positive allele-specific amplification was identified
by the presence of a correct sized PCR amplicon. If a reaction had neither control nor
allele-specific amplicon the reaction was deemed 'not tested'. For single markers two





The G2677T/A (rs2032582) was a triallelic SNP, and allelic/genotypic data was
obtained by seqeuencing using GTCTCATGAAGGTGAGTTTTCAG (forward
primer) and GGGAGGAAGGAAGAACAGTGT (reverse primer) to flank a 572-base
pair region (product size 572 base pairs) (Chapter 5).
Two further SNPs, rsl 186746 rs 1186745 (located 13 base pairs from each other,
intron 27) could not be genotyped using TaqMan due to technical reasons and these
SNPs were sequenced using the TAGTTCTTTTCCCTAATTCCTCTT (forward
primer) and GGTTCACACCATTCTCCTG (reverse primer) (product size 246 base
pairs) (Chapter 6).
The remainder tSNPs for ABCB1/MDR1: rs3789243 (Intron 3), rsl 128503 (Exon
121), rs2235046 (Intron 16) and rsl045642 (Exon 26) were available as Assay-on-
Demand service by ABI-biosystems.
Pregnane-X receptor (PXR)
A full set of five tSNPs (rsl523127, rs2461823, rs7643645, rsl464603 and
rs2472682) were available on Assay-on-Demand service by ABI-biosystems.
Multidrug resistant protein 3 (MRP3)
Eight tSNPs (rs757421, rs2412333, rs739921, rsl2051822, rs2301837, rs879459,
rs2277624 and rs3785911) were on Assay-on-Demand service by ABI-biosystems.
All primers were checked with BLAST program (www.ensembl.ora).
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Chapter 3
The efficacy of corticosteroid
therapy in inflammatory bowel
disease: analysis a 5-year UK
inception cohort
Abstract
Background: Corticosteroids remain the mainstay of first-line therapy in active
inflammatory bowel disease.
Aims: To determine the clinical outcome after the first corticosteroid-therapy and; to
identify factors which predict response/failure.
Methods: 216 (136 UC and 80 Crohn's disease) patients were identified in this 5-year
inception cohort. The outcomes of early (30-days) and late (1-year) response were
used. Multivariate analyses were performed to identify factors associated with
outcome.
Results: 86 (63%) and 60 (75%) UC and Crohn's disease required corticosteroid
therapy respectively. In UC, at 30-days, 69 (51%), 42 (31%) and 25 (18%) patients
demonstrated complete response, partial response and no response respectively. For
Crohn's disease, these outcomes were observed in 32 (40%), 28 (35%) and 20 (25%).
After 1 year, 75 (55%), 23 (17%), and 29 (21%) patients with UC demonstrated
prolonged response, corticosteroid-dependence or required surgery respectively. For
Crohn's disease, these outcomes were observed in 30 (38%), 19 (24%) and 27(35%)
patients respectively. Extensive UC was a predictor of surgery (p=0.001, OR 15.24).
In Crohn's disease, inflammatory disease behaviour was negatively associated with
surgery (p=0.02, OR 0.13).
Conclusion: Although corticosteroids are effective, dependence/resistance remains
common. Patients with extensive UC and fistulising/stricturing Crohn's are most at
risk of failing corticosteroid-therapy.
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3.1 Introduction
For more than 50 years, corticosteroids have represented the mainstay of medical
therapy in active inflammatory bowel disease (IBD)(Truelove SC and Witts LJ 1955).
As with many inflammatory conditions(Barnes 2004; Chikanza and Kozaci 2004;
Seki M et al. 1998; van Schaardenbnrg D et al. 1995; Carmichael et al. 1981), failure
to respond (corticosteroid resistance) and to wean (corticosteroid dependence) are
significant problems; contributing to increasing morbidity secondary to both
continually active disease and prolonged exposure to corticosteroid therapy(Farre 11
and Kelleher 2003; Laine and Hanauer 2003). The increased awareness of the
detrimental effects of prolonged corticosteroid use has led to stringent attempts by
patients and physicians alike to minimise the exposure or indeed to avoid the use
corticosteroids all together. In this context, the use of immunosuppressants such as
azathioprine/6-mercaptopurine and methotrexate are now also firmly
established(Pearson et al. 2000; Sandborn et al. 2000; Jewell and Truelove 1974;
Fraser, Orchard, and Jewell 2002; Feagan et al. 1995; Feagan et al. 2000; Ardizzone
et al. 2006). In the recent years, there has been an expansion of biological therapies, in
particular, monoclonal antibody therapy directed against tumour necrosis factor such
as infliximab in Crohn's disease(Sands et al. 2004; Flanauer et al. 2002) and more
recently in UC(Rutgeerts et al. 2005; Jarnerot et al. 2005b); together with nutritional
therapies(Gonzalez-Huix et al. 1993; Heuschkel 2000; Zachos, Tondeur, and Griffiths
2001).
As described in chapter 1, several studies have attempted to define the prevalence of
corticosteroid resistance in IBD. By defining corticosteroid dependency as initial
response to an adequate dose of corticosteroid but followed by clinical relapse at dose
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reduction or within 30 days after corticosteroid treatment and steroid resistance as no
response within 30 days of corticosteroid therapy, studies have shown rates of
dependency and resistance of 30% amongst patients with IBD(Munkholm et al. 1994;
Faubion et al. 2001). A high frequency of surgical intervention was reported in
corticosteroid dependent (26%) and resistant patients (59%) within 1 month after
corticosteroid treatment(Munkholm et al. 1994). Although factors such as
underdosing and abrupt tapering of corticosteroids maybe responsible for failure of
this therapy, a prospective study involving 48 consecutive patients with active CD,
using a higher oral corticosteroids dose and a slower tapering schedule than used in
the previous studies reported steroid dependency and resistance rates of 63% and
13%, respectively(Reinisch et al. 1995). 1 report the rates of corticosteroid resistance
and dependence in a more recent 5-year hospital-based inception cohort. In order to
provide an accurate comparison, we have utilised previously used definitions in the
studies by Munkholm and Faubion et al. I have assessed the 30-day and 1-year
outcome of the first corticosteroid treatment for active Crohn's disease and UC in this
cohort. This is the first UK dataset in inflammatory bowel disease and the only the
second study worldwide in UC describing the natural history of corticosteroid
therapy. In addition to the descriptive results, 1 provide detailed analyses of clinical
parameters which may identify patients at increased likelihood of early non-response
within 30 days of therapy and surgery within 1-year of follow-up.
3.2 Material and Methods
The data in this study was based on a 5 year hospital-based inception cohort study of
IBD patients diagnosed at the Western General Flospital, Edinburgh, Scotland (1998-
2003). All patients were either referred by their General Practitioners or presented as
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emergencies. This hospital serves an estimated catchment area of 448, 624 persons in
the Lothian region, Scotland, United Kingdom. Tertiary referrals outwith the Lothian
region hospitals were not considered.
Patient identification
I identified patients who were newly diagnosed between 01/01/98-15/08/2003 using 2
methods: Firstly, we analysed the Inflammatory Bowel Disease Database, Western
General Hospital, Scotland. This is a continually updated database which is managed
independently by a dedicated database manager (HD) and represents the core resource
of the IBD genetics programme in the Western General Hospital. Secondly, we
searched the Histopathological Database of the Lothian University Hospitals
(incorporating Western General Hospital) (SNOMED) using the term
INFLAMMATORY BOWEL DISEASE. All case notes were reviewed and, a total of
136 cases of UC and 80 cases of CD which fitted the above criteria were identified.
Information was extracted by reviewing relevant outpatient letters, referral letters and
discharge summaries in addition to biochemistry, radiology, colonoscopy and
histology reports. Patients with the diagnosis of indeterminate colitis were excluded
from the study.
Data collection
All relevant data were collected and entered into a standard proforma data sheet.
Among the details collected were age at diagnosis, sex, date of commencement of
corticosteroid treatment, smoking details, concomitant medication within 30 days of
diagnosis, site and extent of disease. UC phenotype was classified by disease extent,
severity and need for surgery. CD was classified according to the Vienna
Classification of disease location, behaviour and age of diagnosis, as previously




Corticosteroid therapy consisted of either oral/intravenous Prednisolone or oral
Budenoside. Date of corticosteroid commencement, interval between diagnosis and
corticosteroid treatment, date of discontinuation, length of treatment and reason for
discontinuation were documented when the first corticosteroid therapy was started (all
patients in this study are corticosteroid naive). Subsequently, outcomes at 30 days and
1 year after commencement of corticosteroid therapy were assessed.
Dose and taper ofcorticosteroids
Corticosteroid therapy consisted of either intravenous/oral Prednisolone or oral
Budesonide. In patients requiring intravenous treatment, the intended duration of
corticosteroid therapy was 5-7 days with conversion to oral Prednisolone at 40
mg/day if clinical response was evident. Our centre uses intravenous
methylprednisolone 60 mg/day (equivalent dose of 84 mg of oral Prednisolone). The
policy for tapering doses of oral corticosteroids was to decrease the dose of
Prednisolone by 5 mg/week following a usual starting dose of 40 mg/day of one week.
In patients with Crohn's disease requiring oral Budesonide, the starting dose was 9
mg/day and tapering by 3 mg every 3 weeks was performed.
Outcomes/Endpoints
Outcomes and end-points of follow-up were considered at day 30 and 1 year.




Total regression of clinical symptoms, (<2 bowel movements per day, no blood, pus
or mucus in stool and no abdominal pain, fever, weight loss or extra-intestinal
symptoms)
2. Partial Remission:
Regression of clinical symptoms, (<4 bowel movements per day, blood, pus or mucus
in stool or abdominal pain or all 4 less than daily and no systemic symptoms such as
fever, weight loss or extra-intestinal symptoms)
3. No Response:
No regression of clinical symptoms.
At 1 year: After the initial dose of corticosteroid, patients were again classified into 1
of 3 categories: Prolonged response, corticosteroid dependent and Surgery
1. Prolonged corticosteroid response:
Maintenance of complete or partial remission for at least 30 days after treatment has
completed
2. Corticosteroid dependence:
Initial response to an adequate dose of corticosteroid but followed by clinical relapse




Descriptive statistics were displayed using median values and interquartile range.
Univariate analyses were performed to compare variables between responders/non-
responders within 30 days of corticosteroid therapy and surgery/non-surgery 1 year
after initiation of corticosteroid therapy. Categorical and continuous variables were
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analyzed using Chi-square test and Mann-Whitney tests respectively. Odd ratios (OR)
were given with 95% confidence intervals and 2-sided p-values. A p-value of <0.05
was considered significant. Kaplan-Meier survival curve analyses and log-rank test
were performed to demonstrate and compare the cumulative risk of surgery in UC and
Crohn's Disease respectively, using GraphPrism (version 4.00 for Windows,
GraphPad Software, San Diego California USA). Multivariate analysis was performed
using a logistic regression model to test identify clinical parameters which predict the
non-response to corticosteroid therapy within 30 days; and the need for surgery within
one-year of the initiation of corticosteroid therapy respectively. The logistic
regression analyses were performed in the groups of UC and Crohn's Disease
separately. For UC, the variables considered were: sex, age at diagnosis, smoking,
disease extent, the use of 5-ASA/mesalazine and azathioprine. For Crohn's Disease,
the similar variables were used with disease location and behaviour replacing disease




Patient demographics (Table and Figure I)
86 (63%) UC and 60 (75%) CD patients required treatment with corticosteroids
(Figure 1). The demographics and phenotypic details are summarized in Table 1. In
UC, 64 (74%) and 22 (26%) patients were started on oral and intravenous
corticosteroids respectively (Figure 1). Sixty (75%) patients with CD were initially
treated with corticosteroids. Of these, 52 (87%) and 8 (13%) patients were started on
oral and intravenous corticosteroids respectively (Figure 1). Only one patient was
treated with intravenous ciclosporine in this cohort.
Immediate outcome (30 days) (Figure 2)
UC
Of the 86 UC patients, 44 (51%) achieved complete remission, 27 (31%) were in
partial remission and no response was seen in 15 patients (18%). Of the 15 who did
not respond, 6 (40%) proceeded to have surgery within the 30 days, after a median of
8.5 days (IQR: 5.8-14.8 days).
CD
Of the 60 CD patients, 24 (40%) achieved complete remission, 21 (35%) were in
partial remission and no response was seen in 15 (25%). Of the 15 who did not
respond, 4 were hospitalised, 3 of them were commenced on intravenous
corticosteroids and 1 patient, on infliximab. In the non-responder group, 2
subsequently required surgical intervention within the 30 days, after 5 and 28 days
respectively.
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Effect ofcorticosteroid dose/taper on immediate outcome
There were no statistical significant differences in the starting dose of corticosteroids
(Prednisolone, mg ±IQR) between the groups of complete response (40 mg; 30.5-
40.0), partial response (40mg; 20-40) and need for surgery (40 mg; 27.5-40.0)
respectively; in UC (p=0.30). The similar trend was evident in CD: complete (40 mg;
20.0-40.0), partial (40mg; 30.0-40.0) and surgery (40 mg; 32.5-40.0) respectively
(p=0.78). All patients requiring intravenous corticosteroids received similar dosing
schedule (60 mg/day of methylprednisolone). The retrospective nature of this dataset
precluded the ability to determine whether different tapering schedules determined
early or late outcomes.
One year outcome (Figure 2)
In UC, 47 patients (55%) were found to be in prolonged response without
corticosteroid therapy, 15 (17%) and 18 (21%) patients were corticosteroid dependent
and required surgery respectively. In CD, prolonged response was seen in 23 patients
(39%). 14 patients (23%) and 21 (35%) patients were corticosteroid-dependent and
required surgery respectively.
Surgery at one year (Table 2)
UC
Overall, eighteen patients (21%) required surgical intervention. Fifteen patients had
undergone proctocolectomy with ileostomy and the remaining 3 had proctocolectomy
with ileal pouch formation. The indications for surgery were shown in Table 2. In
total, 9 patients failed to respond to intravenous corticosteroids during an acute flare
of severe UC (1 patient demonstrating clinical signs of toxic dilatation). The median
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duration of corticosteroid therapy prior to colectomy was 9 days (IQR 7-15 days).
Nine further patients required surgery in a semi-elective fashion due to chronic
continuous symptoms. Overall, no patients experienced any major operative
complications (e.g. pelvic sepsis or anastamotic leak requiring further
laparotomy).The median time between CS commencement and surgery is 0.25 years
(IQR: 0.03-0.56 years).
CD
Twenty-one patients (35.0%) needed surgery. Seventeen (28.3%) patients had a
resection of the ileocaecal segment with anastomosis, 2 (3.3%) patients required
colectomy with permanent ileostomy and a further 2 (3.3%) required surgical
drainage of perianal abscesses. In this cohort, the median number of days between
initiation of corticosteroid therapy and surgery is 0.39 years (IQR: 0.21-0.68 years).
Survival curve estimates of surgery within 1-year of corticosteroid therapy show that
the rate of surgery tend to be higher in patients with CD compared with UC, p=0.08,
hazard ratio = 2.05, 95% CI 0.94-3.85 (log rank test) (Figure 3).
Univariate analysis: Factors influencing response to corticosteroids
In UC, there were no significant differences in the clinical parameters examined
between the responders and non-responders within 30 days (Table 3a). Following one
year of corticosteroid therapy initiation, II (55.0%) patients with extensive disease
required surgery compared with 7 patients with left sided disease (10.8%) (p=0.0001,
odds ratio 10.13, 95% CI 3.11-32.95). In CD, there were no significant differences in
the clinical parameters examined between the responders and non-responders within
30 days (Table 3b). Following one year of corticosteroid therapy initiation, two
significant differences were observed. Firstly, chi-square test for independence
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demonstrated a significant difference in the need for surgery according to the 3
disease locations (colonic 58.3% vs. 41.7%, ileal 62.5% vs. 37.5% and ileo-colonic
21.9% vs. 79.1%) (p=0.0009). Secondly, the use of 5-aminosalicylate compound
therapy appeared highly protective against surgery (p=0.005, odds ratio 0.10, 95% CI
0.02-0.51).
Multivariate analysis
I have derived 2 separate models for the respective conditions of UC and CD, using
the outcome of non-response within 30 days; and surgery within one year of the
initiation of corticosteroid therapy as the dependent variable (Table 4). The similar
variables examined in the univariate analyses were used in these binary logistic
regression models.
In UC, extensive disease at diagnosis for UC (extent > splenic flexure) was predictive
of surgery within one year of corticosteroid therapy initiation with a highly significant
association (p=0.001, odds ratio 15.24, 95% CI 3.72-62.37). No other clinical
parameters in both models demonstrated significance. In CD, a significant negative
association between 'inflammatory' disease behaviour phenotype and surgery
(p=0.02, odds ratio 0.13, 95% CI 0.02-0.70). The highly significant negative
association between 5-ASA therapy and surgery observed on the univariate level was
not significant when adjusted for other variables (p=0.09).
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3.4 Discussion
This data first and foremostly, emphasise the importance of corticosteroid
resistance/dependence in the management of patients with Crohn's disease and UC.
These observations thereby highlight the real clinical need to understand the
molecular mechanisms behind this phenomenon. Equally, it is also clear that
corticosteroid therapy can remain efficacious and safe in a proportion of patients.
Thus, a subset of patients will inherently respond poorly to corticosteroids: in our
analyses, the subphenotypes of disease such as extensive UC and
stricturing/fistulising Crohn's disease at presentation appear to be associated with this
phenomenon.
It is of interest to observe that the prevalence of corticosteroid resistance and
dependence appear stable across time and population. This is clearly evident when
data from our inception cohort (patients diagnosed between 1998 and 2005) are
compared with the population-based based datasets from Stockholm and the Mayo
Clinic (1979-1983 and 1970-1993 respectively) (Table 5). The overall use of
corticosteroids was higher in our study, 63% in UC and 75% in CD; when contrasted
with 34% in UC and 43% in CD, and 56% in CD in studies by Faubion (Faubion et al.
2001) and Munkholm(Munkholm et al. 1994) respectively. This reflects the hospital-
based nature, and conceivably a more 'severe' spectrum of presentation in this cohort.
As with other inflammatory diseases(Barnes 2004; Barnes 1998; Seki M et al. 1998;
van Schaardenburg D et al. 1995), it would appear that corticosteroid resistance and
dependence occur irrespective of disease and subphenotype - thus the similar results
in our study as compared with the older population-based studies. This argument is
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even more persuasive given the similar trends observed in the paediatric UC
population (Hyams et al. 2005).
With the present study, the overall rates of azathioprine usage were higher than those
reported from the cohorts from Mayo Clinic, (28% vs. 0% in UC and 8% vs. 3% in
CD) (Table 4). However, even the observed rates in our study may be an
underestimate of the current practice in 2006, as our data from 1998-2003 were
reflective of the transitional period in UK before the increasingly widespread use of
early immunosuppressive therapy, a very recent change in clinical practice. Despite
the increased use of azathioprine, there were no overall differences were seen in the
rates of surgery. The use of 5-aminosalicylate compounds was similar in this study
(72% vs. 77% for UC; and 49% vs. 50% in CD in our and Faubion's cohorts
respectively).
Our multivariate analyses suggest that extensive UC is the only significant predictor
of surgery within 1-year of corticosteroid therapy (p=0.001, odds ratio 15.24, 95% CI
3.72-62.37). This observation is consistent with the findings of Jarnerot et al., whose
data suggested that extent and severity of disease correlate with need for
surgery (Jarnerot, Rolny, and Sandberg-Gertzen 1985). In Crohn's disease,
inflammatory disease behaviour phenotype demonstrated a significant negative
association with surgery. The protective effect of 5-aminosalicylate compounds
therapy as shown in Faubion's study was once again demonstated in the current
study(Faubion et al. 2001).
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Recently, much enthusiasm has been directed towards approaches in 'positioning'
new and perhaps more efficacious and better tolerated therapies in the traditional
pyramid of medical therapy in IBD. With the established use of biological therapies
such as infliximab in Crohn's disease, there is also now suggestion of'inverting' this
pyramid - by giving the most efficacious therapy early in the course of active disease
thus allowing patients the maximum chance of early response/remission and
minimizing exposure to corticosteroid therapy(Hanauer 2005). Given the consistent
problems of corticosteroid resistance and dependence(Faubion et al. 2001; Munkholm
et al. 1994; Jarnerot, Rolny, and Sandberg-Gertzen 1985; Hyams et al. 2005); do the
current data now therefore lend its full-hearted support to this approach?
It is noteworthy that in UC and Crohn's disease, the subsets of patients with extensive
UC or fistulizing/stricturing disease behaviour respectively, are at increased
likelihood to require surgery within 1-year of corticosteroid therapy following
diagnosis. Intuitively one might suggest that it is these patients who should be
considered as candidates for an early aggressive approach with immunomodulatory
therapy as the likelihood of corticosteroid therapy failure is increased. However, the
clinical decision-making in the adoption of 2nd line medical or immunosuppressive
therapy remains complex, requiring robust evidence from good clinical trials.
In this context, Homines et al. recently presented data comparing 'top-down' (initial
therapy with infliximab and azathioprine) and 'step-up' (initial therapy with
corticosteroids) in Crohn's disease (Hommes DW et al. 2005). In this study, no
differences were seen in the rates of clinical remission between these 2 groups (77%
and 76% respectively at 1-year follow-up) but the proportion of patients free from
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corticosteroids use at 1-year were higher in the former group (76% vs. 64%). The
finding of mucosal healing was also higher in the 'top-down' group (75% vs. 21%)
but there were no differences in the rate of adverse events. Therefore, the short term
clinical impact of a front-line aggressive strategy in Crohn's disease at least may not
be as significant as initially anticipated. In UC, on the other hand, Ardizzone et al. had
recently clearly demonstrated a benefit in the use of Azathioprine in corticosteroid
dependent patients with UC as compared with the use of 5-aminosalicylate
compounds (Ardizzone et al. 2006). Patients treated with azathioprine demonstrated
significantly higher rates of clinical and endoscopic remission (odds ratio 4.78, 95%
CI 1.57-14.5).
It is of course important to consider whether lack of response of corticosteroids may
be attributed to the size of the initial dose used and the speed of corticosteroid
withdrawal rather than a subset of inherently resistant or dependent patients. While
poor response to corticosteroids may be influenced by such factors as underdosing
and abrupt tapering, a prospective study in 48 consecutive patients with active
Crohn's disease using a higher oral corticosteroid dose and a slower tapering schedule
than used in the previous studies reported steroid dependency and resistance rates of
63% and 13% respectively(Reinisch et al. 1995). In acute severe UC patient group
(167 patients, data presented in the following chapter), our recent Edinburgh data
show that despite high intravenous corticosteroid doses, 40% will still fail to respond
and require colectomy (Ho et al. 2004). In this present study, there were no significant
differences in the starting doses of corticosteroid between each of the outcome groups
within 30-days of initiation. Drawing parallel critical analyses with many other
inflammatory conditions, our data suggest that inherent resistance to corticosteroids
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represents the more significant problem than dosing/tapering(Barnes 2004; Barnes
1998; Seki M et al. 1998; van Schaardenburg D et al. 1995).
There are some limitations to this study . Firstly, the time-points chosen at 30-days
and 1-year in the context of a retrospective analysis, may introduce a degree of bias.
Secondly, the time span between these 2 points may be too wide to accurately record
the corticosteroid requirements and response in between. Thirdly, the clincial decision
to introduce second-line medical therapy such as Azathioprine which may influence
outcomes at 1-year may not be universally applied.
However, it remains pertinent that a large proportion of patients in IBD will respond
to corticosteroids well. Therefore, the important current challenges include the need to
identify patients with likely to respond poorly to corticosteroids and to understand the
molecular mechanisms behind the apparent 'refractoriness' to corticosteroids. In
addition to the clinical parameters implicated in this study, progress in genomic and
proteomic are awaited. Compelling studies of P-glycoprotein 170 expression(Farrell
et al. 2000), increased expression in the beta-splice variant of the glucocorticoid
receptor(Honda M et al. 2000) and T-cell subsets corticosteroid resistance(Hearing et
al. 1999) have not yet been fully translated into clinical practice. In terms of
pharmacogenetics, most pertinently the multidrug resistance gene 1 (MDR1)
polymorphisms and the rare HLA DRB1*0103 allele appear to predict severe
disease(Ho et al. 2005; Potocnik et al. 2004; Bouma et al. 1999; Roussomoustakaki et
al. 1997; Duerr and Chesny IJ 1997).
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In conclusion, this study demonstrates that corticosteroid resistance and dependence
remains a significant problem in a proportion of patients with IBD. Patients with
extensive UC or fistulizing/stricturing CD at diagnosis are most at risk of
corticosteroid failure, and these may be optimum candidates for early aggressive
medical approach. Notwithstanding this, corticosteroids can be a highly efficacious
and cost-effective therapy in a sizeable proportion of patients. This study once again
highlights the need to understand fully the mechanisms of corticosteroid resistance as
the ability to reliably identify patients who will not respond to this therapy will
undoubtedly lead to a new shift in pharmacotherapy in IBD and other chronic
inflammatory diseases, allowing physicians to consider other therapies early and
thereby reducing corticosteroid-related toxicity (Rhen and Cidlowski 2005).
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Figure 1: The description of the 5-year inception cohort in Western General
Hospital, Edinburgh between 1998 and 2005 and the rates of both oral and
intravenous corticosteroid use.
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Figure 2: Outcomes at 30 days and 1 year for CD and UC
Outcome at 30 days Outcome at 1 year
Outcome at 30 days Outcome at 1 year
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Figure 3: Cumulative risk of surgery over 1 year after starting CS therapy. In newly
diagnosed patients with 1BD and treated with corticosteroids, the rate of surgery is






Table 1: Overall demographics of 86 UC and 60 CD patients commenced on
corticosteroids on initial diagnosis, fSmoking status established at time of diagnosis.
{Disease extent established at time of latest follow-up period (1 year). Extensive
disease - >splenic flexure and Left-sided disease- < splenic flexure. □□ Disease












































(within 30 days of CS-therapy)
72 (83.7%) 49 (81.7%)
Azathioprine therapy
(within 30 days of CS-therapy)
28 (32.6%) 8(13.3%)
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Table 2: Indications for surgery for UC and Crohn's disease.
UC N=18










Failure to respond to medical therapy
Ileal disease
17
Failure to respond to medical therapy
Colonic disease
2





























































































































































































































































































































Table 5: The rates of corticosteroid dependence and resistance; and the use of







UC CD CD UC CD
Number of patients 136 80 196 185 173




51% 40% 48% 54% 58%
Partial remission 31% 35% 32% 30% 26%




55% 38% - 49% 32%
CS dependence 17% 24% - 22% 28%
Surgery 21% 35% - 29% 38%
Azathioprine 28% 8% - 0% 3%
5-ASA 72% 49% - 77% 50%
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Chapter 4
Predicting the outcome of severe
ulcerative colitis: Development of a
novel risk score to aid early selection
J




Background: The failure rate of medical therapy in severe UC is high. A risk index,
which aids the identification of patients according to the likelihood of not responding to
intravenous corticosteroid therapy, would be useful to facilitate second-line treatment or
surgery.
Methods: 167 consecutive patients with severe UC between January 1995 and March
2002 were studied. I employed multiple logistic regression to analyze parameters within
the first three days of medical therapy. In addition, I utilised statistical modelling to
formulate a risk score according to the likelihood of medical failure.
Results: Sixty-seven (40%) patients failed to respond to medical therapy. Multivariate
analysis identified mean stool frequency and colonic dilatation within the first three days
and hypoalbuminaemia as independent predictors of outcome (p <0.001, 0.001 and 0.002
respectively). A numerical risk score was formulated based on these variables. Patients
with scores of 0-1, 2-3 and >4 had a medical therapy failure rate of 11%, 43% and 85%
respectively. R.O.C. analysis of this score yielded AUC of 0.88, with a sensitivity of 85%
and specificity of 75% using score >4 in predicting non-response.
Conclusion: This risk score allows the early identification of patients with severe UC
who would be suitable for second-line medical therapy or surgery.
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4.1 Introduction
The natural history of ulcerative colitis (UC) is variable. Whereas many patients with UC
suffer symptoms that can be managed with outpatient medical therapy, a proportion
experience symptoms that prove refractory to treatment, and ultimately require
colectomy. Historically, 15% of patients with UC will develop a severe attack requiring
intensive in-patient medical therapy. Of these, consistent data have shown that 30-40% of
patients will fail to respond to medical therapy and require urgent colectomy(Jarnerot,
Rolny, and Sandberg-Gertzen 1985; Buckell and Lennard-Jones 1979; Travis et al. 1996;
Lindgren et al. 1998; Carbonnel et al. 2000; Chakravarty 1993). The mortality associated
with such attacks has fallen from levels of 31-61% to the present level of 1-2% following
the introduction of high dose corticosteroid therapy and the acceptance of a policy of
early surgery in patients not responding to medical therapy(Truelove et al. 1978).
For patients who fail to respond to corticosteroids, the use of further medical therapy
rather than surgery needs careful thought, bearing in mind that much of the morbidity
(and mortality) of UC is associated with delayed surgery (Hyde and Jewell 1997;
Lindgren et al. 1998). Therefore, the selection of patients that may benefit from second-
line therapy and importantly, the timing of the administration of therapy, are central to
the management of severe UC. A risk index that can stratify patients according to their
respective likelihood of not responding to intravenous corticosteroid therapy early in the
course of treatment will be clinically pertinent to the issues discussed above.
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In the present study, I analysed early clinical parameters within a large cohort of patients
presenting with acute severe UC to identify predictive factors of non-response to medical
therapy. I have developed a simple objective risk score to aid the clinician in decision¬
making, and specifically to help select patients for either early second-line medical
therapy or early surgery depending on the likelihood of non-response to standard medical
therapy. The use of similar risk indices in other fields such as the Rockall score derived
from similar statistical methodology, in predicting mortality in upper gastrointestinal
bleeding has led to clear benefits in aiding clinical management and also the stratification
of patients in further interventional trials(Rockall et al. 1996).
Although as discussed in Chapter 1, two predictive models have been described in
literature, these serve primarily to identify patients for early colectomy rather than to
select patients for second-line medical therapy. In a prospective study involving 49
patients with severe UC, Travis and colleagues proposed that 85% of patients with a stool
frequency of >8/day or 3-8/day with C-reactive protein of 45 mg/dl after 3 days of
intensive medical therapy will fail to respond and require colectomy(Travis et al. 1996).
Lindgren and colleagues developed a regressional formulae to predict the likelihood of
medical failure - number of bowel movements +0.14x CRP (mg/l)>8.0, as the optimum
theoretical cut-off level to predict failure of medical therapy(Lindgren et al. 1998).
The proposed risk score developed from this cohort aimed to identify patients who are at
low, intermediate and high likelihood of not responding to intensive medical therapy.
148
Therefore, with the improvement in medical therapy in severe UC, treatment can be
targeted at patients who will benefit most from early 2nd line medical therapy.
4.2 Methods
Settings
Patients were recruited from the gastroenterology units of two university teaching
hospitals (Western General Hospital and Royal Infirmary of Edinburgh) and a large
district general hospital (St. John's Hospital, Livingston) in the Edinburgh and Lothian
region, Scotland, covering a combined catchment area of 600 000 people.
Patients
All patients admitted for in-patient management of acute UC between January 1995 and
March 2002 were identified using the regional database of medical/surgical admissions
(Lothian Surgical Audit) and respective local hospital discharge databases. Ethical
approval was obtained from the Lothian Research and Ethics Committee and informed
consent was obtained from each patient involved.
Case definitions
The diagnosis of UC was confirmed on clinical, radiological and histological criteria
(Lennard-Jones 1989). A severe episode of UC was defined according to the modified
Truelove and Witts criteria as, >6 episodes of bloody diarrhoea/24 hour with one or more
of the following features: anemia (hemoglobin < 10.5g/dl), fever (>37.8°C), tachycardia
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(pulse >90/min) or elevated ESR (> 30mm/hour). Colonic dilatation was defined by the
diameter of the transverse colon on plain abdominal x-ray, >5.5 cm.
Data collection
For each patient, all clinical data recorded during hospital admission were retrieved from
case note review. Fifty-six variables within the first three days of medical therapy were
recorded. These included demographic data, clinical observations, laboratory parameters,
X-ray and endoscopic assessments of the severity ofUC.
Outcomes
The primary outcome was categorized as response (no colectomy) or non-response to
medical therapy (colectomy) within the period of hospitalisation. Statistical modelling
was also performed on secondary outcomes such as colectomy at 60 days following
presentation (to account for patients who have undergone a semi-elective colectomy or
those with an early severe relapse); and in the setting where intravenous ciclosporin was
considered as failure of 1st line medical therapy (to account for the confounding effect of
second-line medical therapy).
StatisticalAnalysis
Univariate analyses were initially performed to identify potential determinants of
outcome of all 56 variables recorded. Of these, twenty-four potential variables were
appropriate for further analysis following the removal of those variables with no
prognostic significance (Appendix 1). Forward stepwise multiple logistic regression was
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then employed to identify predictive factors (with <x>0.1 taken as a level of exclusion)
associated with our outcomes. To generate a clinical predictive model, variables of
prognostic significance were categorized and re-entered into a logistic regression model.
An integer score was attributed to each category of each variable according to its relative
contribution in the regression model (as determined by its regression coefficient in the
logistic equation). The scores were then grouped to provide a practical triage into low,
intermediate and high risk categories. All analyses were performed using the Minitab
statistical software.
4.3 Results
1211 admissions with inflammatory bowel disease were identified between January 1995
and March 2002. Comprehensive review of these cases led to the identification of 245
patients admitted to hospital with acute flare of ulcerative colitis, of whom, 167 (68%)
patients fulfilled the criteria of Truelove and Witts. Sixty-eight patients (40%) failed to
respond to medical therapy and required colectomy during that admission. The median
time to colectomy was 9 days following admission (interquartile range, IQR- 7 to 15
days) (Figure 1). Two of these patients died during the period of hospitalisation (post¬
operative pneumonia and arterial thrombosis of lower limb respectively). The median
duration of admission for non-responders and responders was 26 and 11 days
respectively.
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Patient details (Table 1)
The median age at presentation was 38 years (IQR - 27-54). Males accounted for 61% of
the patient population. The median duration of relapse prior to admission was 4 weeks
(IQR 2-9.5 weeks). Seventy-six (45%) patients were experiencing the first attack of UC,
91 patients (55%) were known to have UC; and 42 (25%) patients had previous
admissions with severe colitis. Eight (5%) patients were current smokers. Extensive
colitis (beyond the splenic flexure) was present in 131 (81%) patients. Of these, 62(47%)
patients with extensive colitis were non-responders. In comparison, only 10% of patients
with disease limited to recto-sigmoid area failed to respond to medical therapy (p<0.001).
Management (Table 2)
All patients were treated with standard medical therapy of intravenous corticosteroids
(methylprednisolone 60 mg/day or hydrocortisone 400mg/day). In addition, 83% of
patients received oral 5-aminosalicylate (5-ASA) preparations, 45% received concurrent
topical therapy (rectal 5-ASA or corticosteroids), 71% received subcutaneous heparin for
thrombo-embolic prophylaxis, and 13% received intravenous ciclosporin and total
parenteral nutrition.
Twenty-one patients received intravenous cyclosporin at dosage of 4mg/kg. The median
time for cyclosporin therapy was 10 days after the initiation of intravenous
corticosteroids. This however, was shorter in the non-responders (7 days vs. 12 days). No
patients had evidence of colonic dilatation. Nine patients responded, with the remainder
requiring colectomy within the period of hospitalization (p=0.089). Of those that
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responded, 3 patients subsequently required colectomy during follow-up (median time to
colectomy - 2.4 years, range 1.4-3.2 years).
Of the twenty-one (13%) patients who had received intravenous ciclosporin (4mg/kg),
only 9 patients avoided colectomy during the period of hospitalisation. Of those that
responded, 3 patients subsequently required colectomy during follow-up (median time to
colectomy - 2.4 years, range 1.4-3.2 years). The median time for the initiation of
cyclosporin therapy was shorter in the non-responders (7 days vs. 12 days).
Univariate analysis ofclinical and laboratoryparameters (Table 2)
A significantly higher percentage of non-responders presented with stool frequency
>8/day on admission (58.8% vs. 29.3%, p<0.001, OR-O.29, 95% CI 0.15-0.56). On each
of days 1 to 3, there was a consistently maintained difference in stool frequency between
responders and non-responders (data not shown), and we compared the discrimination of
the mean stool frequency over the first three days with data of each individual day. This
derived variable showed a more significant difference between responders and non-
responders than the stool frequencies on any individual days.
Evidence of hypoalbuminaemia (<30g/l) was present in 47% and 28% of non- and
responders respectively on admission (p=0.005). Serum albumin was also noted to be
significantly lower on day one of therapy in non-responders (mean g/1 ±SD) 30.6g/l ±5
compared with responders, 34.1 g/1 ±6 (p=0.001, OR-1.10, 95% CI 1.04-1.17). Similarly,
C-reactive protein levels on day one of medical therapy (median mg/l± IQR) were also
153
significantly higher in non-responders (6.9 mg/I, IQR 2.8-19.2 compared with
responders, 3.9 mg/1, IQR 1.5-9.3 (p =0.02). Colonic dilatation was present in 16 patients
(9.6%) of these, 15 patients required colectomy (p=0.001, OR-0.04, 95% CI 0.00-0.29).
Weaker trends were observed in platelet count and ESR.
Other comparisons, in particular, the proportions of patients experiencing their first
attack, the duration of relapse prior to hospitalisation and clinical parameters such as
neutrophil count, temperature, pulse rates and stool consistency were not associated with
outcome.
Multivariate analysis andmodelling (Table 2)
Mean stool frequency (MSF), the presence of colonic dilatation within the first three days
and serum albumin on day 1 of medical therapy were identified as significant
independent predictors of outcome in our cohort (p <0.001, <0.001 and 0.002
respectively). Notably, C-reactive protein, platelet and ESR measurements implicated in
the univariate analysis did not achieve statistical significance in multivariate analysis.
As significant differences were also observed on univariate analysis of the additional
medical therapies (Table 2), multivariate analysis was carried out separately to assess the
effect of these therapies on the outcomes of our patients. When considered together with
the 24 parameters originally included in the earlier multivariate analysis, only total
parenteral nutrition demonstrated significant association with non-response to medical
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therapy. It is noteworthy that 5-ASA and subcutaneous heparin which were implicated on
univariate analyses did not achieve statistical significance. TPN however, was not
considered in statistical modelling as the median time to the commencement of this
treatment was 6 days (IQR 4-7 days) following the initiation of intravenous corticosteroid
therapy.
In order to generate a scoring system, MSF and serum albumin values were categorized
using integer cut-points guided by the receiver operator characteristic (ROC) curve and
observed relationship with outcomes.
This resulted in the categorization ofMSF as:
• <4 stools/ 24 hours
• >4 stools but < 6 stools/ 24 hours
• >6 stools but < 9 stools/ 24 hours
• >9 stools / 24 hours
And serum albumin as:
• <30 g/1
• > 30 g/1
Colonic dilatation was regarded as present or not present within the first three days of
therapy.
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To formulate a numerical risk score, we used the coefficients generated by the logistic
regression equation, to derive an integer number, approximating the values of the
coefficients for each of the categories above (Table 2).
Other models (Table 4)
1 also explored different settings for modelling. These were;
A. Analyses of outcomes at 60 days to account for early severe relapse or semi-elective
surgery in partial responders.
B. Analyses where ciclosporin treatment was regarded as failures of medical treatment.
C. Analyses where colonic dilatation was excluded as some centers may regard this sign
as an absolute indication for surgery.
In model A, a further 9 patients required colectomy within 60 days (3 partial and 6
complete responders). In model B, 9 patients who had received ciclosporin (but no
colectomy during admission) were regarded as primary treatment failure. For model C,
16 patients with colonic dilatation were excluded. Multiple logistic regression analysis
failed to identify prognostic factors additional to stool frequency, serum albumin and
colonic dilatation.
Final model
Using the coefficients of the regression analyses, the MSF of < 4 stools/ 24 hours, >4 and
<6 stools/ 24 hour, >6 and <9 stools and > 9 stools/ 24 hours were given scores of 0, 1,2
and 4 respectively. The presence of colonic dilatation was attributed a score of 4 (or score
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0, in the absence of this sign) and hypoalbuminaemia (<30g/l), score of 1 (or score 0,
albumin >30g/l) (Table 5). Using the scoring system, each patient in our study was
scored and compared to his/her eventual outcomes.
For an individual patient, the total score was derived from the sum of the score attributed
to MSF (0-4), colonic dilatation (0 or 4) and serum albumin (0 or 1). The minimum score
possible (0) would be attributed to a patient with MSF<4, no evidence of colonic
dilatation or hypoalbuminaemia and a maximum score of 9, to a patient with MSF>9 (4
points) together with the presence of both colonic dilatation (4 points) and
hypoalbuminaemia (1 point).
The rates of non-response according to prognostic scores are demonstrated in Figure 2.
All patients with scores of>6 failed to respond to medical therapy (3 patients scoring 6, 6
patients scoring 7 and one patient scoring the maximum value of 9). Proportions of
patients falling into each score categories were 19%, 23%, 9%, 25%, 13%, 5% and 5%
respectively.
It is possible to triage patients to the groups of low (score 0-1), intermediate (score 2-3)
and high (score >4) risk groups with medical failure rates of 11%, 45% and 85%
respectively. Receiver-operating characteristic (R.O.C) analysis for this risk score yielded
an area under the curve (A.U.C) of 0.876 (AUC of 1.0 indicating perfect test) (Figure 3).
The sensitivity and specificity for predicting non-response to medical therapy with scores
of>4 was 85% and 75% respectively. The AUC of this current model for colectomy at 60
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days following presentation, ciclosporin treatment was regarded as primary treatment
failure and where colonic dilatation were excluded were 0.833, 0.810 and 0.807
respectively.
4.4 Discussion
The present analysis involves the most recent and largest cohort of patients presenting
with severe UC reported in detail. In a 7-year period, I reported on 167 consecutive
patients with acute severe UC satisfying the modified Truelove and Witts criteria.
Consistent with previous studies (Travis et al. 1996; Buckell and Lennard-Jones 1979;
Carbonnel et al. 2000; Jarnerot, Rolny, and Sandberg-Gertzen 1985; Lennard-Jones et al.
1975; Chakravarfy 1993), the failure rate of medical therapy is high (40%). On
multivariate analysis, mean stool frequency and colonic dilatation within the first three
days of therapy and hypoalbuminaemia on day 1 of treatment, were significantly
predictive of the need for surgery within the period of hospitalisation (p<0.001, <0.001
and 0.002 respectively). Using statistical modelling, I have formulated a numerical risk
score that assesses the individual's likelihood of non-response. This risk score enables the
stratification of our patients to those with low (11%), intermediate (45%) and high risks
(85%) of not responding to therapy within 3 days of medical therapy.
Of greatest clinical relevance is the identification of low and high risk groups in which
surgery was either very unlikely or likely. I propose that in the intermediate group (34%
of patients), close monitoring is essential with the option of second-line medical therapy
at an early stage. This benefit may also apply to the high risk group; however, a delay in
surgery in this group may lead to an unacceptable increase in the risk of complications,
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and the case for early surgery (rather than further medical intervention) may be more
compelling in patients with high risk score.
Different clinically relevant settings were considered for statistical modelling -
colectomy at 60 days to account for early severe relapse or semi-elective surgery for
partial responders with chronic continuous symptoms, where second-line therapy such as
ciclosporin was considered as primary treatment failure and where colonic dilatation was
excluded from analysis. Nevertheless, in this cohort, no further factors were identified
from multivariate analysis. 1 have accounted for colonic dilatation in statistical
modelling, on the basis that some may consider this finding as an indication for surgery
by itself. Indeed, approximately 10% of patients in the current cohort had radiological
evidence of this within the first 3 days of hospitalization.
C-reactive protein concentration was a notable exclusion from the multivariate logistic
regression analysis. The explanation for this bears evaluation but it is conceivable that in
a pre-selected group with unequivocal severe disease, the absolute level of acute phase
reactants may not be as useful as the change in response to intensive medical therapy.
Differences observed in 5-ASA, total parenteral nutrition and heparin therapy in
univariate analyses were thought be due to confounding effect (e.g. physician-led
reaction to illness and malnutrition).
Is this risk score relevant to clinical practice? The sensitivity (85%) and specificity (75%)
of this risk score in predicting non-response to medical therapy at the cut-off point of >4
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compared favourably with two other models described in the literature(Travis et al. 1996;
Lindgren et al. 1998). The sensitivity/specificity for the models described by Travis and
Lindgren et al. when applied to our data, were 58%/71% and 61%/88% respectively (data
not shown). This maybe explained by the differences in the severity of illness and
populations, of the cohorts studied in Oxford, Stockholm and Edinburgh, indeed; the two
previous populations did not display significant hypoalbuminaemia and colonic dilatation
that were evident in 40% and 10% respectively in our cohort. This is supported by the
higher colectomy rate observed in our cohort (40% vs. 31%/34% in the cohorts of Travis
and Lindgren respectively).
The ability to categorize patients on day 3 allows the use of potentially toxic second-line
therapy or early surgery targeted to the individual patient according to risk. A recent UK-
wide multi-centre survey conducted by the British Society-IBD network showed that
even in an unselected cohort of patients receiving in-patient medical therapy for acute
UC, 28% of patients required colectomy as a consequence of failed medical therapy.
Consistent with the present data, the usage of intravenous ciclosporin therapy was low
(13%).
Although, the use of second-line medical therapy is complicated by other issues such as
patient choice, familiarity and experience of the treating centre; there is robust data
regarding efficacy and safety of ciclosporin therapy. Van Assche et al. most recently
demonstrated the safety and efficacy (85% response rate) of ciclosporin therapy at
2mg/kg dosage regime. Short term colectomy rate was 8.6%(Van Assche et al. 2003).
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Along with the recent report of favourable long term response in initial responders to
ciclosporin subsequently maintained on Azathioprine therapy(Cohen, Stein, and Hanauer
1999), quality of life following successful ciclosporin therapy is comparable if not better
than patients who have underwent surgery(Cohen RD, Brodsky AL, and Hanauer 1999).
More recently, infliximab as discussed in Chapter 1, has been shown to be useful in acute
severe UC(Jarnerot et al. 2005b). Therefore, the use of second-line medical therapies is
increasing and this risk index provides the guidance in identifying and counselling
patients, for clinicians on a wider scale.
The primary development of this risk score therefore, has important implications in
allowing targeted therapy aimed at the group of patients that will benefit most from early
second-line medical therapy, selection of patients for early surgery, patient counselling
and the stratification of patients according to risk, in future therapeutic trials. These, we
believe, will improve the clinical management of severe UC. This risk model precisely
addresses the positioning of biological therapies such as infliximab in acute severe UC,
with the patients in intermediate and high risk groups in particular benefiting from early
therapy (Figure 3).
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Clinicalobservation Admission(SD) Stoolfrequency>8/da Temperature(°C) Pulse(/min) Stoolconsistency-Fluid(%)
69(41.3%) 37.4(0 7) 90.9(14.3) 140(84%)
40(58.8%) 37.4(0 8) 90.5(13.4) 56(84%)
29(2 .3%) 37.3(0.7) 91.3( 5.5) 84(85%)
0.29(0 15-0.56)
<0.001 0.51 0.73 0.38
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Mean(Day1-3)(SD) Stoolfrequency Pulse Temperature
6.34(3.2) 85.5(12.0) 37.07(0 48)
8.05(3.4) 86.4(13) 37.16(0.52)









Drugspriortoadmission 5-ASA(800-1200mg/day) OralPrednisolone(20- 40mg/day) Topicalther py Azathioprine(2mg/kg/day)
91(56%) 75(46%) 35(22%) 13(8%)
37(5 %) 34(52%) 10(15%) 4(6%)
54(5 %) 41(4 %) 25(2 %) 9(9%)
-
0.93 0.24 0.11 0.46
In-patientdrugtherapy 5-ASA(800-1200mg/day) S.C.heparin(5000U/day) Ciclosporin(4mg/kg) TotalParenteralNutrition Topicalther py
139(83%) 118(71%) 21(13%) 22(13%) 75(4 %)
50(74%) 60(88%) 12(18%) 19(28%) 25(37%)
89(8 %) 58(5 %) 8(8%) 2(2%) 50(5 %)
3.14(1.35-7.32) 0.19(0.08-0.43) 0.08(0.02-0.29)
0.008 <0.001 0.06 0.004 0.09
Laboratory parametersf(SD) Haemoglobin(g/1) Neutrophil(xlO9) Platelet(xlO9)" ESR(mm/hr) CRP(mg/l)§ Albumin(g/1)
12.0( 3) 9.7(3.7) 426.3(148.7) 44.8(26.5) 4.4(2.1-13.3) 32.7(6 2)
11.7(2 3) 9.8(4.4) 461.0(164.0) 50.5(28.9)
6.9(2.8-19.25) 30.6(5 0)
12.3( 2) 8.9(3.4) 402.5(133.0) 41.0(24.2) 3.9(1.5-9.35) 34.1(6 2)
0.97(0.95-0.99) 0.99(0 97-1.0) 0.98(0.95-1.01) 1.10(1.04-1.17)
0.09 0.18 0.01 0.04 0.02 0.001
(ContinuedfromTableI).
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Table 2a: Multiple logistic regression analysis of clinical parameters within first three
days of medical therapy identified mean stool frequency (MSF), the presence of colonic
dilatation and day 1 serum albumin as significant predictors of failure ofmedical therapy.
Variables Coefficient SE P-value Odds 95% CI
Coefficient ratio Lower Upper
MSF -0.378 0.06 <0.001 0.68 0.61 0.78
Colonic -3.548 1.11 0.001 0.03 0.00 0.20
dilatation
Day 1 0.09 0.03 0.002 1.10 1.03 1.15
serum
albumin
Table 2b: MSF and serum albumin were grouped into the categories above using ROC
curve analysis and adapted according to clinical relevance. These categories were re¬
entered into the logistic regression model. MSF <4/day was used as reference index in
MSF category. Formulation of integer risk score for each category was based on the
strength of contribution to logistic equation based on the coefficient {For example- The
coefficient ofMSF>9 is -4.27, therefore an integer score of 4 was given, coefficient of
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MSF 4-<
6/day
-1.40 0.73 0.055 0.25 0.06 1.03
Stool 6-<
9/ day
-2.20 0.69 0.002 0.11 0.03 0.43
Stool >
9/day
-4.3 0.84 <0.001 0.01 0.00 0.07
Colonic
dilatation




-1.24 0.44 0.005 0.29 0.12 0.69
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Table 3: Multiple logistic regression of clinical parameters within 1st three days of
medical therapy and medical therapy (5-ASA, topical therapy, subcutaneous heparin,
total parenteral nutrition -TPN, ciclosporin). Only TPN was shown to be significant in
predicting outcome with MSF, colonic dilatation and day 1 albumin.
Variables Coefficient SE P-value Odds 95% CI
Coefficient ratio Lower Upper
MSF -0.435 0.08 <0.001 0.65 0.55 0.76
Colonic -3.489 1.15 0.003 0.03 0.00 0.29
dilatation
Day 1 0.09 0.04 0.025 1.10 1.01 1.19
serum
albumin
TPN -2.968 0.93 0.001 0.05 0.01 0.32
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Table 5: Integer risk score attributable to each category derived from the coefficients of
the logistic regression equation. Overall risk core = [score attributable to mean stool
frequency (0, 1, 2 or 4)] + [presence of colonic dilatation (0 or 4)] + [presence of











Figure 1: Outcome of 167 consecutive patients with severe UC.
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Figure 2: Rate of failure of medical therapy according to numerical risk score in 167
patients presented with acute severe UC.
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Figure 3: Receiver-operator characteristic (ROC) curve of risk score, yielding an area
under curve (AUC) of 0.876. The AUC of this current model for colectomy at 60 days
following presentation, cyclosporine treatment was regarded as primary treatment failure












Figure 3: The new model ofmanagement of severe ulcerative colitis.
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Allelic variations of the multidrug
resistance gene (MDR1) determine




Background/Aims: The MDR1 gene encodes P-glycoprotein 170, an efflux transporter
which is highly expressed in intestinal epithelial cells. The MDR1 exonic SNPs C3435T
and G2677T have been shown to correlate with activity/expression of P-glycoprotein
170.
Methods: Case-control analysis of MDR1 C3435T and G2677T SNPs in a large well-
characterized Scottish-Caucasian cohort (335 UC, 268 CD and 370 healthy controls). 2-
locus haplotype and detailed univariate and multivariate genotypic-phenotypic analyses
were performed.
Results: The MDR1 3435 TT-genotype (34.6% vs. 26.5%, p=0.04, OR 1.60, 95% CI
1.04-2.44) and T-allelic frequencies (58.2% vs. 52.8%, p=0.02, OR 1.28 95% CI 1.03-
1.58) were significantly higher in patients with UC compared to controls. No association
was seen with CD. The association was strongest with extensive UC (TT-genotype,
42.4% vs. 26.5%, p=0.003, OR 2.64 95% CI 1.34-4.99 and T-allele, 63.9% vs. 52.8%,
p=0.009, OR 1.70 95% CI 1.24-2.29), and this was also confirmed on multivariate
analysis (p=0.007). The G2677T SNP was not associated with UC or CD. These 2 SNPs
lie in linkage disequilibrium in our population (D' 0.8-0.9 and r2 0.7-08). 2-locus
haplotypes showed both positive (3435T/G2677 haplotype; p=0.03, OR 1.44) and
negative (C3435/2677T haplotype, p=0.002, OR 0.35) associations with UC.
Homozygotes for the haplotype 3435T/G2677 were significantly increased in UC
(p=0.017, OR 8.88 95% CI 1.10-71.45).
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Conclusion: Allelic variations of the MDR1 gene determine disease extent as well as
susceptibility to UC in the Scottish population. The present data strongly implicate the




Recent attention has focussed on the multidrug resistance 1 (MDR1) gene and its product,
the P-glycoprotein 170 as a potential determinant of susceptibility to IBD(Ho, Moodie,
and Satsangi 2003). P-glycoprotein 170, which functions as an ATP-dependent efflux
transporter pump is highly expressed in the epithelial surfaces of intestine, biliary
ductules, proximal tubules of kidneys and central nervous system where it forms the basis
of the blood-brain barrier(Thiebaut et al. 1987; Cordon-Cardo et al. 1989; Fojo et al.
1987). Interindividual variability of P-glycoprotein expression in the intestine plays a role
in the determining the pharmacokinetics of wide-ranging number of substrates.
Nevertheless, the exact physiological role in the gut remains unknown. The high
constitutive levels of expression of P-glycoprotein 170 in the gut suggest a role in
protection not only against xenobiotics but bacterial products.
As reviewed in depth in chapter 1, MDR1 gene is an attractive candidate gene for IBD for
several reasons. Firstly, mdr-la deficient mice develop a UC-like phenotype when
maintained in specific pathogen free environment which is reversed by
antibiotics(Panwala, Jones, and Viney 1998). Bone marrow transfer studies show that
these mice develop colitis primarily due to deficiency of mdr-1 in the epithelial rather
than the lymphoid cells. Secondly, MDR-1 gene maps to chromosome 7q22 which has
been identified as a putative locus of susceptibility for IBD, by genome-wide scanning in
a UK cohort. Recent subsequent meta-analysis of all genome-wide scans confirms
suggestive linkage to this region (van Heel et al. 2004). Most recently, compelling data
by Langmann et al. have demonstrated that the MDR1 gene expression is downregulated
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in IBD with expression significantly reduced in the colonic tissue of patients with UC but
not CD (Langmann et al. 2004).
The MDR1 gene is composed of 28 exons and is 209 kb in length(Hoffmeyer et al.
2000b; Cascorbi et al. 2001b; Kim et al. 2001b). Two SNPs, exonic variant C3435T and
G2677T/A have been shown to correlate with activity/expression of P-glycoprotein 170.
The C3435T SNP in exon 26 has been most extensively investigated and was first shown
to correlate with expression of P-glycoprotein 170 (Hoffmeyer et al. 2000b). In this
study, the TT genotype was associated with lowered intestinal P-glycoprotein 170
expression with functional consequence as inferred by increased digoxin uptake
following oral administration(Cascorbi et al. 2001a). This has been replicated in other
pharmacokinetic studies(Hitzl et al. 2001; Kim et al. 2001a; Johne et al. 2002b). In
addition, the effect of the MDR1 C3435T SNP and its postulated correlation with P-
glycoprotein 170 activity/expression has been shown to play a role in drug-resistant
epilepsy (Siddiqui et al. 2003), immune recovery after initiation of anti-retroviral therapy
in HIV (Fellay et al. 2002) and the development of renal cell carcinoma(Siegsmund et al.
2002). The G2677T/A SNP in exon 21 results in 2 distinct amino acid changes namely,
893Ser (G2677T) or the much rarer, 893Thr (G2677A); and has been shown to be
associated with altered transporter function or expression (Kim et al. 2001a; Tanabe et al.
2001). Several studies have suggested that the C3435T and G2677T SNP may lie in
linkage disequilibrium(Johne et al. 2002a; Kim et al. 2001a; Zheng et al. 2002;
Horinouchi et al. 2002).
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I aimed firstly to investigate the contribution of the MDR1 C3435T and G2677T SNP in
a large independent well-characterized population of Scottish-Caucasians. I then
determined whether 2-locus haplotypes provide a stronger association with disease than
individual SNPs, in order to resolve the controversies regarding the contribution of this
gene to disease susceptibility. In addition to this, I rigorously conducted a detailed sub-
phenotypic review of all subjects genotyped to assess whether these variants are
particularly implicated in determining disease extent and behaviour in 1BD. In order to
clarify whether MDR1 genotypes may influence drug responsiveness in UC, I further




This study was approved by the Lothian Research and Ethics Committee (LREC) and
written consent was obtained from all patients. A total of 335 patients with UC and 268
with CD were recruited from the Lothian region, Scotland, United Kingdom. The
diagnosis of IBD was determined by standard clinical, radiological, endoscopic and
histological criteria. Table 1 summarizes the clinical characteristics of patients studied.
The median ages of diagnosis for UC and CD were 35.0 years (IQR 25.3-50.3) and 26.6
years (IQR 19.9-37.0) respectively. The ethnicity of this study population was
predominantly Scottish-Caucasian (99%). There were more males in the UC cohort
(54.5%) than in CD (43.5%).
177
Phenotypic assessment
UC phenotype was classified by disease extent, severity and need for surgery. The extent
of disease was documented at time of latest follow-up. Extensive disease was defined as
disease extending beyond splenic flexure, left-sided colitis as disease extending to the
splenic flexure and proctitis, limited to the rectum as determined by histological and
macroscopic evidence. In discordant cases, the histological evidence was used. Patients
who had developed acute severe attack of UC (satisfying the Truelove and Witts criteria)
requiring intensive in-patient medical therapy were regarded to have severe UC. Within
the severe UC, a further subset of patients who had failed to respond to medical therapy
and consequently required surgery were categorized under the phenotype - need for
surgery. Other phenotypic details such as smoking, family history, presence of primary
sclerosing cholangitis (PSC) and other extra-intestinal manifestations were also recorded.
CD was classified according to the Vienna Classification of disease location, behaviour
and age of diagnosis, as previously described (Gasche et al. 2000). We have previously
shown that disease behaviour is not stable over time, and therefore have analyzed disease
behaviour only at time of diagnosis and at latest follow-up (Smith et al. 2004).
Controls
370 healthy controls which comprised of actively recruited healthy subjects (n=105) and
blood donors (n=265) were all recruited from the Lothian region between 2000-2002.
There were no differences in the demographics between these 2 groups. There overall
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gender distribution was 179 males: 191 females; median age of recruitment was 37.1
years (IQR 25.9-47.0).
Genotyping
Genotyping was performed using TaqMan (AB1, San Diego, CA). TaqMan probes were
available from ABI-assay-on-demand/design - C3435T (rsl045642) and G2677T/A
(rs2032582). Sequence and reactions were described in Chapter 2.
The G2677T/A is a tri-allelic SNP, with reported frequencies of the rare A-allele in
European Caucasian ranging from undetected to 4% (Furuno et al. 2002; Cascorbi et al.
2001b; Kim et al. 2001a; Gaikovitch et al. 2003) (Gerloff et al. 2002). I have sequenced
200 chromosomes of the UC group (100 individuals) and confirmed a G2677A-allelic
frequency of only 2% in our population. In view of this low frequency, 1 have chosen to
genotype the 2 common variants of the G2677T/A SNP, using TaqMan reaction.
Statistical analysis
Genotype and allelic frequencies between cases and controls were compared using a 2X2
table and Fisher's exact test. Odd ratios (OR) were given with 95% confidence intervals
and 2-sided p-values. A p-value of <0.05 was considered significant. All calculations
were performed using the Graph Pad Instat programme (Graph Pad Software, San Diego,
USA). Fisher's exact test was utilized to evaluate if the homozygote and heterozygote
frequencies for each SNPs deviate from Hardy-Weinberg equilibrium. 2-locus haplotypes
frequencies were measured using the the expectation-maximization algorithm utilizing
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the SNPHAP programme (bioinformatic programmes available and accessed via the
Medical Research Council-Rosalind Franklind Centre of Genomic Research website:
www.rfcgr.mrc.ac.uk)(Zhao. Curtis, and Sham 2000).
Multivariate analysis was performed using a logistic regression model to test the
association between phenotype and genotypes. Two methods were used for haplotypic
association with disease, and these were: log-likelihood ratio method where inferred
haplotypes were compared in case, control and case/controls combined and secondly, by
directly comparing the haplotype frequencies between cases and controls. The log-
likelihood ratio tests whether a model where haplotype frequencies in case are different
than controls or a model where there are no differences between case and controls fitted
the data obtained better(Zhao, Curtis, and Sham 2000). Significance for association was
calculated using the test statistic 2*(ln(L case)+ln(Lcontrol)-ln(Lcase/Lcontrol), which
has a j2 distribution with n-1 degrees of freedom (where n=number of inferred
haplotypes). We measured the linkage disequilibrium between SNPs using Cocaphase
Software (bioinformatic programmes available and accessed via the Medical Research
Council-Rosalind Franklind Centre of Genomic Research website: www.rfcgr.mrc.ac.uk~).
The log-likelihood analysis and direct haplotype comparison are complementary methods
to detect association in haplotypic datasets. Log-likelihood analysis is used specifically to
address the problem of phase uncertainty encountered when direct comparisons are made
from haplotype frequencies which are inferred. Direct haplotype comparison assumes that
all haplotypes are known without error and therefore can be counted. Flowever, there
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remains a degree of uncertainty even in the case of estimated diplotypes. Although, the
likelihood based method will test for association, it does not however, provide an
estimate of the size of the effect and for this; we used the most likely diplotypes to do so.
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5.3 Results
The effect of MDRl C3435T and G2677T polymorphism on overall disease
susceptibility
Both T-allele and TT-genotype of the MDRl 3435 SNP were significantly increased in
patients with UC compared with healthy controls (58.2% vs. 52.8%, p=0.02, OR 1.28, CI
1.03-1.58 and 34.6% vs. 26.5%, p=0.04, OR-1.60, CI 1.04-2.44 respectively) (Table 2a).
No significant differences in allele or genotype frequencies were seen in patients with CD
(53.0% vs. 52.8%, p=0.43 and 26.9% vs. 26.5%, p=0.81 respectively) when compared
with controls. A trend towards higher T-allele and genotype frequencies in UC were
observed when compared with CD, (58.2% vs. 53.0, p=0.12 and 34.6% vs. 26.9%,
p=0.07).
No significant differences in carriage rate (presence of one or two copies of alleles) of
3435T in the 3 groups (UC 81.8%, CD 79.1% and HC 77.8%) were detected. This data
suggests that the TT-genotype rather than T-allele carriage play the more significant role
in the association with UC. The odds ratio, comparing with the CC-genotype, for the TT-
genotype was 1.59 (95% CI 1.04-2.44) and CT-genotype was 1.12 (95% CI 0.76-1.66).
Therefore, a stronger significance was also obtained when we compared the
homozygosity rate (TT-genotype/non-TT genotype) in UC (p=0.02, OR 1.47, 95% CI
1.06-2.03).
No significant differences were observed for allelic and genotype frequencies for MDRl
G2677T polymorphism on overall disease susceptibility for either UC or CD (Table 2b).
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There was no overall association with IBD in the present population for the G2677T SNP
(p=0.26) although the G2677 allele frequency showed a trend to be higher in patients
with UC compared with controls (54.6% and 51.2% respectively). All genotype
frequencies in both cases and controls were consistent with Hardy-Weinberg equilibrium.
In addition to this, I performed a gender matched analysis for both C3435T and G2677T
SNP with controls (335 and 268 healthy controls with male frequencies of 48.5% and
43.5% for UC and CD respectively). The association observed with C3435T SNP and UC
remained significant with the TT genotype (p=0.05, odds ratio 1.58, 95% CI 1.02-2.45)
and T-allele (p=0.03, odds ratio 1.26, 95% CI 1.03-1.06) both significantly increased. No
other significant differences were detected in gender-matched analysis (full details
available on request).
Linkage disequilibrium between C3435T and G2677Tpolymorphisms
The C3435T and G2677T SNP are in linkage disequilibrium with each other, in this
population. In cases, the D' =0.8, r2=0.7 and controls, D' =0.9, r2=0.8 Therefore, we
proceeded to perform 2-locus haplotypes association tests with UC and CD.
The effect of2-locus haplotype (C3435T/G2677T) on disease susceptibility
Using the log-likelihood ratio test as described earlier, I demonstrated an association of 2-
locus haplotypes of C3435T/G2677T with UC (p=0.0056, 3 degrees of freedom). On
single haplotype analysis, the carriage of 3435T/2677G haplotype conferred an increased
risk to UC (odds ratio 1.44, p=0.03, 95% CI 1.03-1.99) (Table 3). In contrast, carriage of
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the 3435C/2677T haplotype is associated with a protective effect in UC (odds ratio 0.35,
p=0.002, 95% CI 0.17-0.69). Similar trends were observed with the same haplotypes in
CD, but these failed to reach significance (3435C/2677T allele, p=0.20 and 3435T/2677G
allele, p=0.13).
It is noteworthy that a significantly higher number of patients with UC were homozygotes
for both TT 3435 and GG 2677 compared to a low frequency in healthy controls (8
patients possessing 3435TT and GG 2677 genotype vs. 1; p=0.017, OR 8.88 95% CI
1.10-71.45). A similar trend was observed- in patients with CD (5 patients possessing
3435TT and GG 2677 genotype; p=0.08, OR 6.82, 95% CI 0.79-58.77). Combining
UC/CD yielded a greater significance, with p-value = 0.013, OR 8.34, 95% CI 1.09-
64.07). There were no obvious associations observed in simple and compound
heterozygotes of either UC or CD with HC.
As carriers of double homozygote mutants were uncommon (14 individuals in total), we
analyzed the phenotypes of these patients. In UC, 6/8 patients had pancolitis of whom 4
required surgery as a consequence of severe disease. Of the 5 patients with CD carrying
these 2 mutations, 1 patient had colonic disease (L2), 3 ileo-colonic disease (L3) and 1
ileal disease (LI); 3/5 of these patients required surgery for active disease.
184
Genotype-plienotype analysis: Univariate analysis
The T-allele and TT-genotype of the MDR1 C3435T showed highly significant
association with the phenotype of extensive disease (OR 1.70, 95% CI 1.24-2.29,
p=0.009 and OR 2.64, 95% CI 1.34-4.99, p=0.0027 respectively). Both the frequencies of
T-allele and TT-genotype of MDR1 C3435T were increased in patients with left-sided
colitis and proctitis but these differences were not significant. A significantly higher T-
allele frequency was also observed in patients with severe disease (OR 1.39, p=0.04, 95%
CI). Although the T-allele and TT-genotype frequencies were even higher in the
subgroup of patients who had required surgery for failure of medical treatment for severe
UC (T-allele frequency 60.3% and TT-genotype 41.3%), significance was not achieved in
this smaller group (Table 4).
Interestingly, for the MDR1 G2677T SNP, trends of association to severe disease and
surgery were observed for the GG-genotype and G-allele. In patients with severe disease
who required surgery, the GG genotype frequency was 41.2% compared with 27.5% of
controls (p=0.11, OR 1.85, 95% CI 0.89-3.85). This trend was not observed in the sub¬
group of patients with extensive disease.
I did not observe any associations with sub-phenotypic categories of CD (data not
shown); specifically colonic CD was not associated with either SNPs (TT genotype
frequency, 24.7% vs. 26.5% for controls, p=0.9).
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Multivariate analysis
The phenotypes of disease extent, severity and need for surgery were considered in our
multivariate model. Multivariate analyses show that the TT genotype of MDR1 3435
remained significant associated with extensive disease (p=0.007). The phenotypes of
severe disease and surgery were not significant (p=0.8 and 0.4 respectively). Other
models which included age of onset, smoking status, presence of PSC and extraintestinal
manifestations revealed no additional associations. No associations were observed with
CD.
5.5 Discussion
This study firstly provides replicated confirmation for the association of the MDR1
C3435T SNP with UC following the initial case-control study reported by Schwab et al.
In addition, I have made novel observations with respect to genotype-phenotype
correlations, notably the strong association of the C3435T SNP with extensive UC.
Finally, the haplotypic analyses involving C3435T and G2677T SNPs provide further
new insights into the complexities of the contribution of the MDR1 gene - both
protective and susceptible haplotypes were identified.
Indeed in view of the strength of the phenotypic associations identified in the present
study, it is of interest to reconsider whether the positive association with C3435T SNP
seen in Schwab's study (43% of patients had extensive UC in that cohort) may have been
driven by this phenotype. A significant association with extensive UC was not detected in
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that study but that may have been due to lack of statistical power in a smaller sub-group
(n=63). This highlights the important point of phenotypic heterogeneity when
considering future association studies in this and other candidate genes in IBD.
The haplotypic data provide further insight into the contribution of the MDR1 gene in
determining susceptibility, and disease phenotype. By combining the 2 SNPs, the
haplotype 3435T/G2677 was shown to confer an increased susceptibility to UC (p=0.03,
OR 1.44, 95% CI 1.03-1.99) whereas haplotype C3435/2677T appeared to protect against
the development of UC (p=0.002, OR 0.35, 95% CI 0.17-0.69). The effect was most
pronounced in patients who were homozygotes for both MDR1 3435 TT and 2677 GG
genotype but we note that the overall number of this group was very low (2.4%). The
likelihood ratio for the haplotypic distribution in UC was also significantly different
when compared with controls (p=0.0056). Thus, it appears that these variants can alter
the risk of developing UC in a bi-directional fashion. It is particularly interesting that the
at-risk haplotype contains allelic variants associated with reduced P-glycoprotein
expression in vivo, whereas the alleles on the protective haplotype have been associated
with increased expression.
In the recent years, the case for the involvement of the MDR1 gene and P-glycoprotein
170 in determining susceptibility in IBD has become increasingly persuasive. It is clear
however that the role of the MDR1 gene/P-glycoprotein 170 in inflammation is likely to
be more complex than originally thought. Most pertinently, there appears to be cell, tissue
and even regional organ specific differences in the regulation of both the function and
187
expression of P-glycoprotein 170(Yacyshyn, Maksymowych, and Bowen-Yacyshyn
1999; Lin et al. 1999; Zhao et al. 1993; Murakami et al. 2002; Moodie et al. 2003).
Increasingly, in vitro and ex vivo studies, including data from our unit involving the
HLA-B27 transgenic mice suggest that P-glycoprotein expression is in fact reduced in the
presence of colonic inflammation(Moodie et al. 2004; Mizoguchi et al. 2003; Iizasa et al.
2003). This together with the findings by Langmann et al., demonstrating down-
regulation of MDR1 (with other detoxification genes) in colonic tissue of patients with
UC, puts forward a compelling argument for an influential role of P-glycoprotein in
determining susceptibility to UC(Langmann et al. 2004). We hypothesize that low levels
ofP-glycoprotein 170 expression in the GI colonic epithelium increases susceptibility and
high levels are protective.
Based on our data, the C3435T and not G2677T SNP is primarily associated with UC.
This leads on to the question whether C3435T is the functional variant or in linkage with
another variant. Given that we did not show an association with G2677T alone and that 2-
locus haplotypes were not superior in determining risk, we clearly cannot ascribe the
significant association seen with C3435T to be secondary to linkage with G2677T/A. The
functional effect of the C3435T, a synonymous SNP that does not involve amino-acid
change nevertheless remains controversial. It remains possible that this silent SNP can
affect P-glycoprotein 170 activity/expression through for example, effects on mRNA
stability or codon preference. However, it is pertinent that the correlation between
C3435T SNP and P-glycoprotein 170 activity/expression does not appear consistent
across ethnic groups. Studies in Caucasian populations showing an association with
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MDR1 3435 TT-genotype and lowered P-glycoprotein 170 activity/expression, but the
reverse is true for studies involving Japanese populations (Nakamura et al. 2002;
Drescher et al. 2002; Sakaeda et al. 2001). Therefore, we propose that the argument that
this SNP lies within tight LD with another unidentified causal variant remains the most
plausible explanation.
Does MDR1 have a role as a pharmacogenetic marker? Farrell and colleagues, suggested
that high P-glycoprotein 170 expression was associated with failure of medical treatment
in IBD(Farrell et al. 2000). The study did not investigate the genetic contribution of the
MDR1 gene. The stratification to severe disease and need for surgery in our study, was
originally driven by the hypothesis that the CC-genotype (in which some studies have
shown to be associated with high expression) can predict corticosteroid resistance (severe
disease) and therefore surgery. This in fact was not shown in our study with the trend
being completely reversed (MDR1 3435-TT genotype higher in both patients with severe
disease and requiring surgery). Recent data from the Oxford dataset in abstract form even
suggest that the TT-genotype of the MDR1 3435 SNP may in fact be useful to predict
surgery in UC, in conjunction with other genetic markers(McGovern et al. 2004).
Are allelic variants of the MDR1 gene implicated in Crohn's disease? Overall, I did not
detect any associations with CD and the sub-phenotypes according to Vienna
Classification of age of onset, disease location and behaviour (data not shown). In
particular, no association was seen when 1 specifically considered only Crohn's colitis
with either of the 2 SNPs. There were however, trends of associations with 2-locus
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haplotype (haplotypes 3435T/2677T, OR-O.85, p=0.18; C3435/2677T, OR-1.39, p=0.19;
and 3435T/G2677, OR-1.29, p=0.16). This CD population is smaller, and given the
heterogeneity involved in the presentation of CD, there may be statistical limitations in
conclusively confirming or refuting the hypothesis of association with CD.
In conclusion, this study provides robust evidence to support a role of the MDR1 gene in
the pathogenesis of UC. Germline MDR1 variation determines both disease
susceptibility, and course in the Scottish population. The data point to the presence of
more than one functional variant or a more haplotype-specific effect, and underline the
need for parallel functional studies, and haplotype analyses (Soranzo et al. 2004).
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Table la: Demographics and clinical characteristics of UC study population (n=335) *-
Severe UC defined as patients who had developed severe acute attack ofUC satisfying




Age of onset 35.0
(years) (25.3-50.3)
Age of onset <16 years 10(3%)
Current smoker 28 (8.5%)
Ex-smoker 135 (40.4%)
Never smoked 172 (51.4%)
Ethnicity
Scottish Caucasian 99%
Others (1 Jew, 1 Japanese and 2 Asians)
Disease extent
Extensive disease (>Splenic flexure) 118 (35.2%)
Left-sided colitis 149 (44.5%)
Proctitis 68 (20.3%)
Severe disease* 113 (33.7%)
Surgery for severe disease 63 (18.8%)
Extra-intestinal manifestations 31 (9.4%)




Table lb: Demographics and clinical characteristics of patients with CD. Disease







Age of onset, years 26.6
Median (+IQR) (19.9-37.0)
Age of onset 203
(<40 years, Al) (75.7%)
Ethnicity
Scottish Caucasian 99%





Ileal (LI) 83 (30.9%)
Colonic (L2) 118(39.9%)
Ileo-colonic (L3) 57(21.3%)
Upper GI (L4) 21 (7.9%)
Disease behaviour
(at diagnosis)
Inflammatory (B1) 196 (73.1%)
Stricturing (B2) 21 (7.8%)
Penetrating (B3) 51 (19.0%)
(at latest follow-up)
Inflammatory (Bl) 95 (35.4%)
Stricturing (B2) 43 (16.1%)
Penetrating (B3) 130 (48.4%)
Surgery 122 (45.8%)
Extra-intestinal manifestations 59 (22.1%)
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Table 2a: Genotype and allelic frequencies ofMDR1 C3435T polymorphism in UC and
CD, compared with controls. UC vs. CD: TT-genotype, p=0.12, OR 1.48, 95% CI 0.93-
2.36 and T-allele, p=0 07, OR 1.24, 95% CI 0.98-1.24.
CC CT TT C T TT vs. CC Tvs. C
(%) (%) (%) (%) (%) Odds ratio Odds ratio
(95% CI) (95% CI)
UC 61 158 116 280 390 0.04 0.02
(n= 335) (18.2) (47.2) (34.6) (41.8) (58.2) 1.60 1.28
(1.04-2.44) (1.03-1.58)
CD 56 140 72 252 284 0.81 0.43
(n=268) (20.9) (52.2) (26.9) (47.0) (53.0) 1.08 1.03
(0.68-1.69) (0.83-1.29)
Healthy 82 190 98 354 386
controls (22.2) (51.3) (26.5) (47.8) (52.8)
(n=370)
Table 2b: Genotype and allele frequencies ofMDR1 G2677T polymorphism in UC and
CD, compared with controls. UC vs. CD: GG-genotype, p=0.48, OR 1.19, 95% CI 0.75-
5, 95% CI 0.93-1.89.
GG GT TT G T GG vs. TT G vs. T
(%) (%) (%) (%) (%) Odds ratio Odds ratio
(95% CI) (95% CI)
UC 95 176 64 366 304 0.16 0.19
(n= 335) (28.3) (52.5) (19.1) (54.6) (45.4) 1.37 1.15
(0.89-2.09) (0.93-1.42)
CD 75 133 60 283 253 0.57 0.57
(n=268) (27.9) (47.8) (22.4) (52.8) (47.2) 1.15 1.07
(0.74-1.79) (0.86-1.34)
Healthy 102 174 94 378 362
controls (27.6) (47.0) (25.4) (51.2) (49.8)
(n= 370)
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Table 3: 2-locus haplotypes of C3435T/G2677T SNPs with UC/CD. Contingency tests
were used to test the association of the inferred haplotypes in the groups of UC and CD
respectively as compared with the control group (total number of a particular
haplotype/total number of remaining haplotypes compared between case and controls













































































Table 4: Genotype-phenotype analysis for C3435T and G2677T SNP in UC
C3435T















UC (14.4%) (43.2%) (42.4%)





















































UC (27.1%) (50.9%) (22.0%)














































The ABCB1/MDR1 gene determines
susceptibility and phenotype in
ulcerative colitis: definition of critical




Background: Several lines of evidence suggest a role for the multidrug resistance gene
(ABCB1/MDR1) in the pathogenesis of inflammatory bowel disease (IBD).
Aims: To investigate the overall contribution of MDR1 gene to susceptibility of UC and
CD using a gene-wide haplotype tagging approach.
Methods: Six haplotype tagging SNPs (tSNPs) representing the haplotypic variations of
the ABCB1/MDR1 gene were identified initially following the characterization of the
haplotype structure of this gene in 24 CEPH Caucasian trios. Genotyping was performed
in 249 ulcerative colitis (UC) and 179 Crohn's disease (CD) patients and 260 healthy
controls (HC).
Results: Using log-likelihood analysis, a highly significant association between the
common haplotypes and UC (p=4.22xl0"7) was observed but not with CD (p=0.22). This
significant association was critically dependent on one tSNP, intronic variant rs3789243.
All haplotypes with this variant retained a highly significant association (p= 3.2 x 10~7-
3.6 x 10"12) whereas significance was lost when rs3789243 was dropped in systematic
haplotypic analysis. The effect of this tSNP was independent of C3435T SNP (previously
shown to be associated with UC). The association with UC was also shown to be
strongest with the phenotype of extensive disease (p= 1.7 X 10"7).
Conclusion: This 'candidate gene' approach provides the strongest yet evidence to
support the contribution of the ABCB1/MDR1 gene in determining risk to UC but not
CD in our population.
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6.1 Introduction
As demonstrated in chapter 5, the candidate polymorphism C3435T of the MDR1 gene is
associated with UC and extensive disease in the Scottish dataset. Although this SNP has
been shown to be associated with expression of P-glycoprotein 170, the mechanisms
whereby this variant (and the G2677T/A SNP) affect gene transcription has yet to be
clarified. There are several reasons to suspect that the effect seen can be ascribed to
linkage disequilibrium with an unknown causal or set of variants. The C3435T SNP is a
silent wobble mutation. Site-specific mutagenesis experiments have demonstrated that the
C3435T and G2677T/A substitution have no effect on P-glycoprotein function in vivo
(Morita, Yasumori, and Nakayama 2003). Haplotypes derived from these two SNPs
showed a stronger association with P-glycoprotein activity (inferred from digoxin
uptake)(Johne et al. 2002a). Furthermore, the correlation between C3435T SNP and P-
glycoprotein activity/expression does not appear consistent across ethnic groups. Studies
in Caucasian populations have shown a general trend of association between the MDR1
3435 TT-genotype and lowered P-glycoprotein activity/expression, whereas this
association appears generally reversed in the Japanese(Nakamura et al. 2002; Drescher et
al. 2002; Sakaeda et al. 2001).
These candidate polymorphisms have now been studied extensively in several other
datasets since our initial study. Presently, a total of nine studies have examined the effect
of these candidate SNPs (C3435T and G2677T) either singly or in combination in
determining susceptibility to inflammatory bowel disease (Table l)(Schwab et al. 2003c;
Brant et al. 2003; Croucher et al. 2003; Glas et al. 2004; Potocnik et al. 2004; Ho et al.
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2005). The overall results have been inconsistent: 3 studies have reported no associations
with either CD or UC, a further 4 studies demonstrated associations with UC and a
further 2 studies demonstrated associations with CD. Several factors are pertinent when
considering the apparently inconsistent results from these studies. The two most
important points which may confound the overall picture are phenotypic (given previous
association with extensive disease) and genetic heterogeneity.
To obtain a more robust assessment of the contribution of the ABCB1/MDR1 gene to
disease susceptibility, we utilized an approach where highly informative 'tagging' SNPs
(tSNPs) which represent the haplotypic variations of this gene are used to test for
association. This involved a three-step approach where firstly the ABCB1/MDR1
haplotype structure was initially characterized by re-sequencing this gene in 24 CEPH
Caucasian trios. Having established the pattern of LD, we then identify a set of SNPs
which represent or 'tag' the common variations of the region, in this case, the gene. We
then genotyped the tSNPs in the study population and employ likelihood calculations to
determine whether there is a difference between case and control populations. In this
study, we have identified 6 tSNPs by using a selection strategy which is 'block' free
initially described by Weale et al (Weale et al. 2003). This is therefore a 'gene'-wide
study and also implicitly a candidate gene rather than a candidate polymorphism study.
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6.2 Material and Methods
Patients and controls
A total of 249 patients with UC and 170 patients with CD were studied together with 260
healthy controls. Table 2 summarizes the clinical characteristics of studied patients. The
median ages of diagnosis for UC and CD were 35.8 years (IQR 26.4-50.2) and 27.3 years
(IQR 21.0-42.7) respectively. The ethnicity of our study population in both cases and
controls were Scottish-Caucasians. There were more males in the UC cohort (54.5%) and
fewer in CD (44.5%). These differences were not significant when compared with
controls In the UC group, 42% and 29% of patients had extensive and severe disease
respectively.
Re-sequencing of the ABCBl/MDRl gene and the selection of tSNPs
The re-sequencing of 12 amplicons distributed along the length of the ABCBl/MDRl
gene and corresponding to a total of 4.1 kb identified 17 SNP loci in 24 Caucasian CEPH
trios (Soranzo et al. 2004)(Table 3). Three loci had a low minor allele frequency (<6%)
and were therefore excluded from further analysis as these low frequency variants were
unlikely to be responsible for the previously documented observed association between
UC and the common C3435T SNP(Ho et al. 2005; Schwab et al. 2003a). Using 14 SNPs
with high minor allele frequency, 2114 haplotypes were obtained where only haplotypes
with frequencies >1%, equating to 39 common haplotypes were used for further analysis
(corresponding to 95% of the total haplotypic variation of this gene). A set of 6 tSNPs
were identified that provide a coefficient of determination of at least 0.80 in predicting all
the known SNPs (Table 4) (Weale et al. 2003; Goldstein et al. 2003).
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The criteria for the choice of tSNPs were i) average r2 weighted by allele frequency
between the tSNPs and all SNPs were > 0.80 and ii) minimum r2 between the tSNPs and
each individual SNPs in the gene was 0.80. All genotype data was entered into the TagIT
program (criterion 5 in TAGIT 3.00 at wvvw.genome.duke.edu/research/centers/pg2") with
a minimum haplotype r2 of 0.80 to select the tSNPs. Haplotype r2 is the coefficient of
determination from a regression model of an allelic or haplotype state in question against
haplotypes determined by tSNPs' set. This method does not rely on heuristically defined
haplotype block structure. All genotyping were done using TaqMan technology
(sequence reactions available on request).
Genotyping
Genotyping of the subjects in the study was performed using TaqMan technology (tSNPi,
2,3,4) (ABI, San Diego, CA) or resequencing of PCR products (rs3789243, tSNPs,6) using
ABI 3700 Big Dye Terminators. Sequences for tags 11 and 12 were scored twice
independently using the Sequencher software (Gene Codes Corporation, Ann Arbour,
Michigan, USA). The sequence reactions were described in Chapter 2.
Statistical analysis
The statistical methods to compare allelic and genotypic frequencies were described in
the previous chapter. Haplotype frequencies of the ABCB1/MDR1 tSNPs were inferred
using the expectation-maximization (EM) algorithm implemented in SNPHAP
program(Zhao, Curtis, and Sham 2000). Haplotypic associations with disease were
assessed in two ways: 1) A log-likelihood ratio analysis was implemented in the EH and
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PM programs (bioinformatic programmes available and accessed via the Medical
Research Council-Rosalind Franklind Centre of Genomic Research website:
www.rfcgr.mrc.ac.uk)(Zhao. Curtis, and Sham 2000; Qin, Niu, and Liu 2002). This
involves the calculation of the log-likelihoods of estimated frequencies for each cases,
controls and case and controls combined. Significance for association is calculated using
the test statistic 2*(ln(L case)+ln(Lcontrol)-ln(Lcase/Lcontrol), which has a £
distribution with n-1 degrees of freedom (where n=number of inferred haplotypes). 2)
Contigency tests were also used to test the association for all haplotypes showing a
frequency difference between cases and controls. We measured the linkage
disequilibrium between SNPs using Cocaphase Software (also accessed via the Medical
Research Council-Rosalind Franklind Centre of Genomic Research website:
www.rfcgr.mrc.ac.uk).
6.3 Results
Based on the haplotypic information from the initial re-sequencing of 24 CEPH trios, we
have selected a set of 6 tSNPs with good performance (with a coefficient of
determination of at least 0.80 in predicting all the known SNPs) (Table 4) (Weale et al.
2003; Goldstein et al. 2003); and genotyped these tSNPs in a panel of 249 and 179
individuals with UC and CD respectively and 260 healthy controls in a Scottish-
Caucasian population. The genotypic frequencies of the 6 selected tSNPs are shown in
Table 5. The G-allele of rs3789243, tSNP, (p=0.03, OR 1.31, 95% CI 1.03-1.68) and
GG-genotype (p=0.04, OR 1.76, 95% CI 1.06-2.92) were significantly higher in patients
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with UC compared with controls. No other significant differences were observed in UC
or CD.
Using the log-likelihood ratio analysis which tests the association between the inferred
haplotypes using disease/control partition (using EH+ which makes a likelihood
assessment that includes statistical uncertainty in phase estimation), 1 detected a strong
association of haplotypes with UC, with a highly significant p-value of 4.22x10"7 (35
degrees of freedom). In contrast, no association was seen with CD (p=0.22). The log-
likelihood analysis was most significant in the phenotype of extensive UC (colitis
extending beyond the splenic flexure) (p=1.7 X 10"7), and less in recto-sigmoid disease
(0.0089) (Table 6). No association was seen within the sub-phenotypes of disease
location and behaviour in CD (data not shown).
I further analyzed all combinations of haplotypes to (i) determine which tSNP/s is/are
responsible for the observed association and (ii), whether the effect observed is haplotype
specific. I therefore performed a log-likelihood analysis on all possible sets of 2-, 3-, 4-
and 5-locus haplotypes (a total of 56 different sets of haplotypes). Only haplotypes
containing rs3789243, tSNPi were found to retain a significant association with UC
(Table 7). It is particularly noteworthy that in the 26 haplotypes without rs3789243,
tSNPi, none of these approached significance.
Eleven haplotypes (from a total of thirty) containing rs3789243, tSNPi but without
rs!045642, tSNP4 (C3435T), demonstrated highly significant association. Conversely,
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there was no association seen in the total of 15 haplotypes which contained rs 1045642,
tSNP4 (C3435T), but not rs3789243, tSNP|. This imply that rsl045642, tSNP4 (C3435T)
is not responsible for the overall association seen using the 6-locus haplotype. We have
focussed on rsl045642, tSNP4 (C3435T) due to the controversies surrounding the
contribution of this SNP to disease susceptibility as highlighted in Table 1.
Having found an overall association with UC, I systematically examined the direct
haplotypic frequencies (as inferred using the PL-EM program). For each of the 2, 3, 4 and
5-locus haplotypes, we have selected and compared their inferred respective haplotypic
frequencies between the groups of UC and controls. These specific haplotypes which
were most significantly associated with UC are shown in Table 8. It is pertinent that these
haplotypes all contained the G-allele of rs3789243, tSNPi .again confirming the critical
importance of this tSNP. Similarly, the strongest effect was determined by 2-locus
haplotype composed of tSNPi and tSNPs, with an odds ratio of 3.27 (p <0.00001, 95% CI
2.26-4.72).
6.4 Discussion
This 'gene-wide' approach provides the most robust evidence yet to support the genetic
contribution of the ABCB1/MDR1 gene to the susceptibility of UC. I observed a highly
significant association (log-likelihood ratio test p= 4.22x10"7) with UC and not CD in our
population. As this study accounted for the haplotypic variations across the gene, the
results are much stronger than the previously published studies utilizing candidate
polymorphisms, C3435T and G2677T/A(Ho et al. 2005; Schwab et al. 2003a; Croucher
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et al. 2003; Brant et al. 2003; Glas et al. 2004; Potocnik et al. 2004). In addition, we have
again shown that the contribution of germ-line variations of the ABCB1/MDR1 gene is
primarily most significant in the phenotype of extensive colitis. There remains a degree
of controversy of whether the ABCB1/MDR1 gene contributes only to disease
susceptibility in UC and not CD. Previous genetic studies have presented a more
inconsistent picture (Table 1). The negative result which we have found from our
haplotypic approach sets a statistical limitation to the importance of common variants in
this gene and their contribution to CD-susceptibility in our population.
Confirming the initial impression of the complex contribution of the ABCB1/MDR1
gene, this data shows that the highly significant association is critically dependent on an
upstream intronic variant rs3789243, tSNPi which is also independent from the effect of
the often cited rsl045642, tSNP4 (C3435T). Although it is not possible to conclusively
disprove the case for the rsl045642, tSNP4 (C3435T) as the 'causal' variant for
previously observed association, this finding strongly suggest this is not likely to be the
case. This lends considerable support to the current thinking that C3435T and G2677T/A
(in exons 26 and 21 respectively) are not the causal variants but lie in linkage
disequilibrium with it/them. The replication at the haplotype level based on the tSNPs
identified by our study, in other European Caucasian populations is now crucial and will
be more powerful than further candidate SNP analysis in this field in IBD, as already
more extensive variation has been studied and tagged in this essentially gene-based
study(Neale and Sham 2004).
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The 'block' free haplotype tagging approach utilized by this study, which circumvents the
heuristically defined block boundaries, originally described by Weale and
Goldstein(Weale et al. 2003; Goldstein et al. 2003) have been shown recently following
extensive empirical evaluations to be efficient and effective method to represent both
known and unknown common variations(Ahmadi et al. 2005). In the case of this study, I
have successfully used this method in an area of which controversy still exist e.g. the
genetic contribution of the ABCB1/MDR1 gene to susceptibility of IBD. In this current
approach, I have not determined the extent of LD outwith the ABCB1/MDR1 gene.
Therefore, it is conceivable that this set of tSNPs can also pick up long range LD signals
from neighboring regions in contrast to the more conventional concept of tagging major
haplotypes in blocks of high LD(Kamatani et al. 2004). Nevertheless, with the data from
the mdr-la knock-out models and other expression studies both in human and animals
which strongly implicate the role of P-glycoprotein 170, the product of the
ABCB1/MDR1 gene in the aetiopathogenesis of IBD, it is less likely that the strong
signal that we have obtained are derived from outwith the gene (Panwala, Jones, and
Viney 1998; Langmann et al. 2004; Maggio-Price et al. 2002; Maggio-Price et al. 2005)
(Iizasa et al. 2003; Mizoguchi et al. 2003).
Future work should be directed towards deep re-sequencing the associated interval
surrounding rs3789243, tSNPi in a cohort of patients with extensive UC, of which we
have demonstrated to be the sub-phenotype most implicated by this gene. Although 1
have further fine localized the region of interest in this gene, the ease or difficulty in pin¬
pointing the 'causal' variant/s remains unpredictable. It is possible that the extent of
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linkage disequilibrium could be so high that the 'causal' variant could lie anywhere in the
block on the associated chromosome. This difficulty has been highlighted in the recent
studies focusing on the IBD5 locus, cytokine gene cluster in chromosome 5q31-33, a 250
kB haplotype of high LD which conferred susceptibility to CD (Peltekova et al. 2004;
Newman et al. 2005). It seems increasingly certain that once haplotypic replication has
been attained in the case of ABCB1/MDR1 gene, functional studies examining the effect
of the list of putative casual variants derived from further fine localization will be the
direction to take.
It is pertinent that the implications of these findings may extend beyond the field of
inflammatory bowel disease. As suggested earlier, there has been much interest
surrounding the issue of the identification of the 'causal' variant/s underlying reported
genetic associations of the candidate SNP rsl 045642, tSNP4(C3435T), with other clinical
conditions such as drug-resistant epilepsy(Siddiqui et al. 2003; Soranzo et al. 2004),
immune recovery after initiation of anti-retroviral therapy in HIV(Fellay et al. 2002),
increased risk to renal cell carcinoma(Siegsmund et al. 2002) and other drug responses in
the field of pharmacogenetics. It would be of great interest to examine the contribution of
these tSNPs in these other conditions. The economy and applicability afforded by this
approach is now well-demonstrated. If variations of the ABCB1/MDR1 gene are indeed
implicated in these conditions, similar degrees of associations can be anticipated.
By using a 'gene-wide' haplotype approach which is increasingly accepted as the model
for future genetic association studies(Neale and Sham 2004), we have now provided very
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strong evidence to implicate the genetic involvement of the ABCB1/MDR1 gene in
susceptibility to UC but not CD in our population. This data also crucially enable further
targeted fine localization in the search for the critical 'causal' variant for the observed
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Table 2: Demographics of patients studied. Extensive disease was classified as disease >
splenic flexure, severe disease classified as patients who had developed severe attack of
UC which satisfied the Truelove and Witts criteria. For CD, disease location and
behaviour were classified according to the Vienna Classification(Gasche et al. 2000).







Sex (Females) 45.5% 55.5%
Age of diagnosis 35.8 28.9






Disease extent/location Extensive disease- 41.7%
Colonic (L2) - 30.7%
Ileocolonic (L3) - 20.1%
Upper GI (L4) - 6.1%
Inflammatory (Bl)-72.9%
Disease behaviour Severe disease - 29.7% Stricturing (B2) -8.0%
Penetrating (B3) -19.1%
Need for surgery 20.0% 45.8%
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Table 6: Log-likelihood significance between the common haplotypes of ABCB1/MDR1
haplotypes and UC/CD. Extensive disease - colitis extending beyond the splenic flexure;
and left sided disease-colitis limited to the splenic flexure. No significant association






Ulcerative colitis 249 4.22x10"7
Extensive disease 102 1.7 X 10"7
Left sided disease 147 0.0089
Crohn's disease 179 0.22
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Table 7: Analysis of all combinations of 2-, 3-, 4- and 5-locus haplotypes using log-
likelihood analysis using UC/control partition. Only haplotypes containing Tag 1 retains





1 2 503.62 436.52 968.29 3 56.3 3.63E-12
1 3 507.33 452.26 983.56 3 47.94 2.19E-10
1 4 505.16 480.54 999.17 3 26.94 6.06E-06
1 5 472.27 496.84 974.38 3 10.54 0.01
1 6 424.34 452.29 879.29 3 5.32 0.15
2 3 295.63 311.72 608.96 3 3.22 0.36
2 4 440.26 429.72 873.5 3 7.04 0.07
2 5 472.23 493.67 968.44 3 5.08 0.17
2 6 425.4 452.81 878.41 3 0.4 0.94
3 4 433.68 422.09 858.82 3 6.1 0.11
3 5 475.85 495.62 973.91 3 4.88 0.18
3 6 429.24 455.24 884.78 3 0.6 0.89
4 5 465.29 486.93 954.25 3 4.06 0.25
4 6 428.03 451.09 881 3 3.76 0.29
6 388.64 423.44 813 3 1.84 0.61
1 2 3 544.03 480.03 1055.67 7 63.22 3.42E-11
1 2 4 685.64 593.3 1313.2 7 68.52 2.94E-12
1 2 5 720.78 663.78 1415.47 7 62.28 5.28E-11
1 2 6 673.86 623.34 1325.78 7 57.16 5.56E-10
1 3 4 679.17 599.38 1307.53 7 57.96 3.85E-10
1 3 5 724.22 679.35 1429.82 7 52.5 4.65E-09
1 3 6 677.6 638.79 1340.9 7 49.02 2.25E-08
1 4 5 712.55 702.84 1429.8 7 28.82 0.000156
1 4 6 674.93 666.54 1355.88 7 28.82 0.000156
1 5 6 642.43 682.77 1331.02 7 11.64 0.11
2 3 4 469.76 465.45 939.96 7 9.5 0.22
2 3 5 512.41 538.71 1055.14 7 8.04 0.33
2 3 6 465.85 497.81 965.75 7 4.18 0.76
2 4 5 644.58 650.65 1300.66 7 10.86 0.14
2 4 6 610.61 613.42 1229.5 7 10.94 0.14
2 5 6 640.68 678.1 1322.71 7 7.86 0.35
3 4 5 638.17 644.06 1286.99 7 9.52 0.22
3 4 6 603.91 607.71 1215.81 7 8.38 0.30
3 5 6 644.83 679.46 1328.18 7 7.78 0.35
4 5 6 633.9 668.4 1305.81 7 7.02 0.43
1 2 3 4 715.11 625.13 1377.24 14 74 3.61E-10
1 2 3 5 760.74 706.22 1500.98 14 68.04 4.36E-09
1 2 3 6 713.65 664.71 1410.99 14 65.26 1.37E-08
1 2 4 5 889.11 813.5 1739.34 14 73.46 4.53E-10
1 2 4 6 854.91 775.99 1667.28 14 72.76 6.08E-10
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1 2 5 6 883.46 846.54 1762.42 14 64.84 1.63E-08
1 3 4 5 882.85 820.8 1734.86 14 62.42 4.4E-08
1 3 4 6 847.81 784.08 1662.42 14 61.06 7.64E-08
1 3 5 6 886.76 861.71 1776.6 14 56.26 5.25E-07
1 4 5 6 875.87 883.46 1777.64 14 36.62 0.0008
2 3 4 5 674.05 685.84 1367.03 14 14.28 0.43
2 3 4 6 639.88 647.42 1294.67 14 14.74 0.39
2 3 5 6 680.84 721.43 1408.6 14 11.7 0.63
2 4 5 6 811.58 827.75 1650.99 14 23.32 0.06
3 4 5 6 805.34 822.06 1637.83 14 20.86 0.11
1 2 3 4 5 918.42 844.61 1802.25 31 78.44 5.49E-06
1 2 3 4 6 833.1 806.05 1728.67 31 79.1 4.42E-06
1 2 3 5 6 922.69 866.53 1845.63 31 72.8 3.21E-05
1 2 4 5 6 1048.9 988.59 2081.2 31 87.0 3.24E-07
1 3 4 5 6 1042.2 997.24 2076.4 31 73.92 2.29E-05
2 3 4 5 6 840.7 860.4 1714.6 31 27 0.67
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Table 8: Comparison of direct haplotypic frequencies between UC and controls. We
have selected for each of the respective 2, 3, 4 and 5-locus, the most significant
haplotypes (see Table 4) for analysis. For each of the selected haplotypes, the inferred
haplotypic frequencies for UC and controls were compared using Fisher's exact test. The

































Investigation into the contribution of
Pregnane-X Receptor (PXR/NR1I2)
gene and susceptibility to
inflammatory bowel disease: Parallel




Background: The Pregnane X-receptor gene (PXR/NR1I2) regulates an array of
genes involved in the response to xenobiotics. Dysregulation of this gene may
critically influence intestinal barrier defence and susceptibility to inflammatory bowel
disease (IBD). Recent data in an Irish dataset have suggested strong associations
between polymorphisms within the PXR/NR112 gene and IBD.
Aims: The allelic variants of rs 1523127/-24381 of the PXR/NR1I2 gene previously
implicated in the Irish dataset are now investigated in the Scottish dataset. A
candidate gene-wide association study to assess in detail the contribution of this gene
to disease susceptibility was also performed.
Methods: 387 ulcerative colitis (UC), 328 Crohn's disease (CD) patients and 338
healthy controls (HC) were studied. This study has >95% power to replicate previous
association with the rs 1523127/-24381 variant (p <0.05). Five tagging SNPs (tSNPs)
were selected by re-sequencing PXR/NR1I2 gene in 32 CEPH Caucasian trios, using
a multimarker criterion, haplotype r2 >0.80 to predict all SNPs/haplotypes. Single
marker, log-likelihood and genotype-phenotype analyses using the Montreal
classification were used to test for association.
Results: No association was seen with rs 1523127/-24381 SNP with UC, CD or IBD
(A-allelic frequency 60.5% UC, 59.5% CD, 60.0% IBD and 60.6% HC; p= 0.96, 0.69
and 0.82 respectively). The homozygosity rates were 35.9%, 31.1%, 33.7% and
35.6% for UC, CD, IBD and HC respectively (p=0.91, 1.00 and 1.00 respectively).
The log-likelihood analyses comparing overall haplotypic distribution of the 5 tSNPs,
demonstrated no associations with UC, CD or IBD (p=0.90, 0.90 and 0.79
respectively). There were no associations observed between each of the 5 tSNPs with
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UC, CD and IBD respectively. Genotype-phenotype analyses did not show any
associations with the studied variants and haplotypes.
Conclusion: Germ-line variation of the PXR/NR1I2 gene does not have a major
effect on susceptibility to IBD or disease phenotype in the Scottish population.
However, epigenetic modification of this gene may be an important pathogenic event;
and other genes in epithelial barrier function remain plausible candidate genes.
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7.1 Introduction
Increasing evidence suggest a role in epithelial transporter and xenobiotic
metabolising genes in the maintenance of intestinal barrier defence (Ho, Gaya, and
Satsangi 2005). Much of the earlier interest was derived from data based on animal
models(Panwala, Jones, and Viney 1998; Maggio-Price et al. 2002; Maggio-Price et
al. 2005) and genetic studies involving the P-glycoprotein 170 pump (PgP 170) the
gene product of MDR1 gene, as demonstrated in Chapters 6 and 7 in this thesis. The
MDR1 gene is one of the many genes in the family of ATP-binding cassette (ABC)
transmembrane transporters which are highly expressed in intestinal epithelial cells
with very diverse functions - most pertinently the transport of drug substrates,
endogenous steroid/cholestrol compounds, bile acids and other xenobiotics
(Langmann et al. 2003). Other ABC transporters such as ABCC1-3 (multidrug
resistance proteins 1-3) have also been demonstrated to have similar roles(Langmann
et al. 2003).
Langmann and colleagues have recently further developed the argument for the
contribution of defective detoxification in the development of IBD(Langmann et al.
2004). In this study, DNA microarray analysis involving non-affected colonic tissue
of CD and UC, revealed a cluster of strongly down regulated detoxification genes (of
the glutathione and sulfo-transferase family) and ABC transporters (including MDR1)
in UC, together with the near complete loss of the transcriptional regulator pregnane
X receptor (PXR). The expressions of MDR1 and PXR were both reduced in tissues
of patients with UC in subsequent rt-PCR analysis in the same study. PXR is a nuclear
hormone receptor that is ligand-activated by a large number of structurally and
pharmacological diverse endogenous and exogenous compounds (including
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pregnanes, corticosteroids, rifampicin and bile acids)(Staudinger et al. 2001; Chrencik
et al. 2005; Schuetz et al. 2001; Willson and Kliewer 2002). PXR regulates the
induction of many genes including CYP3A4 and the ABC transporter family genes
(which includes MDR1). The function and expression of MDR1 is closely regulated
by PXR(Kliewer, Goodwin, and Willson 2002).
Central to the findings of Langmann et al., is the suggestion that PXR play a pivotal
role in the maintenance of epithelial barrier defence. It is postulated that dysregulated
PXR expression and function leads to a widespread effect on the downstream
detoxification genes therefore predisposes to increased risk of intestinal inflammation.
On this basis, Dring and colleagues have hypothesised that germ-line variations of the
PXR/NR1I2 gene may confer susceptibility to IBD. The authors performed a case-
control study involving 422 patients with IBD (185 UC and 237 CD) and 350 healthy
controls, using 8 candidate polymorphisms in this gene. Highly significant
associations were demonstrated with UC, CD and IBD as a whole. This effect was
most significant for the two individual SNPs in the promoter region of this gene;
when compared between the IBD cohort and controls, -23585 (rs3814055)
(p=0.000008; OR 1.62; 95% CI, 1.31-2.00) and -24381 (rs 1523127) (p= 0.0002; OR,
1.50; 95% CI, 1.21-1.84).
In order to clarify the genetic contribution of the PXR/NR1I2 gene to the
susceptibility to IBD, this candidate gene was resequenced and replication exercise of
previous associations observed in the Irish dataset were performed. To provide a more
complete assessment of the genetic contribution of this gene to disease susceptibility,
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I utilised the candidate gene-wide strategy using a haplotype-tagging approach as
successfully applied in the previous chapter.
7.2 Material and methods
Patients
A total of 387 patients with UC and 328 with CD were recruited from the Lothian
region, Scotland, United Kingdom. The diagnosis of IBD was determined by standard
clinical, radiological, endoscopic and histological criteria. Table 1 summarizes the
clinical characteristics of patients studied. The median ages at diagnosis for UC and
CD were 35.2 years (IQR 25.9-50.4) and 28.5 years (IQR 21.0-41.1) respectively. The
ethnicity of our study population was Scottish-Caucasian. There were more males in
the UC cohort (54.0%) than in CD (36.6%). 356 healthy controls which comprised of
102 actively recruited healthy subject and+ 254 blood donors from the Lothian region
(50.8% males and age of recruitment 31.1 years, IQR 25.9-47.0).
Phenotypic assessment
The phenotypic data for both UC and CD were categorised using the new Montreal
Classification(Silverberg et al. 2005). UC phenotype was classified by disease extent,
severity and need for surgery. Extensive disease was defined as disease extending
beyond splenic flexure (E3), left-sided colitis as disease extending to the splenic
flexure (E2) and proctitis (El), limited to the rectum using maximal colonoscopic
evidence over time of follow-up. Patients who had developed acute severe attack of
UC (satisfying the Truelove and Witts criteria) requiring intensive in-patient medical
therapy were regarded to have severe UC (S3). Within the severe UC, a further subset
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of patients who had failed to respond to medical therapy and consequently required
surgery were categorized under the phenotype - need for surgery. Other phenotypic
details such as smoking, family history, presence of primary sclerosing cholangitis
(PSC) and other extra-intestinal manifestations were also recorded. CD was classified
according to the new Montreal Classification of disease location (L1-L4), behaviour
(B1-B3, with p-as perianal) and age of diagnosis (A1 <16 years, A2 17-40 years and
A3 >40 years). I have presented disease behaviour data at 5-year following diagnosis.
Resequencing ofthe PXR/NR1I2 gene and the selection of tSNPs
The exons, promoter region and intronic boundaries were re-sequenced in 16
unrelated Centre d'Etude du Polymorphisme Humain (CEPH) individuals by using 10
randomly spaced amplicons across the PXR/NR112 gene. All SNPs discovered were
resequenced in 32 CEPH trios. Haplotypes and their respective frequencies were
estimated and constructed from all genotyped SNPs using the partition-ligation
expectation-maximization algorithm(Zhang et al. 2004). A set of tSNPs were then
selected to 'tag' the majority of the constructed haplotypes. The selection criteria were
described in Chapter 7.
Statistical analysis
The statistical methods to compare allelic and genotypic frequencies were described
in Chapter 6. The log-likelihood ratio tests to test for association, and the contingency
tests between constructed haplotypes were described in detail in Chapter 7. A power
calculation was undertaken using previous reported association with the rs 1523127/-
24381 variant in the Irish dataset using a genotypic model of analysis (i.e. based on a
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2 by 3 contingency table). Based on the size of the 1BD cohort, this study has a 98%
power to replicate this association at the level of p <0.05.
7.3 Results
Re-sequencing ofPXR/NR1I2 gene
Re-sequencing of the exons, promoter region and intronic boundaries in 16 unrelated
CEPH white individuals over a region spanning 7.4 kB revealed 15 SNPs with a
minor allele frequency of greater 10%. These SNPs were further genotyped in 32
CEPH trios. 26 haplotypes with inferred frequencies of >0.5% were used for further
selection of tSNPs. Using 15 SNPs with high minor allele frequency, a set of 5 tSNPs
(rs 1523127, rs2461823, rs7643645, rsl464603 and rs2472682) were identified that
provide a coefficient of determination, haplotype r of 0.80 in predicting all the known
SNPs/haplotypes. These tSNPs were genotyped in 387 UC, 328 CD patients and 338
healthy controls. All genotype data for these groups were in Hardy-Weinberg
equilibrium.
Single variant analyses and replication of previously implicated candidate
polymorphisms (Table 2)
The rs3814055 (-23585) and rs 1523127 (-24381) SNPs were in strong linkage
disequilibrium, with an r2-value of 0.96. Both these SNPs were strongly associated
with IBD in Dring's study. In view of this linkage magnitude, only one of the variants
can be studied without any loss of information of the other and the rs 1523127/-24381
variant was genotyped in the Scottish dataset. We did not observe any associations
between this SNP and susceptibility for IBD and controls in our study (A-allelic
frequencies, p=0.82, odds ratio 0.97, 95% CI 0.81-1.17; and AA-genotype frequencies
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p=l .00, odds ratio 0.99, 95% CI 0.66-1.49) (Table 2). No associations were seen with
either UC or CD respectively.
The rs6785049 (-7635) variant which was also significantly associated with IBD in
Dring's study was in strong linkage with a further tSNP used in this study
(rs2472682) with an r2-value of 0.86. In the Scottish dataset, this SNP (rs2472682)
was also not associated with IBD (T-allele, p=0.97, OR 1.00, 95% CI 0.82-1.22 and
TT-genotype, p=0.82, OR 0.96, 95% CI 0.62-1.47). There were no significant
differences between UC, CD and healthy controls respectively for the other respective
tSNPs (Table 2).
Log-likelihood analyses (Table 3)
Providing the more robust assessment of the contribution of the genetic variations of
this gene to disease susceptibility, the log-likelihood analysis which examine the
differences between the overall haplotypic distribution between case and control
(which makes a likelihood assessment that includes statistical uncertainty in phase
estimation), showed no associations with UC, CD or IBD (p=0.90, 0.90 and 0.78
respectively). On direct haplotypic comparisons between case and controls (total of 32
haplotypes), we did not observe any significant differences between UC and CD, with
controls. We presented data on the four commonest haplotypes and showed no
significant differences in the groups of UC, CD and HC (Table 3b).
Subphenotypic analyses using Montreal Classification
In addition, on subphenotypic analysis using the Montreal classification, no
associations were observed for both single variants and haplotypes for age of
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diagnosis, disease location and behaviour for CD; and disease extent, severity and
surgery for UC.
Comparisons between Scottish and Irish study populations (Table 4)
Using the rs 1523127/-24381 SNP, it is noteworthy that significant differences in the
allelic and genotype frequencies exist between the Scottish and Irish healthy control
populations (A-allele frequencies: p=0.03, OR 1.27, 95% CI 1.02-1.58 and AA-
genotype frequencies: p=0.01, odds ratio 1.75, 95% CI 1.12-2.72). The minor allelic
frequency of our control population was 40% compared with the identical frequencies
of 39% for CEPH population obtained from HapMap Project
(http://www.hapmap.org) and our initial sequencing of the 32 CEPH trios
respectively. This contrasted with the higher frequency, 45% observed in the Irish
control population. These differences were very much less marked when comparing
the allelic and genotypic frequencies between the Scottish and Irish patient
populations (A-allele frequencies: p=0.05, OR 1.20, 95% CI 1.00-1.44 and AA-
genotype frequencies: p=0.17, odds ratio 1.33, 95% CI 0.90-1.98)
7.4 Discussion
The PXR/NR1I2 gene represents an attractive candidate gene in determining
susceptibility to IBD. The recent associations between candidate polymorphisms
within this gene and IBD in the Irish population are exciting and bear further
examination. In this study, I have attempted to replicate the previous association by
Dring et al. in the Scottish population. Secondly, we have proceeded to use a more
exhaustive method to assess the overall contribution of this gene to disease
susceptibility by using a multimarker haplotype-tagging approach that captures the
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genetic variations of this gene. In contrast to the study by Dring et al., I did not
replicate the previous association of the rs 1523127, -24381 variant with IBD (UC and
CD respectively). In addition, our haplotypic analyses did not show any association.
A number of issues deserve further discussion in view of the apparent discordant
findings between this and Dring et al.'s study. Firstly, do these data reflect true
genetic heterogeneity between the Irish and Scottish populations? The Scottish
population is traditionally characterised by low rates of admixture and considered to
be ethnically close to the Irish. This has recently been demonstrated in the similar low
rates of NOD2/CARD15 gene mutations in these populations as compared to other
European and North American studies (Arnott et al. 2004a). Indeed, the
NOD2/CARD15 data have led to the search of common founder effects in the
Scottish, Irish and other North European populations(Gaya et al. 2006). Thus, the
argument in favour of genetic heterogeneity is intuitively considered to be minimised.
Closer examination of the present data reveals that the discrepancies between the
conclusions arise due to differences not in the comparison between patient groups, but
between controls in Ireland and Scotland. It is of great interest to note that the allelic
and genotypic frequencies of the rsl 523127/-24381 SNP (which was studied in both
the Irish and Scottish datasets) were significantly different between the control
populations of Ireland and Scotland. The allelic frequencies of this variant was 40% in
the Scottish and 45% in the Irish control population respectively (p=0.03, odds ratio
1.24, 95% CI 1.03-1.49). The data for CEPH population obtained from HapMap
Project, our initial genotype data in 32 CEPH trios and the white Caucasian
populations in the study by Zhang et al. (for which the natural allelic variants of this
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gene were originally characterised) were 39%, 39% and 40% respectively
(www.hapmap.org)(Zhang et al. 2001). In fact, data from both Irish and Scottish-IBD
cohorts revealed also minor allelic frequencies of 38% and 40%. Thus it may be
possible that cryptic stratification of the control population may belie the positive
results demonstrated in the Irish study.
What other possible explanations exist? It is widely accepted that phenotypic
heterogeneity e.g. composition of the 1BD cohort can sometimes explain apparent
inconsistent results across different study groups with the most relevant examples
being the NOD2/CARD15 gene and IBD5 risk haplotype(Ahmad et al. 2002;
Cuthbert et al. 2002; Noble et al. 2005; Vermeire et al. 2005; Torok et al. 2005;
Armuzzi et al. 2003; Giallourakis et al. 2003; Mirza et al. 2003; Negoro et al. 2003).
The Irish dataset suggested an association with several subphenotypes in IBD (CD-
ileal and colonic disease location, UC- pancolitis). Our cohort has been the subject
rigorous phenotypic assignment using the new Montreal Classification, including
disease behaviour, disease severity, age of onset and smoking habit; and it is pertinent
that no associations were observed both from single marker or haplotypic analyses.
Specifically, we did not replicate the associations previously suggested with disease
location in CD and extent in UC.
Thirdly, the power of the sample size has emerged as central factor in determining the
validity of a replication study in complex genetics. The difficulties encountered, are
well-demonstrated in the studies of DLG5 gene(Stoll et al. 2004) and OCTN1/2
gene(Peltekova et al. 2004) in inflammatory bowel diseases, and these have been
reviewed in detail by Trinh and Rioux(Trinh and Rioux 2005). The current study is
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adequately powered to detect the previous associations demonstrated in Dring's study,
assuming the effect size of rs 1523 127/-24381 SNP (>95% at a p<0.05). It is therefore
unlikely that the findings represent a type 2 error. In addition, the haplotype r2 of 0.80
reflected a predictable state of the tagged variants by the haplotypes defined by the
selected five tSNPs and thus, a statistically powerful method to detect even a weak
signal or effect from this locus or gene. This negative this gene-wide haplotype
analysis therefore sets a statistical limit to the importance of this gene in conferring
susceptibility to IBD in our population.
How robust is the current approach in detecting association in a genetic model
between different populations? Ahmadi and colleagues recently demonstrated the
applicability of this approach in a proof-of-concept study by assessing the
contribution of 55 genes in 2 populations by using a set of tSNPs selected using a
multiple-marker criterion (haplotype r2) that selects tSNPs independently of any
underlying block structure, ignoring heuristically defined block boundaries(Ahmadi et
al. 2005). Extensive empirical evaluations, including a direct assessment of
association with candidate functional SNPs in a new, larger population sample,
validated the performance of these tagging SNPs and confirmed their utility for
linkage-disequilibrium mapping in pharmacogenetics. Similarly, De Bakker et al.
have shown that such approach is economical and efficient, with very little loss of
power compared to traditional single pair-wise methods(de Bakker et al. 2005).
Notwithstanding the negative findings of this study, dysregulation of PXR/NR1I2
gene leading to the development of gut inflammation, remains plausible and could be
influenced through other ways for example, epigenetic mechanisms or a situation
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where multiple susceptibility genes are necessary for biological effect, thus providing
a possible explanation for the wide spectrum of disease location and behaviour in
1BD. The PXR/NR1I2 gene shares a considerable overlap with the Constitutive
Androstane Receptor (CAR) in the regulation of a number of epithelial transporter
and xenobiotic-metabolizing enzymes, and the contribution of the latter gene has not
yet been studied. The number of target genes for both PXR/NR1I2 and CAR is
considerable (more than 20) including the Cytochrome P450 genes and ABC
transporters. Germ-line variations of one of the ABC transporters, the ABCB1/MDR1
gene has been shown to confer susceptibility to IBD (in particular UC) in several
study populations(Schwab et al. 2003b; Brant et al. 2003; Ho et al. 2005; Ho et al.
2006b; Urcelay et al. 2006; Potocnik et al. 2004). It is not inconceivable that all the
other genes which are regulated by PXR/NR1I2 and CAR may all be good
independent candidate genes; or in conjunction with PXR/NR1I2 and CAR. In such
circumstances, gene-gene interactions or regulatory SNPs controlling gene expression
may be pertinent, and by genotyping the entire 'family' of xenobiotic-metabolising
enzymes can we reliably established the genetic contribution of these genes (and
indeed PXR/NR112).
In conclusion, genetic variations in PXR/NR1I2 gene do not have a major effect on
susceptibility to IBD in the Scottish population. Further studies in different ethnic
and study populations are necessary to provide a clearer role for this gene in IBD.
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Table la: Demographics and clinical characteristics of UC study population (n=387).
Disease location (El - proctitis, E2 - left sided disease and E3 - extensive colitis) and
severity (S3- severe UC as defined by Truelove and Witts criteria) are defined using the




Age of onset 35.2
(years) (25.9-50.4)
Age of onset <16 years 11 (2.8%)
Current smoker 43 (11.1%)
Ex-smoker 154 (39.8%)









Surgery for S3 79 (30.4%)
Extra-intestinal manifestations 45 (11.6%)




Table lb: Demographics and clinical characteristics of patients with CD. Disease
location (LI-Ileal, L2-colonic, L3-ileocolonic, L4-upper GI); behaviour (Bl-
inflammatory, B2-stricturing, B3-penetrating and p-perianal) and age of onset (Al-
<16 years, A2- 17-40 years and A3->40 years) were defined according to the





































Extra-intestinal manifestations 118 (43.1%)
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Table3a:Log-likelihoods gnificancebetw ethcomm nhaplotyp sfPXR/NR1I2gehapl typesandIBD/UC/CD.Signific ncfor associationic lculatedu ingtheestatistic2*(ln(Lcase)+ln(Lcon rol)-ln(Lc se/Lc ntrol)),w i hhaX~distribu ni hn-1degr eof freedom(wheren=numberofinferr dhaplotyp s) Log-likelihoodP-va ue IBDvs.controls0.79 UCvs.controls0.90 CDvs.controls0.90 Table3 :Comparisonf4commhaplotypfrequenc esb tweencasa dontrol . HaplotypeUC (%)CD (%)HC (%)
UCvs.H P-value OR 95%CI
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ATP-Binding cassette 3/ Multidrug
Resistance Protein 3 (ABCC3/MRP3)
gene and inflammatory bowel disease
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Abstract
Background/Aims : Increasing evidence implicates the dysregulation of intestinal
epithelial defence mechanisms and xenobiotic metabolism in inflammatory bowel
disease (IBD). Downregulation of a group of efflux transporters/xenobiotic
metabolizing genes including multidrug resistance 1, ABCB1/MDR1 and the
transcriptional regulator, Pregnane X-receptor (PXR) in IBD have been
demonstrated ; inherited variations of both genes have been associated with IBD. The
ATP-binding cassete sub-group C, family 3 (ABCC3) gene encodes multidrug
resistance protein 3 (MRP3) an efflux epithelial transporter pump which is highly
expressed in the gut, sharing close homology with ABCB1/MDR1.
Methods : A candidate gene-wide haplotypic analysis of the ABCC3 gene in a total
of 1197 patients with IBD (669 UC, 528 CD) and 613 healthy controls in two
independent case-control cohorts of Scottish and Swedish descent were utilised. Eight
tagging SNPs (tSNPs) were selected with a minimum haplotype r2 of 0.80 represent
the haplotypic variations of this gene. Single marker, log-likelihood and genotype-
phenotype analyses using the Montreal classification were used to test for association.
Results : Using log-likelihood analysis, haplotypic variations in ABCC3 gene were
associated with IBD, UC and CD in Scottish (p=0.00046, 0.004 and 0.001
respectively) and Swedish cohorts (p=0.001, 0.003 and 0.004 respectively).
Genotype-phenotype associations with inflammatory behaviour phenotype (Bl), ileo-
colonic disease (L3) in CD and extensive UC (p=0.005, 0.02 and 0.04 respectively)
were present. The possession of described risk allele of PXR gene (rs 1523127)
increased the associaton with IBD (p=0.005) whereas no epistatic interactions were
evident with ABCB/MDR1 variants and smoking habit. Significant single marker
association was observed in 4 out of 8 tSNPs within the Scottish IBD, UC and CD
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patients (maximal association tSNP6 rs879459 p=0.006, OR 1.52, 95% CI 1.14-2.04 ;
tSNP6, rs879459, p=0.0008, odds ratio 1.72, 95% CI 1.25-2.38; and tSNP3,
rs739921, odds ratio 1.41, 95% CI 1.11-1.78 respectively).
Conclusions : These findings provide strong evidence for a role for ABCC3/MRP3 in




As discussed earlier, recent genetic studies have now implicated the organic cation
transporters 1 and 2 (OCTNl/2)(Peltekova et al. 2004), drosophila large gene 5
(DLG5)(Stoll et al. 2004), multidrug resistance 1 (ABCBl/MDRl)(Ho et al. 2005;
Ho et al. 2006b), pregnane X-receptor (PXR/NR112)(Dring et al. 2006) and myosin
1X9 (MYOB9) genes in the susceptibility to IBD. The functions of all these genes are
associated with the maintenance of intestinal epithelial integrity and barrier defence.
In addition, the NOD2/CARD15 gene which represents the most widely replicated
genetic association with CD(Ogura et al. 2001b; Hugot et al. 2001a), is associated
with defective defensin production thereby compromising the gut barrier
defence(Wehkamp et al. 2005; Lala et al. 2003). Following the recent microarray data
in human IBD by Langmann and colleagues, the critical importance of detoxification
genes and epithelial efflux transporter proteins (in the ATP-binding cassete family,
ABC transporters) in IBD are re-emphasised as evident from the significant down-
regulation of Pregnane X-receptor, the key transcriptional regulator of most of the
xenobiotic and ABC proteins (including ABCB1/MDR1 gene) (Langmann et al.
2004) (Kliewer, Goodwin, and Willson 2002). As shown in the preceeding chapter,
variations of the PXR gene is not implicated in disease susceptibility in the Scottish
population. Given the previous positive associations with ABCB1/MDR1 gene with
UC in our dataset, I hypothesized that other efflux transporters that share a close
homology with P-glycoprotein 170 (the gene product of ABCB1/MDR1) and also
controlled by transcriptional regulator PXR, namely the ABC transporters may
contribute to disease susceptibility.
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In this present study, I have studied in detail the contribution of the ABCC3 (.ATP-
binding cassette, sub-family C (MRP3), member 3, multidrug resistance protein 3,
MRP3) which was implicated in Langmann's study in IBD. The ABCC3 gene is 56
kb in length and maps to chromosome 17q21 region. This gene encodes for the multi-
resistantprotein 3 transporter pump (MRP3) which mediates the basolateral efflux of
sulfated bile salts, lipophilic substances conjugated with glucuronate, sulphate or
glutathione, across the basolateral membrane of polarized cells and glucuronide-
conjugated organic anions(Kullak-Ublick, Stieger, and Meier 2004). MRP3 is highly
expressed in cholangio-, entero- and colonocytes. In animal models, MRP3 is poorly
expressed in stomach and upper small intestines with marked up-regulation in the
colon and to a lesser extent, the ileum (Rost et al. 2002; Mutch et al. 2004). To
determine whether variations of ABCC3 gene are associated with disease
susceptibility, I employed a 'gene-wide' haplotype-tagging strategy in a large Scottish
dataset and sought to replicate potential positive findings in a further Swedish dataset.
8.2 Material and Methods
In this study, a total of 387 patients with UC and 328 with CD recruited from the
Lothian region, Scotland, United Kingdom as previously described were genotyped.
The diagnosis of IBD was determined by standard clinical, radiological, endoscopic
and histological criteria. Table 1 summarizes the clinical characteristics of patients
studied. The median ages at diagnosis for UC and CD were 35.2 years (IQR 25.9-
50.4) and 28.5 years (IQR 21.0-41.1) respectively. The ethnicity of our study
population was Scottish-Caucasian. There were more males in the UC cohort (54.0%)
than in CD (36.6%). 338 healthy controls which comprised of 102 actively recruited
healthy subject and 254 blood donors from the Lothian region (50.8% males and age
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of recruitment 31.1 years, IQR 25.9-47.0). In the Swedish dataset, 284 and 192
individuals with UC and CD respectively were recruited from hospitals in the
Stockholm County were assessed. The Swedish controls (male : female - 126/151
healthy volunteers recruited from Karolinske Univeristy Hospital and day case
surgery patients ; median age 49.61 year, IQR 38.45-62.67). The demographics and
clinical details of these patients are shown in Table 2. These patient groups and
controls have been previously described in previous studies(Torkvist et al. 2006b;
Noble et al. 2005; Ho et al. 2005).
Haplotype tagging ofABCC3 gene
The ABCC3 gene was re-sequenced in 16 unrelated Centre d'Etude du
Polymorphisme Humain (CEPH) individuals by using randomly spaced amplicons
across the ABCC3 gene from position -49186865 to -49243698 in chromosome 17.
All SNPs discovered were further genotyped in 32 CEPH trios. Haplotypes and their
respective frequencies were estimated and constructed from all genotyped SNPs using
the partition-ligation expectation-maximization algorithm(Zhang et al. 2004). We
used a haplotype r2 method described by Weale and Goldstein to select the current
tSNPs(Weale et al. 2003; Goldstein et al. 2003). The criteria for the choice of tSNPs
were i) average r weighted by allele frequency between the tSNPs and all SNPs were
>0.80 and ii) minimum r2 between the tSNPs and each individual SNPs in the gene
was 0.80. All genotype data was entered into the TagiT v.3 (criterion five)




Case and control frequencies were compared using a 2X2 contingency table and
Fisher's exact test. Odd ratios (OR) were given with 95% confidence intervals and 2-
sided P-values using the Graph Pad Instat programme (Graph Pad Software, San
Diego, USA). Haplotype frequencies of the ABCC3 tSNPs were inferred using the
expectation-maximization (EM) algorithm (Zhao, Curtis, and Sham 2000). Haplotypic
associations with disease were assessed by using log-likelihood ratio analysis
implemented in the EH and PM programs as discussed in previous chapters (Zhao,
Curtis, and Sham 2000; Qin, Niu, and Liu 2002). We measured the linkage
disequilibrium between SNPs using r2 values(Hill W.G. and Robertson A 1968).
Further haplotypic analyses were performed using the Montreal Classification as the
partition for log-likelihood analyses (e.g. we compared the haplotypes of patients with
extensive UC with controls)(Silverberg et al. 2005). The similar analyses were also
performed in stratified sets within the case group according to smoking status, sex and
allelic variations of the recently cited ABCB1/MDR1 (rs3789243) and PXR gene
(rs 1523127) (only in the Scottish cohort) (Ho et al. 2006b; Ho et al. 2006c; Dring et
al. 2006). In addition to this, we investigated the relative estimated constructed
haplotype frequencies of the ABCC3 gene in the Scottish, Swedish and controls,
using the chi square method (2x2 tables).
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8.3 Results
In total, 1197 patients with IBD (669 UC, 528 CD) and 613 healthy controls were
genotyped with 8 tSNPs capturing the haplotypic variations of the ABCC3 gene in
this current study. All tSNPs satisfied the Hardy-Weinberg equilibrium. The average
genotyping success was 95%.
Single variant and haplotypic associations ofABCC3 gene in the Scottish cohort
Significant association with IBD was demonstrated with 4 out of 8 tSNPs within the
Scottish cohort (Table 4), with the most significant association ascribed to tSNP6
(rs879459, p=0.0058, odds ratio 1.52, 95% CI 1.14-2.04). Within the Scottish cohort,
associations were observed for both UC (maximal association with tSNP6, rs879459,
p=0.0008, odds ratio 1.72, 95% CI 1.25-2.38) and CD (tSNP3, rs739921, odds ratio
1.41, 95% CI 1.11-1.78). Using the log-likelihood ratio analysis which tests the
association between the inferred haplotypes using disease/control partition (using
EH+ which makes a likelihood assessment that includes statistical uncertainty in
phase estimation), I detected a strong association of haplotypes with IBD in the
Scottish dataset, with a p-value of 0.00046 (using 44 degrees of freedom, based on the
cut-off of 45 haplotypes with an inferred frequency of >0.5%). Haplotypic
associations of the ABCC3 were more strongly associated with CD (p=0.001)
compared with UC (p=0.004).
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Genotype-phenotype association ofABCC3 gene in the Scottish cohort
I performed further genotype-phenotype haplotypic analyses using the Montreal
Classification partition, with significant associations demonstrated with the
phenotypes of inflammatory behaviour (Bl-at latest follow-up) (0.005), ileal-colonic
CD (p=0.02) and extensive UC (p=0.04). We have further stratified our current
dataset using previously implicated tSNPs of the multidrug resistance gene,
ABCB1/MDR1, rs3789243; rs 1523127/-24381 of the Pregnane X-receptor gene,
PXR/NR112 and smoking habit to investigate for interactions between these factors. It
is of interest to note that the carriage of risk allele tSNP rsl 523127/-24381
PXR/NR1I2 retained a highly significant association of ABCC3 tSNPs with IBD (A-
allele carriage p=0.005 vs. G-allele carriage p=0.06) (Table 5b). In contrast, there
were no interactions with ABCB1/MDR1 or smoking habit in the Scottish dataset.
Formal single variant analyses of the 8 tSNPs with the variants of PXR/NR1I2 and
ABCC3 as described above, did not reveal significant interactions between these
alleles and disease susceptibility in IBD, UC and CD (data not shown).
Haplotypic association of ABCC3 gene and genotype-phenotype analyses in the
Swedish cohort
In the Swedish dataset, no significant associations were demonstrated at the single
locus level using the tSNPs. Nevertheless, there remains a highly significant overall
haplotypic association, with a p-value of 0.004 for IBD. Haplotypic associations were
both significant for UC and CD (p=0.003 and 0.004 respectively). It is of interest to
note that the phenotypic associations with inflammatory behaviour (Bl) and ileo-
colonic CD (L3) were retained (p=0.01 and 0.03 respectively) similar to Scottish
dataset.
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Comparison ofconstructed haplotypefrequencies between case and controls
In Table 6, we present the ten common inferred haplotype frequencies in the current
dataset. Within this subset, only one haplotype (22121222) was significantly
associated with CD (p= 0.02, odds ratio 1.76, 95% CI 1.11-2.82). A total of 256
haplotypes were inferred from 8 tSNPs with 45 haplotypes of frequency >0.5%
accounting for 85% of the inferred haplotypes. This suggests that the observed
overall haplotypic association as evident from log-likelihood analyses may be driven
by several different haplotypes collectively.
Given that our current tSNP selection strategy does not rely on heuristically defined
block boundaries, we re-tested our tSNPs by using the available HapMap phase II
(HapMap data release 21, July 2006 National Centre for Biotechnology Information
[NCBI] build 35 assembly, dbSNP build 125) data to determine whether these tSNPs
reside within a defined haplotype block in ABCC3 gene. Based on the solid spine LD
analysis, the ABCC3 gene is composed of 5 haplotype blocks (4-10 kb) (Figure 1).
On these criteria, each defined haplotype block was represented by one or more of our
current tSNP, therefore suggesting that the ABCC3 gene is well-represented but also
the 'causal' variant may reside anywhere along the length of this gene.
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8.4 Discussion
The present data provides strong novel evidence for a role in the ABCC3 gene in
determining susceptibility to inflammatory bowel disease. By using a gene-wide
haplotype approach which captures the majority of the haplotypic variations of this
gene, the association with IBD was most significant within the Scottish dataset
(p=0.00046), with both the sub-phenotypes of UC and CD implicated (p=0.004 and
0.001 respectively). Using log-likehood analyses on the haplotypic level, this finding
was replicated in a separate Swedish cohort (p=0.001, 0.004 and 0.003 for IBD, CD
and UC respectively). Detailed phenotypic sub-analyses again revealed consistent
sub-phenotypic associations with inflammatory behaviour and ileo-colonic disease in
CD in both Scottish and Swedish cohorts. This present study therefore demonstrate
independent associations in two Northern European cohorts.
The involvement of ABCC3 gene now emphasises the importance of ABC efflux
transporters in the maintanence of gut barrier defence and susceptibility to IBD.
Within this group, ABCB1/MDR1, CFTR and PXR have recently been implicated. I
have characterised the gene expression pattern of the entire ABC transport protein and
interestingly demonstrate that the expression of ABCC3/MRP3 gene is lowest distally
(with an increasing gradient, similar to ABCB1/MDR1). Genetic mutations within the
ABC transporters family are known to result in human diseases, for examples
MRP2/ABCC2 (Dubin-Johnson's syndrome)(Toh et al. 1999), ABCG5/8
(sitosterolaemia)(Lu et al. 2001) and most strikingly CFTR gene predisposing to
cystic fibrosis(Gadsby, Vergani, and Csanady 2006). If variations of the ABCC3 gene
can confer susceptibility to IBD, the mechanism underlying this remains tentatively
unknown. Recent data have shown that bile acids can play a role in gut barrier
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defence and the maintenance of luminal microflora. Classically, the dominant role of
bile acids is to aid the absorption of lipid absorption by micellar solubilization. A
second novel role, that is the inhibition of bacteria growth in the distal small bowel
and colon, has been now been suggested and supported by several lines of evidence.
In liver cirrhosis in both humans (Bauer et al. 2002) and animals(Lorenzo-Zuniga et
al. 2006), decreased bile acid secretion leads to secondary bacterial overgrowth
occurs ; and in animals, the ligation of bile duct leads to similar picture (Slocum et al.
1992; Ding et al. 1993) ; bile and unconjugated bile acids have also been shown to
inhibit bacterial growth in v/7ro(Binder, Filburn, and Floch 1975; Begley, Gahan, and
Hill 2005). By feeding of bile or conjugated bile acids in conditions of bile acid
deficiency in the intestine, a reduction/abolition of bacterial overgrowth and bacterial
translocation to intestinal lymph nodes have been demonstrated(Lorenzo-Zuniga et al.
2006; Ding et al. 1993). In a seminal study, Inagaki and colleagues presented further
compelling evidence, based on mice studies, that the antibacterial effect of conjugated
bile acid in the distal intestine is mediated by a cellular pathway involving a further
nuclear receptor, the farnesoid X receptor (FXR), an orphan receptor that is activated
by conjugated bile acids(Inagaki et al. 2006). Genetic variations of a further
transcriptional regulator of bile acid transporters (including MRP3), Steroid and
Xenobiotic receptor (SXR/PXR), have been shown to influence survival and modify
disease progression in primary sclerosing cholangitis, which is extricably associated
with IBD(Karlsen T.H. et al. 2006).
We therefore postulate that defective bile acid metabolism mediated by inherited
variations of the ABCC3 gene may confer susceptibility to IBD (by virtue of reducecd
mucosal protection). In our current analyses, the existing interaction between
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PXRJNR112 and ABCC3 is pertinent and points to the importance of the xenobiotic-
metabolism pathway in the pathogenesis of IBD. Emerging data show that the
xenobiotics response/defence mediated via several key transcriptional regulators such
as Pregnane-X receptor, are also intricately linked to NFKB signalling pathways and
inflammatory response(Zhou et al. 2006b; Gu et al. 2006a). These again highlight the
multifactorial model of IBD pathogenesis; and in the case of ABCC3 /MRP3 may
influence susceptibility critically in the presence of other genetic and environmental
factors. Our current data further supports the importance of xenobiotic-and efflux-
transporters and suggest a novel role in ABCC3/MR.P3 gene and bile acid transport in
determining IBD-susceptibility.
It is noteworthy that 4 out 8 tSNPs used demonstrated significant associations with
IBD in the Scottish dataset. In contrast, the negative findings on a single locus level as
evident in the Swedish dataset did not exclude the involvement of this gene on a
haplotypic level. Several explanations are possible: Firstly, the current statistical
approach used in this study focused on the coefficient of determination (i.e. haplotype
r2) in a regression model uses haplotypes defined by the tSNPs to predict the state of
the tagged SNPs. This method was employed as it offered considerable economy and
power over single marker approaches(de Bakker et al. 2005). The current data
suggests that the collective 8-locus haplotype markers are capturing an unknown
variant for which the singular tSNPs are not in the Swedish cohort. The apparent
differences between single locus and multimarker haplotypic associations reflect the
fundamental differences between statistical power, efficiency and analyses. Further
examples of highly significant 'haplotypic' associations observed in parallel with
marginal 'genotypic' associations have also been well-demonstrated in complex
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disease, in the examples ofNODI gene sliding haplotypes with IBD(McGovern et al.
2005); and the ADAM33 gene with asthma(Van Eerdewegh et al. 2002). Secondly, the
smaller sample size in the Swedish cohort may diminish the power to replicate single
variant association significantly. However, by comparing the commonly inferred
haplotypes in IBD and controls between these two populations, we have not detected
significant differences in between respective Scottish and Swedish case/control
groups. This suggests that despite obvious phenotypic heterogeneity between Scottish
and Swedish datasets, the argument for genetic heterogeneity is minimised as
demonstrated in recent studies in NOD2/CARD15 frequencies between these
populations (Arnott et al. 2004a; Torkvist et al. 2006a).
In conclusion, our present study provides compelling evidence for the involvement of
the ABCC3/MRP3 gene in determining susceptibility to IBD. This and recent genetic
studies highlight the critical importance of barrier function in the aetiopathogenesis of
IBD. Elucidating the functional mechanisms of ABCC3/MRP3 together with
ABCB1/MDR1 and their respective crosstalk with the innate immunity will provide
new insights into shared causal mechanisms underlying intestinal inflammatory
diseases.
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Table la: Demographics and clinical characteristics of UC study population (n=387).
Disease location (El - proctitis, E2 - left sided disease and E3 - extensive colitis) and
severity (S3- severe UC as defined by Truelove and Witts criteria) are defined using
the Montreal Classification(Silverberg et al. 2005). t-Unknown status not used in the
description of smoking status and disease extent. JSurgery rates in cohort with full




















































Azathioprine 107 (27.6%) -
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Table lb: Demographics and clinical characteristics of patients with CD. Disease
location (LI-Ileal, L2-colonic, L3-ileocolonic, L4-upper GI); behaviour (B1 -
inflammatory, B2-stricturing, B3-penetrating and p-perianal) and age of onset (Al-
<16 years, A2- 17-40 years and A3->40 years) were defined according to the
Montreal Classification.
Scottish Swedish
Characteristics Crohn's disease Crohn's disease
(n-328) (n=192)
Sex (M/F) 120/208 109/108
Smoking
Current 88 (26.8%) 39 (23.5%)
Ex-smoker 136(41.5%) 62 (37.4%)
Never 93 (28.4%) 64 (38.6%)
Unknown 11 (3.3%)
Age of onset, years 28.5 24.8
Median (+IQR) (21.0-41.1) (18.7-37.2)
Age of diagnosis
A1 28 (8.5%) 34(15.7%)
A2 215 (65.6%) 135 (62.2%)
A3 85 (25.9%) 48 (22.1%)
Drug therapy
Infliximab 45 (13.7%) -
Azathioprine 135 (41.2%) -
Disease Location
LI 108 (33.0%) 29 (13.4%)
L1+L4 7 (2.2%) 6 (2.8%)
L2 108 (33.0%) 103 (47.7%)
L2+L4 4(1.2%) 0 (0%)
L3 77 (20.4%) 66 (30.6%)
L3+L4 15 (4.6%) 2 (0.93%)
L4 13 (4.0%) 0 (0%)
Unknown 5 (1.5%) 9 (4.17%)
Disease behaviour
B1 171 (52.1%) 139 (69.5%)
Blp 40(12.2%) 3 (1.5%)
B2 41 (12.5%) 39 (19.5%)
B2p 4(1.2%) 2 (1.0%)
B3 54(16.5%) 7 (3.5%)
B3p 9 (2.7%) 9 (4.5%)
Unknown 9 (2.7%) 17
Surgery 216(65.8%) 102 (47.0%)
Extra-intestinal manifestations 118 (43.1%) -
PSC 4 (1.8%)
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rs2277624 tSNP7 Synonymous Coding
rs3785911 tSNP8 Intronic/Downstream
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Table 5a: Log-likelihood significance between the common haplotypes of ABCC3
gene haplotypes and 1BD/UC/CD. Significance for association is calculated using the
test statistic 2*(ln(L case)+ln(Lcontrol)-ln(Lcase/Lcontrol), which has a






Current smoker IBD 0.29 0.32
ABCB1/MDR1 G-allele (rs3789243) 0.79 -
PXR/NR1I2 C-allele (rsl523127) 0.005 -
CD




LI + (L1+L4) 0.19 0.65
LI 0.15 0.69
L2+ (L2+L4) 0.35 0.07
L2 0.28 0.08
L3+ (L3+L4) 0.02 0.03
L3 0.02 0.03
L4 0.92 0.89
B1 + Blp 0.005 0.01
B1 0.006 0.01
B2 + B2p 0.84 0.78
B2 0.71 0.64









Table 5b: Stratified log-likelihood analyses based on previously implicated A-allele
of the PXR rs!523127 SNP (Dring et al.) using 8 tSNP set.
rsl523127/-24381 A C
IBD (n=715) 858 (60.0%) 572 (40.0%)
HC (n=334) 405 (60.6%) 263 (39.4%)
Log-likelihood analysis on




Table 6: Comparisons of ABCC3 estimated haplotype frequencies in IBD, UC and
CD populations and healthy controls. *-Significantly higher no. of haplotypes for CD
population for this haplotype, p= 0.02, odds ratio 1.76, 95% CI 1.11-2.
Scottish cohort Swedish
Haplotype IBD UC CD HC IBD UC CD HC
(%) (%) (%) (%) (%) (%) (%) (%)
1. 22221222 13.3 11.6 15.4 12.8 11.3 10.9 11.7 12.7
2. 22121222 5.5 4.5 6.8* 4.0 4.9 4.7 5.2 5.4
3. 12221222 4.8 4.5 5.1 5.7 5.0 5.5 4.4 5.2
4. 22221221 4.8 4.5 5.1 5.7 5.1 4.5 5.8 5.5
5. 21221222 4.6 4.9 4.2 5.0 3.1 2.9 3.4 3.2
6. 22221212 3.9 3.7 4.0 2.7 3.8 3.7 4.0 3.9
7. 22211222 3.8 3.6 4.1 4.6 3.2 3.2 3.1 3.4
8. 22221122 2.3 2.4 2.1 1.5 2.9 3.1 2.6 2.8
9. 12121222 2.0 1.7 2.2 1.8 2.2 2.4 2.0 2.2
10. 22121221 2.0 1.7 2.2 1.8 2.2 1.9 2.6 2.4
262






The current data generated from this thesis have several key and novel implications.
Firstly, the importance and predictability of corticosteroid resistance and dependence in
inflammatory bowel disease have now been demonstrated. The inception cohort in this
study, represents the most recent observation on the natural history of inflammatory
bowel disease and corticosteroid usage (compared with population-based cohorts in
1970-80s). This study also highlighted the key feature in the variability of the clinical
course of IBD is determined by the response to corticosteroids in particular, in patients
with extensive UC at time of diagnosis and the phenotype of fistulising disease in
Crohn's. It is pertinent that with the safety issues surrounding the new biological
therapies (such as the developments of hepatosplenic T-cell lymphoma and progressive
multifocal leukoencephalopathy associated with infliximab and natalizumab
respectively) becoming increasingly relevant in clinical practice, there remains a need to
understand the mechanisms underlying corticosteroid resistance/dependence and thereby,
allowing appropriate stratification of patients to more potent therapies (reducing both
biological and corticosteroid-related toxicity)(Mackey et al. 2007; Van Assche et al.
2005). Secondly, the development of a robust predictive model (the Ho-index) which
stratifies patient according to the risk of non-response to intravenous corticosteroids in
acute severe UC, also represents further progress in the above mentioned strategy of
targeting therapy towards subsets of patients who are most likely to achieve maximal
benefit. The current model was developed using the largest series of acute severe UC, and
has its advantages in identifying subsets of patients at low-, intermediate and high-risk of
failed medical therapy. This is again, particularly relevant in the context of risk-
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counselling. This study propose the use of second-line medical therapies such as
infliximab or ciclosporin in patients in the intermediate risk group (risk score 2-3). These
clincial studies have critically provided the assimilation of highly accurate phenotypic
and follow-up data of these patients, permitting very detailed statistical analyses to be
performed.
Thirdly, the identification of the ABCB1/MDR1 and ABCC3/MRP3 genes as
susceptibility genes in UC (and 1BD for the latter) further implicate the importance of gut
barrier defence and xenobiotic-metabolizing pathways in the aetiopathogenesis of IBD.
In addition to animal data (mdrla-knock out colitis model for example), functional
studies have now demonstrated key signalling cross-talk between Pregnane X-receptor
gene (transcriptional regulator of ABCB1/MDR1 and ABCC3/MRP3), with NFKB and
inflammatory response(Gu et al. 2006b; Zhou et al. 2006a). It is of interest to note that
variations of both genes are associated primarily with extensive disease - again
highlighting a further critical factor in future association studies, namely phenotypic
heterogeneity. Fourthly, I have now demonstrated the feasibility and applicability of the
gene-wide haplotype approach in association studies in complex diseases, in its use in
ABCB1/MDR1 gene (Chapter 6). This represented one of the earliest study employing
the current technique which is now a widely accepted approach with the availability of




The implications as discussed in the earlier section, logically follow on to further
important questions :
• Given the predictability of corticosteroid resistance/dependence in IBD, the
potential pharmacogenomic contribution to this phenomenon should be
investigated. Although the molecular mechanisms of corticosteroids in
inflammation are well-known, the innate variability of response is ill-understood.
Therefore, the next logical step will be to develop a comprehensive
pharmacogenetic model in corticosteroid resistance using IBD as the
inflammatory disease model. I have now employed a high-throughput analysis
involving 70 (768 tSNPs) key genes in corticosteroid-related pathways and
epithelial drug transport proteins using both 1-year inception outcomes and also a
novel Cox-regressional hazard model in our detailed IBD cohort. This currently
funded study is unique in its longitudinal approach and the genetic coverage of
candidate genes. I intend to rapidly extend this study to inter-population studies
(including paediatric IBD cohorts) and also other inflammatory diseases
(pertinently - asthma) (Translational Reseach Grant, Chief Scientist Office - Dr.
Gwo-Tzer Ho 2006).
• In acute severe UC, I have demonstrated that clinical markers of disease severity
can be assimilated into statistical models (Ho-index) with good performance in
sensitivity/specificity to predict the outcome of an acute attack of severe UC. It is
noteworthy that other important predictive factors of clinical course such as the
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propensity to develop severe disease and the identification of earlier markers of
poor outcome remain elusive. Presently, genetic variants associated with
extensive and severe disease, at best, only modestly predict medically resistant
UC or surgery. There remains a need to identify early biomarkers of severe
disease and outcome. 1 have considered two further rational approaches : Firstly,
the use of proteomics both in sera and faeces, in identifying early biomarkers of
corticosteroid resistance/surgery are funded and in progress. (Project Grant, Chief
Scientist Office 2006). Secondly, the use of genome wide association studies
(GWAS) to further investigate genetic variants of disease severity and extent are
in progress, and the results are eagerly awaited. Both complementary approaches
promise to provide new insights both to disease outcome and pathogenesis.
Furthermore, I have now completed a recent pilot study in the use of faecal
calprotectin to predict outcome in acute severe UC.
• The functional consequence of the implicated sequence variations of
ABCB1/MDR1 and ABCC3/MRP3 will provide critical new insights to disease
pathogenesis. 1 have now fully characterised the expression patterns of the entire
ABC-transporter superfamily (Ho G.T., et al. 2007). The most striking
observation again, is the downregulation of MDR1 in UC. MDR1 expression is
significantly lower in UC (basal and inflamed states; FoldChange 1-9 and 1.8; p=
9.0x10"10 and 5.6x10"A compared with inflamed/non-inflamed controls
respectively). MDR1 constitutive expression demonstrates a decreasing gradient
distally, lowest in the rectosigmoid region (p=0.001 left vs. right colonic
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expression), (with a expression gradient - lowest in rectosigmoid region). In
addition to this, a further 15 (31%) genes were differentially expressed in IBD.
Functional work is currently focussed in elucidating the exact mechanism of
ABCB1/MDR1 and ABCC3/MRP3 in the maintenance of gut barrier defence in
inflammatory bowel disease. For both these genes, the current working hypothesis
is that low MDR1 and MRP3 expressions predispose to inflammation and high
levels protect. The modulations of the expressions of these proteins at the
epithelial level and therein determine susceptibility to disease can be evaluated.
The utilisation of Th2 colitis model (Oxazolone) and transgenic B27 rat colitis
models with the modulation of MDR1/MRP3 expressions (either via PXR and
other known environmental inducers to upregulate ; and known inhibitors or
silencing RNAs to downregulate) with the assessement of the consequent severity
of colitis is proposed. In addition to this, the mechanisms can be further explored
using an in vivo model to assess the exact mechanistic effects of MDR1 function
(for example) in response to exposure to pathogen-associated protein motifs (such
as lipopolysaccharide, muramyl dipeptide and flagellin) and its crosstalk with
other aspects of innate immunity such as toll-like receptors, inflammatory
signalling pathways and regulatory proteins. By establishing the co-regulatory
signalling pathways, the specific effects of the implicated variants of
ABCB1/MDR1 and ABCC3/MRP3 can also be investigated (Clinican Scientist





















At diagnosis At latest follow-up
Proctitis □ Proctitis □
Left-sided (<splenic) □ Left-sided (<splenic) □
Extensive (splenic) □ Extensive (splenic) □
Details of severe UC
Truelove and Witts? □
Stool >6 on admission □
Fever >37.8C □














Presence of fever 1-3
Colonic dilatation 1-3
These are indices taken from 1st 3 days of GCS therapy. For blood results put in
any results in chronological order within the 1st 3 days of therapy.
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Details of patient
Previous presentations or hospitalization? □
Drugs on admission:
5-ASA: YES/NO
Which type: Asacol / Pentasa / Balsalazide / Sulphasalsazine / Osalazine
Oral Prednisolone YES / NO
Drugs therapy for severe UC
IV HC or 6MP (circle): YES / NO
How long for? :
IV cyclosporine YES / NO
Date started :


















Date of latest follow-up:_
Relapse: YES / NO




















Active / Ex-smoker /Non-smoker
DISEASE: UC / CD
MANAGED AS: In-Patient/ Out-Patient
Date of Diagnosis
(more or less when patient was
officially diagnosed or when IBD
treatment implemented):
Date of Latest Follow-up:
Date of Case Notes Review:













Infliximab / Ciclosporin /









Section 2 (b). Corticosteroid (CS) Commencement (fill in ifCS-therapv was NOT
started at
Diagnosis/Index Admission)
IV /ORAL Date Started Date Ended Duration Dose
Section 3. Immediate Outcome at 30 days (DATE: ) after
Corticosteroid
Commencement (refer to Section 2(a) or 2(b) for Start Date ofCS-therapy)
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• Azathioprine / 6MP/
Methotrexate
• ORAL steroids step-up to IV
Regression of symptoms,
e.g:
• BO < 4 /day
• Stools: No blood/pus/mucus
• No abdominal pain
• OR All above symptoms, but
not





• BO < 2 /day
• Stools: No blood/pus/mucus
• No abdominal pain, fever,
weight loss, extra-intestinal
symptoms
STEROID DOSE at 30 DAYS (optional):
OTHER DETAILS
Section 4: Intermediate Outcome at 90 days (DATE: ) after
Corticosteroid
Commencement (refer to Section 2(a) or 2(b) for Start Date ofCS-therapy)
No Response




• Azathioprine / 6MP /
Methotrexate
• ORAL step-up to IV Steroids
CS-Dependent
Either
• Failure to wean, i.e recurrence of
active disease upon dose reduction
• Flare within 30 days of complete CS
withdrawal
• Steroid Courses: > 2 within 90 days




• Off steroids, without
need for further treatment
STEROID DOSE at 90 DAYS (optional):
OTHER DETAILS:
Section 5: OUTCOME at 1 YEAR (DATE: ) after Corticosteroid
Commencement (refer to Section 2(a) or 2(b) for Start Date ofCS-therapy)
No Response
No regression; requiring either:
• Surgery
• Infliximab / Azathioprine
CS-Dependent:
Either
• Failure to wean
• Flare within 30 days of CS
withdrawal
• Steroid Courses: > 3 within lyr
Prolonged Remission
Either
• >30 days steroid-free
remission
• Steroid Courses: < 2 within
lyr
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• Azathioprine / 6MP /
Methotrexate
• Infliximab / Other TNF-
therapies
STEROID DOSE at 1 YEAR (optional)
OTHER DETAILS:
Notes:
1. Disease severity/location/extent should already be in database.
2. All patients with corticosteroid therapy should fall into each of the categories stated.
3. Upon initial diagnosis, we shall include data of all corticosteroid therapy within 3 months of
diagnosis: this is to capture all treatments (e.g. patients who had been started on milder treatments
such as 5ASA for example).
4. Please note subheadings for major outcome points at 3, 6 and 12 months.
For UC: For CD:
Disease extent: El (proctitis! Disease location: Ileal (LI)
E2 (left sided - up to splenic Colonic (L2)
flexure) Ileo-colonic (L3)
E3 (extensive - beyond splenic Upper GI (L4)
flexure)
Disease severitv: Disease behaviour: Inflammatory (Bl)
S3 (fulfilling modified Truelove and Witts criteria): Stricturing (B2)
"> 6 episodes of bloody diarrhoea/24 h Penetrating (B3)
with one or more of the following features: (Add p - if penetrating)
Anaemia (<10.5 g/dl); Fever (>37.8 °C);
Tachycardia ( >90/min); ESR >30 mm/h)
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